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Resorption of alveolar bone after tooth extraction is a common problem. Bone replacement 
materials are used to enhance socket healing and reduce alveolar bone loss. The success of the 
graft is dependent on multiple factors including the presence of growth factors. This is the first 
in vivo study to investigate the expression of the pleiotrophin family of cytokines in association 
with a grafting material during bone regeneration.  
Objective: To investigate the role of the growth factor family of pleiotrophin/midkine and their 
receptors, during osteogenesis with and without a grafting material, after tooth extraction in a 
sheep model.  
Methods: Thirty Romney-cross ewes were anaesthetised and all premolar teeth on the right 
side were extracted. The sockets were randomised to controls sites with no treatment and test 
sites with Bio-Oss® graft material and Bio-Gide® membrane. Samples were harvested after 
sacrificing animals 4, 8, and 16 weeks post-grafting (n=10 per time-point). Tissue for qRT2-
PCR gene analysis was recovered from the socket next to the first molar using a trephine 
(Ø=2mm). Each socket was fixed, decalcified, paraffin-embedded and sectioned. 
Immunohistochemistry (IHC) was conducted to localise pleiotrophin and midkine and their 
receptors anaplastic lymphoma kinase (ALK), receptor-type tyrosine-protein phosphatase zeta 
(RPTPζ) and notch-2.  
Results: Within the healing sockets high expression of genes for pleiotrophin, midkine, notch-
2, and ALK were found at all time-points and in both grafted and non-grafted sites, while 
RPTPζ was only expressed at low levels. The relative gene expression of the PTN family of 
cytokines were not statistically different at the three time-points and between test and control 
groups (p>0.05). Immunohistochemistry found pleiotrophin and midkine in association with 
new bone, notch-2 in the connective tissue and intranuclear localisation of RPTPζ and ALK in 
association with cuboidal osteoblasts involved in bone formation.  
Conclusions: The pleiotrophin family was expressed in both non-grafted and grafted sockets 
during osteogenesis in a sheep model of alveolar bone regeneration. The discovery of the 
pleiotrophin/midkine family as important during alveolar bone regeneration is novel and opens 
up new avenues of research. Growth factor supplementation with pleiotrophin and/or midkine 
during healing may be an approach for enhanced regeneration or to initiate healing where 
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1 Introduction and literature review 
Insufficient alveolar bone or unfavourable bone architecture as a consequence of tooth 
extraction is a common problem. This can impact on the ability of obtaining an ideal implant-
supported restorative outcome (Schropp et al., 2003). Loss of alveolar bone can be the result 
of previous periodontal disease, periapical pathology, congenital malformation or trauma to 
teeth and bone (Van der Weijden et al., 2009). An overview of the clinical procedure involved 
in bone augmentation is been provided in Figure 1. 
 
Figure 1. Bone augmentation procedure at the implant site 22. A. Limited amount of bone at 
implant site; B. Large bone concavity precluding implant placement; C. Occlusal view after 
grafting with DBBM granules; D. The grafted area covered with a collagen membrane; E.  
Sutures to obtain primary wound closure; F. Re-entry surgery after 9 months revealed a good 
integration of the deproteinated bovine bone mineral (DBBM) particles into the newly formed 
bone; G. Implant placed in a prosthetically ideal position; H. Radiographs before and after 
regeneration and implant placement of the DBBM. Photos adapted from Hȁmmerle et al, 2008 
(Hämmerle et al., 2008). 
 
Guided bone regeneration (GBR) using bone graft materials is advocated for the correction of 
jaw bone defects before implant placement (Buser et al., 1993; Buser et al., 1995; Hämmerle 
& Karring, 1998). Bone preservation with grafting materials is also widely used to counteract 
dimensional changes in the tooth sockets following extraction (Vignoletti et al., 2012). 
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Autogenous bone grafts are the "gold standard" in alveolar bone augmentation, prior to oral 
implant placement (Sakkas et al., 2017; Fernandez de Grado et al., 2018). However, the use of 
autografts is limited due to restricted donor site and harvesting morbidity. The two most 
frequently reported complications associated with intraoral autografts are significant graft 
resorption and oral exposure of the material (Proussaefs & Lozada, 2005; Nkenke & Neukam, 
2014). Research activities have been directed toward the investigation of biomaterials as 
substitutes for alveolar bone (Hämmerle et al., 2008).  
A number of graft materials have been used clinically with varying reports of success (Balshi 
& Wolfinger, 2003). Of the available graft materials, deproteinated bovine bone mineral 
(DBBM) has been most commonly used in dentoalveolar grafting. Bio-Oss® (Geistlich 
Switzerland) is a DBBM material and an alternative or adjunct to autogenous bone for intraoral 
application. Whether used alone or as a mixed graft, Bio-Oss® is osteoconductive, with bone 
forming around the graft particles (Berglundh & Lindhe, 1997; Norton et al., 2003). In certain 
conditions, the combination of DBBM and a collagen membrane can be used successfully for 
horizontal bone augmentation (Hämmerle et al., 2008). The particles themselves appear to be 
replaced, albeit slowly (Piattelli et al., 1999) and it has been characterised as a semi-permanent 
grafting material (Piattelli et al., 1999). Bio-Oss® is one of the grafting materials commonly 
used in the Faculty of Dentistry at Otago University (New Zealand) during bone preservation, 
regeneration and augmentation procedures. 
When investigating new bone augmentation biomaterials, sheep have been increasingly used 
as an animal model, and have been described as excellent for biocompatibility testing (Nuss et 
al., 2006). Sheep have been advocated by various biomedical researches as a useful animal 
model because they closely correlate with human weight and physiology. Furthermore, their 
rapid recovery from anaesthesia, ease of handling and acceptance to society as research animal 
has resulted in an increase in their use as a large animal model (Newman et al., 1995). Various 
models of intra-oral healing have been established (Duncan, 2005), including intra-oral models 
designed for testing regenerative materials (Danesh-Meyer et al., 1995). However, 
investigations of the mechanisms of healing in this animal model, at the molecular level, are at 
an early stage (Baharuddin et al., 2015).  
Bone remodelling involves osteoclastic bone resorption in balance with osteoblastic bone 
synthesis and it is tightly regulated (Parfitt, 1984). Different systemic and local regulatory 
factors, including cytokines and growth factors, control bone remodelling (González, 2000). 
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Previous research using suppression subtraction hybridisation to detect differentially regulated 
genes during bone formation detected high levels of a transcript for pleiotrophin. Pleiotrophin 
is a small, stable protein and represents a promising novel growth factor to enhance bone 
growth and regeneration (Tare et al., 2002). 
Pleiotrophin and its family member midkine are heparin-binding growth factors (Kadomatsu 
et al., 1988) with 50% structural homology and contain similar conserved C- and N-domains. 
Mouse models with either pleiotrophin or midkine genes knocked out, exhibit similar moderate 
abnormalities (Sakurai et al., 2001; Kaplan et al., 2003). Mice with both pleiotrophin and 
midkine simultaneously knocked out displayed severe abnormalities such as reduced birth rate 
and female infertility (Muramatsu et al., 2006). These results suggested that the functions of 
pleiotrophin and midkine overlap. The human and sheep pleiotrophin genes have been 
sequenced (Li et al., 1990) and they encode a protein of 168 amino acids. The conservation of 
pleiotrophin amino acid sequences among species is remarkable and, to the best of our 
knowledge the highest of any of the known cytokines (Li et al., 1992). Pleiotrophin/midkine 
have several functional receptors, such as anaplastic lymphoma kinase (ALK) , receptor-type 
tyrosine-protein phosphatase zeta (RPTPζ) and Notch-2 (Xu et al., 2014). Pleiotrophin 
promotes adhesion, migration, growth, and differentiation of human osteoprogenitor cells 
(Yang et al., 2003). As such it may be a good target molecule to functionalise scaffolds and 
DBBM materials. 
The present study investigated the protein and gene expression of pleiotrophin family of 










1.1 Bone anatomy and biology 
1.1.1 Normal bone 
Maxillary and mandibular bones are formed by membranous bone formation (Clarke, 2008). 
Alveolar processes develop during tooth formation and eruption to support the teeth in their 
sockets (Schroeder, 1986), and  are composed of cortical and trabecular bone. In health, cortical 
bone is dense and solid and surrounds the marrow space. However, trabecular bone is much 
more porous and the trabecular plates and rods are spread within the bone marrow. Bone is 
composed of 50-70% mineral (mostly hydroxyapatite), 20-40% organic matrix, 5-10% water 
and <3% lipid (Clarke, 2008). The Haversian system or osteon is the structural unit of bone 
and consists of a central vascular channel surrounded by concentric layers of mineralised bone 
(Atwood, 1963).  
 
1.1.2 Bone modelling and remodelling 
Bone modelling is the process by which bones are shaped or reshaped by the independent action 
of osteoblasts and osteoclasts. During bone modelling, bone formation and resorption are not 
tightly coupled. Bones widen with aging in humans and it is well recognised that physical 
activity can stimulate it. Bone modelling defines skeletal development and growth but 
continues throughout life.  
Bone remodelling is a process in which osteoclasts and osteoblasts work in a coupled manner 
to reshape a bone surface. It involves continuous removal of old bone and replacement with 
newly synthetised matrix and subsequent mineralisation of the matrix to bone. Remodelling 
begins before birth and continues to death (Clarke, 2008; Langdahl et al., 2016). 
 
1.1.3 Preosteoblasts, osteoblasts and osteocytes 
Bone marrow contains a small population of mesenchymal stem cells that are capable of 
establishing bone formation. The differentiation of mesenchymal cells to osteoblasts is known 
to be induced by Bone morphogenetic proteins (BMPs) which are members of the 
Transforming Growth Factor-beta (TGF-β) superfamily of protein growth factors. The rate of 
replication of precursors, their differentiation toward mature osteoblasts, and the death of 
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mature cells determine the number of osteoblasts. (Canalis et al., 2003). Based on their 
function, location, and morphology, three types of osteoblasts have been identified at the bone 
surface and include: preosteoblasts, active osteoblasts and inactive (resting) osteoblast (Holtrop 
& Hall, 1990; Franz-Odendaal et al., 2006). In the mammalian system, spindle-shaped 
osteoprogenitor cells differentiate into large cuboidal active osteoblasts. Preosteoblasts, which 
are less cuboidal in shape and located at a distance from the bone surface, are recognisable by 
their expression of alkaline phosphatase (Clarke, 2008). Active mature osteoblasts have large 
nuclei, enlarged Golgi structures and extensive rough endoplasmic reticulum. They do not 
divide and are responsible for secreting type I collagen and other matrix proteins essential for 
bone formation. During osteogenesis, osteoblasts produce osteoid and differentiate into 
osteocytes embedded in the mineralised matrix in distinct lacunae (Franz‐Odendaal et al., 
2006). Throughout this process of cellular transformation, alkaline phosphatase production is 
reduced, and casein kinase II and osteocalcin are elevated (Mikuni‐Takagaki et al., 1995). 
Several factors regulate the multistep molecular pathway of osteoblast transformation to 
osteocytes. The transcription factors, RUNX2 and SP7 (Osterix), are crucial for osteoblast 
differentiation during both intramembranous and endochondral ossification (Nakashima & de 
Crombrugghe, 2003). The time taken for an osteoblast to transform into an osteocyte varies in 
different bone sites and different animals. In newborn mice, labelled osteocytes are seen in the 
periodontal surfaces of the molar root from day 10, as opposed to day 19 in the periodontal 
alveolar bone (McCulloch & Heersche, 1988; Franz‐Odendaal et al., 2006). 
 
1.1.4 Osteocytes and bone remodelling 
Several roles have been identified for osteocytes in maintaining bone metabolism. Isolated 
chick osteocytes have been shown to support osteoclast activation and formation, in the 
absence of any osteotropic factors (Tanaka et al., 1995). This capacity was also described for 
the mouse osteocyte-like cell line MLO-Y4. Conditioned media from MLO-Y4 cells supports 
bone formation and osteoblast differentiation (Heino et al., 2004). These findings showed that 






1.1.5 Osteoclasts and bone remodelling 
Activated multinucleated osteoclasts are created by the differentiation of 
monocyte/macrophage precursor cells which leads to the initiation of bone remodelling. 
Osteoclast differentiation and activation is regulated by the family of tumour necrosis factor 
(TNF) receptor (TNFR)/TNF-like proteins: osteoprotegerin (OPG), receptor activator of 
nuclear factor (NF)-κB (RANK) and RANK ligand (RANKL) (Boyle et al., 2003). The bone 
resorption by osteoclasts in a remodelling cycle takes about two to four weeks (Iñiguez-Ariza 
& Clarke, 2015). 
 
1.2  Alveolar ridge preservation  
The alveolar processes undergo significant structural changes when teeth are lost. The dynamic 
nature and magnitude of these changes, when studied in animal models, are discussed later in 
this review. Physiological changes affecting hard and soft tissues, may affect the outcome of 
future treatments aimed at restoring missing teeth. A major factor in the success of prosthetic 
restorations is the volume of bone availability for ideal implant placement, which when limited 
can result in a compromised aesthetic result (Vignoletti et al., 2012). Filling the tooth socket 
with different grafting materials, with or without a membrane, has been proposed to counteract 
these tissue changes following tooth extraction (Fickl et al., 2008a; Fickl et al., 2008b). 
Alveolar ridge preservation with socket grafting, when compared to tooth socket healing 
without grafting, has been associated with less horizontal and vertical bone resorption. The 
most favourable outcome in terms of horizontal ridge preservation has been achieved when the 
bone grafting materials (xenograft or allograft) were covered with an absorbable collagen 
membrane (Troiano et al., 2018; Avila-Ortiz et al., 2019). Extraction sockets with damaged 
walls compared to extraction sockets with intact walls, benefit significantly more from alveolar 
ridge preservation (Bassir et al., 2018). It was also shown that significantly less augmentation 
at implant placement was needed in preserved tooth sockets (Horváth et al., 2013); and 
radiographic marginal bone loss, which has been widely used to investigate implant success, is 





1.2.1 Tooth socket healing 
Clinically, socket healing is defined as the closure of the socket entrance by epithelialised soft 
tissue. Bone in-fill can be observed 3 to 6 months post-extraction on radiographic images 
(Schropp et al., 2003). Dimensional changes have consistently been observed in alveolar bone 
following tooth extraction in humans (Atwood, 1963; Pietrokovski & Massler, 1967; 
Pietrokovski et al., 2007). The changes in the extraction socket during healing have also been 
studied in different animal models such as rabbits (Kuboki et al., 1988), rats (Lin et al., 1994; 
Kanyama et al., 2003; Sato & Takeda, 2007) and dogs (Cardaropoli et al., 2003; Cardaropoli 
et al., 2005).  
 
1.2.2 Bone remodelling in the tooth socket 
Socket healing is a process of three overlapping phases. Initially, a blood clot and granulation 
tissue form in the “inflammatory phase”. The granulation tissue is gradually replaced with a 
provisional connective tissue matrix and the “proliferative phase” begins. In this phase, new 
immature woven bone is formed. Finally, in the “modelling and remodelling phase” the 
immature tissue is removed and replaced by a mature bone new matrix (Amler, 1969; 
Cardaropoli et al., 2003). Bone modelling occurs earlier than bone remodelling and about two-
thirds of the modelling process occurs within the first 3 months of healing (Schropp et al., 
2003). Bone remodelling in humans is however highly variable among individuals and may 
take several months (Trombelli et al., 2008). Bone modelling and remodelling is three to five 
times faster in dogs than in humans (Council, 1981; Kimmel & Jee, 1982; Araújo et al., 2015a).  
In the dog model simultaneous resorption of inner and outer surfaces of the socket walls 
resulted in considerable vertical buccal bone reduction after just eight weeks of healing. 
(Araújo & Lindhe, 2005).  
 
1.2.3 Stimulating factors in socket healing 
Growth factors play an important role in the regulation of cellular activities. They frequently 
bind with high affinity to extracellular matrices, especially heparin-like carbohydrates of 
heparan sulfate proteoglycans (Ruoslahti & Yamaguchi, 1991). This is helpful for the 
sequestering of growth factors within tissues and their controlled release when required 
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(Lindahl et al., 1994). Studies on the tooth extraction socket in rabbits showed that cytokines 
and growth factors such as fibroblast growth factor-2 (FGF-2), vascular endothelial growth 
factor (VEGF), transforming growth factor (TGF)-β1, bone morphogenetic protein (BMP)-2, 
and platelet derived growth factor (PDGF)-A, regulate tooth socket healing. These growth 
factors have been shown to be produced and act via autocrine and paracrine mechanisms in 
response to wounding stimuli (Lalani et al., 2003; Fisher et al., 2004). Increased levels of bone 
morphogenetic protein 7 (BMP-7) have been reported during early and intermediate healing 
phases, a period of increased bone modelling and remodelling activity, and associated with the 
deposition of woven bone from provisional matrix in humans (Trombelli et al., 2008). 
 
1.2.4 Socket healing with bone graft materials 
Grafting sockets with different materials and the use of membranes have been proposed to 
prevent post-tooth extraction alveolar ridge reduction. Experimental studies in a dog model 
demonstrated that placement of the xenograft (Bio-Oss Collagen®) in the extraction socket 
failed to inhibit the modelling and remodelling process when examined after three months. 
However, the graft supported the hard-tissue formation especially in the cortical region and the 
alveolar bone profile was better preserved by compensating for the buccal bone loss (Araújo et 
al., 2008; Araújo et al., 2009). This was in line with a human study that observed a reduction 
in height of the buccal bone in grafted and non-grafted sockets after four months. While the 
cross-sectional area of the grafted sites exhibited a reduction of only 3% from their initial 
dimensions, the corresponding reduction in the non-grafted sites was 25% (Araujo et al., 
2015b). 
 
1.3 Different types of grafting materials  
The use of bone graft materials aims to facilitate bone healing. The biological rationale for 
utilisation of a bone graft is based on three different healing mechanisms: 1. Osteogenesis - the 
graft material contributes to new bone growth; 2. Osteoconduction - the graft material serves 
as a scaffold for new bone growth; 3. Osteoinduction – the graft material stimulates 
osteoprogenitor cells to differentiate into osteoblasts that then begin formation of new bone 
(Brunsvold & Mellonig, 1993). Bone materials for regenerative procedures are classified 
according to their origin, as discussed below. 
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1.3.1 Autogenous grafts 
Autogenous bone grafts are derived from intraoral or extraoral sites of the same individual and 
are thought of as the ‘gold standard’. As a grafting material they possess the essential 
components to achieve osteogenesis, osteoinduction and osteoconduction. However, autografts 
require an additional surgical procedure which can cause complications such as donor site 
injury and morbidity (Darby, 2011). They are limited to restricted donor sites and the graft may 
show an unpredictable resorption rate (Johansson et al., 2001; Nkenke & Neukam, 2014). 
 
1.3.2 Allografts  
Allografts refers to tissue that is harvested from living human donors or cadavers. Allografts 
are devitalised and often sterilised, mainly through the processes of decalcification, 
deproteinisation, irradiation and/or freeze-drying. Although all cellular material is removed 
during the processing stages, they still contain bone stimulating factors such as BMPs and the 
grafts show both osteoconductive and osteoinductive properties (Delloye et al., 2007). These 
materials are available as fresh frozen bone (FFB), freeze-dried bone allograft (FDBA) or 
demineralised freeze-dried bone allograft (DFDBA)(Darby, 2011). Allografts have a higher 
failure compared to autografts, which has been associated with activation of major 
histocompatibility complex (HMC) antigens (Delloye et al., 2007). Other concerns relating to 
allografts include the risk of transmission of infectious disease, loss of biologic and mechanical 
properties due to their processing, increased cost and availability (Zwingenberger et al., 2012). 
 
1.3.3 Xenografts 
Disadvantages inherent in autogenous and allogenic bone harvesting procedures directed 
research activities toward the use of bone substitute materials as an alternative. Xenografts are 
defined as a bone graft material obtained from another species such as bovine, porcine, equine 
or coral (Sheikh et al., 2017). They generally act as a scaffold for osteogenic cells, promoting 
the migration and subsequent attachment of these cells, thus showing osteoconductive 
capabilities (Thaller et al., 1993; Hämmerle et al., 1997). Bio-Oss® (Geistlich, Switzerland) is 
a DBBM that is currently the most commonly used in alveolar bone grafting.  
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1.3.3.1 Different animal and human studies on Bio-Oss® 
Bio-Oss® can be used with or without barrier membranes. It is available in two different particle 
sizes including small Bio-Oss® granules (0.25-1 mm) and large Bio-Oss® granules (1-2 mm). 
Small-size granules are recommended clinically for alveolar ridge preservation and were used 
in this study.  
Bio-Oss® has been studied extensively in both preclinical animal studies and human trials. The 
biological effects of Bio-Oss® on bone healing have been investigated in rabbit calvarial bone 
(Thaller et al., 1993; Hämmerle et al., 1997). It has also been assessed radiographically and 
histologically in sinus grafts conducted in chimpanzees (McAllister et al., 1999). The effect of 
Bio-Oss® on guided bone regeneration around implants has been investigated in monkeys 
(Hämmerle et al., 1998), and the cellular responses of bone cells to Bio-Oss® studied in rats 
(Tapety et al., 2004). There are multiple studies investigating the healing response of bone 
defects and tooth implants to Bio-Oss® in dogs (Wetzel et al., 1995; Clergeau et al., 1996; 
Berglundh & Lindhe, 1997; Araújo & Lindhe, 2009). Also Bio-Oss® has been studied for use 
in sinus lifting (Smith et al., 2018), bone regeneration (Liu et al., 2013) and alveolar ridge 
preservation (Lander, 2016) in sheep. In human studies, the clinical and radiographic outcomes, 
as a result of Bio-Oss® application, have been examined in alveolar ridge preservation (Mardas 
et al., 2010), guided bone regeneration and implants (Zitzmann et al., 1997; Jung et al., 2013) 
and guided tissue regeneration (Camelo et al., 1998). 
 
1.3.3.2 Histological and clinical findings for Bio-Oss® in healing  
Sites grafted with Bio-Oss® showed greater microvascular density after six months. There was 
also a higher percentage of vessels and stromal cells positive for the angiogenic growth factor 
VEGF in the areas undergoing new bone formation, compared to areas with mature bone, 
suggesting a relationship between angiogenesis and osteogenesis (Degidi et al., 2006). It has 
been suggested that the microstructure and porous morphology of Bio-Oss® can enhance 
formation of new bone by maintaining space (Tapety et al., 2004). 
Bio-Oss® particles when used for grafting have been shown to be biocompatible and well 
incorporated within the remodelling tissue (Artzi & Nemcovsky, 1998). Histopathology 
conducted nine months following tooth extraction and application of Bio-Oss® within human 
tooth sockets, found newly formed bone consisting of mainly cellular woven-bone and 
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amorphous DBBM in the coronal area and lamellar bone only in the apical region. On average, 
the tissue consisted of 64% bone tissue, 23% connective tissue and 30% graft material (Artzi 
et al., 2000). The presence of Bio-Oss® particles at six months up to 42 months post-grafting 
in sockets, showed that these particles are resistant to resorption (Skoglund et al., 1997; Artzi 
& Nemcovsky, 1998). Clinical evidence supports the use of DBBM to enhance socket healing, 
preserve alveolar ridge and improve outcomes for implants (Bartee, 2001). One to four-year 
follow-up of the implants placed in grafted sockets showed 95 to 100% survival rate. The 
marginal bone loss in these implants was significantly lower than the implants placed in non-
grafted healed sites (Ramanauskaite et al., 2019). 
The mechanism of incorporation of Bio-Oss Collagen® in the host tissue involves different 
healing phases. In the first step, the biomaterial was surrounded by the fibrin network of the 
coagulum, and polymorphonuclear cells (PMNs) migrated to the surface of Bio-Oss® particles. 
In the second phase, the PMN cells were replaced by multinuclear osteoclasts. One to two 
weeks later, osteoclasts disappeared from the bone granules. In the next phase, osteoblasts 
attached to the bone granules and laid down bone mineral in collagen bundles forming a 
provisional matrix of integrated Bio-Oss® particles (Araújo et al., 2010). However, biopsies 
taken three to six months post-grafting with Bio-Oss® report that the graft particles were mainly 
surrounded with connective tissue and only isolated graft particles were in contact with bone 
(Becker et al., 1998). Human socket samples seven months post-grafting with Bio-Oss® showed 
that only 40% of the circumference of the graft particles were in contact with woven bone; and 
the central portion of the augmented bone was occupied by connective tissue which included a 
small amount of new bone and the graft particles (Carmagnola et al., 2003). Direct bone to 
graft contact was much higher (85%) in monkey samples six months post-grafting with Bio-
Oss® (Hämmerle et al., 1998). An attempt at horizontal and vertical augmentation of large one-
wall defects with Bio-Oss® in dogs, failed to show bone formation and the graft particles were 
encapsulated within a well-defined connective tissue (Carmagnola et al., 2000). Long-term 
healing of Bio-Oss® grafted into murine alveolar bone sites displayed the histological findings 
of bone healing typically found in human and animal models. However, gene expression 
analysis of sites with Bio-Oss® showed significant expression of the genes associated with bone 
haemostasis and osteoclast function. This supports the concept that osteoconductive bone 
materials, despite their apparently inert osseous phenotype, are biologically active substances 




1.3.4 Alloplasts (synthetic bone graft substitutes) 
Alloplasts or synthetic bone graft materials are composed of inert materials. Calcium sulphate, 
calcium phosphate ceramics, calcium phosphate cements, bioactive glass or combinations 
thereof are most commonly used as synthetic bone substitutes (Zwingenberger et al., 2012). As 
these grafts are completely synthetic, there is no donor site and no limitations in the quantity 
available for grafting and no risk of disease transmission (Darby, 2011). Mechanical properties 
are major disadvantages of synthetic bioceramics and limit their use in load- bearing 
applications (Huang et al., 2014). The fragility and unpredictable absorption rates of CaP bone 
substitutes results in less favourable clinical outcome and their limited clinical application 
(Haugen et al., 2019). 
 
1.4 Barrier membranes and their use in tooth socket preservation 
Barrier membranes are commonly used to secure the bone graft within the defect, as well as to 
guide regeneration of the soft tissues over the defect. They are divided into two major types: 
resorbable and non-resorbable. Cellulose and expanded polytetrafluoroethylene (ePTFE) were 
the first non-resorbable membranes. Titanium mesh was developed to reinforce membranes 
and to ensure the retention of shape. The major disadvantage of non-resorbable membranes is 
that a second surgical procedure is required for their removal. Resorbable membranes are 
biocompatible, and once positioned into the defect site they gradually degrade, without an 
additional surgery. Resorbable membranes can be divided into collagen-based and synthetic 
membranes (Wnek & Bowlin, 2008). In vitro studies comparing the cytotoxicity of resorbable 
(synthetic PLA, collagen) and non-resorbable (ePTFE) membranes in contact with fibroblasts 
and osteoblast-like cultures, indicated a slight to moderate cytotoxic reaction to e-PTFE and 
PLA membranes, while collagen membranes were highly compatible and had greater ability to 
integrate well into the connective tissue (Alpar et al., 2000). Synthetic polymers such as 
polylactic acid (PLA), poly-ε-caprolactone and polyglycolic acid (PGA), as well as their 
copolymers and derivatives, are degraded by hydrolysis in vivo that can induce a foreign body 
reaction to acidic polymers, and increase the potential for fibrous tissue encapsulation during 
wound healing (Pilipchuk et al., 2015). Hence, the dental field has moved towards the use of 
natural, protein-based collagen membranes. Collagen-based membranes are considered to be 
bioactive as they provide binding sites for migrating cells in a wound, which ultimately aids in 
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the promotion of tissue regeneration (Ferreira et al., 2012). Bio-Gide® (Geistlich, Switzerland) 
is the leading collagen membrane for oral tissue regeneration. It is a bilayer membrane with 
one compact layer covered by a dense film to prevent invasion of soft tissue into the bone 
defect (Schlegel et al., 1997). 
Comparison of sockets preserved using Bio-Oss® with or without a bioresorbable collagen 
membrane show a significantly higher osseous fraction in the group augmented with Bio-Oss® 
and the collagen membrane (Perelman-Karmon et al., 2012). 
 
1.5 Animal models 
1.5.1 The rational for using animal models to test potential therapeutics 
Animal models are extensively used to evaluate the pathogenesis of the diseases and different 
treatment modalities. The aim is to find an animal model which shows good feasibility and also 
closely resembles the human condition being investigated. There are advantages and 
disadvantages for each animal model and these factors should be carefully assessed. 
 
1.5.2 Different animal models  
Animal model selection in biological research aims to find analogues to humans with respect 
to healing response (Davidson et al., 1987). The most commonly used animal models in bone 
research are the dog, sheep, goat, pig and rabbit models. Rabbit has been commonly used for 
bone studies but shows the least similarity to human bone, with different composition and 
microstructure (Wang et al., 1998). Osteogenesis was encouraged and a significant amount of 
new bone was formed in the tibia of rabbits after creating a space and preventing soft tissue 
ingrowth using a teflon membrane (Dahlin et al., 1989). Rabbits however have limited 
application for the assessment of multiple implant materials because of their size (Pearce et al., 
2007). Despite a good similarity between pig and human bone composition (Thorwarth et al., 
2005) and the bone regeneration rate (Laiblin & Jaeschke, 1979), there are difficulties with the 
size of pigs and ease of handling. The dog is one of the most commonly used large animals for 
dental research. However, their status as companion animals has raised ethical issues regarding 
their ongoing use. The degree of similarity between the dog and human is dependent on the 
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size and the breed of the dog. The mineral density of bone is higher in dogs compared to 
humans, while the organic composition is similar. The dogs bone microstructure is also 
different to humans. In humans a bone cross-sectional view shows secondary osteonal bone 
structure with similar osteon size. Dog bone has secondary osteonal bone in a center with some 
plexiform bone adjacent to the periosteum and endosteum on each side (Wang et al., 1998). 
The mean turnover rate of bone in young adult female beagles also varies considerably 
depending on the site, being between 16% to over 300% per year. In the mandible, the annual 
bone turnover rate is between 76% in the incisal area to 108% in the rest of the mandible. In 
contrast, the average annual bone turnover rate in a young adult female human ranges between 
10-55% (Kimmel & Jee, 1982; Hernandez-Gil et al., 2006). Goats are used for research and 
are generally more accepted by the public as they are a food producing animal like sheep. 
However, goats tend to have a more inquisitive nature compared to sheep which can make 
confinement for long durations more challenging (Pearce et al., 2007). 
The relative merits of various characteristics of animal sourced bone to human bone are 
indicated in Table1.  
 
Table 1. Relative similarity between animal and human bone structure 
 Dog Pig Rabbit Sheep/Goat 
Macrostructure ** ** * *** 
Microstructure ** ** * * 
Bone composition *** *** ** ** 
Bone remodelling ** *** * ** 
*least similar, ** moderately similar, *** most similar, table adapted from Pearce et al. 2007 
(Pearce et al., 2007). 
 
 
1.5.3 Using sheep as an animal model 
There has been an increase in the use of sheep as model for bone research. Sheep are generally 
accepted by the animal research societies, are raised in large numbers, and can be used in large-
scale studies (Newman et al., 1995). Ease of handling, similar body weight, bone mineral 
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composition and remodelling rate to human are all advantages (Turner, 2007). Moreover, the 
healing and regeneration rate of bone/tissue is similar to that found in the human (Cipitria et 
al., 2013). There are however differences with sheep having a bone structure consisting of 
primary osteons less than 100 µm in diameter, whereas humans have, at maturity, a large 
complement of secondary bone (Eitel et al., 1981). Mandibular bone remodelling and bone 
resorption also tend to increase in sheep with aging (Atkinson et al., 1982), and they have 
significantly higher density compared to human bone (Nafei et al., 2000). Bone ingrowth into 
porous implants and rate of remodelling in the ovine model has been observed to be similar to 
human bone regeneration (Willie et al., 2004). In dentistry the sheep model has been used to 
study extraction socket healing following alveolar ridge preservation (Lander, 2016; Liu et al., 
2016), periodontal defects (Baharuddin et al., 2015), maxillary sinus augmentation (Smith et 
al., 2018) and implant treatments (Vlaminck et al., 2008; Duncan et al., 2015; Duncan et al., 
2016; Duncan et al., 2018). In summary, sheep have been described as excellent animal model 
to study the biocompatibility of bone augmentation biomaterials (Nuss et al., 2006). 
 
1.5.4 Study of pleiotrophin and midkine in animal species 
Pleiotrophin was initially isolated and sequenced in bovine uterus and neonatal rat brain (Li et 
al., 1990; Merenmies & Rauvala, 1990). Homologues have been reported in other species such 
as human, chicken, mouse, fish, frogs and insects (Englund et al., 2006). 
 
1.6 Structure and function of pleiotrophin 
Pleiotrophin (PTN), also known as heparin binding growth factor (HBGF-8) and heparin-
binding growth-associated molecule (HB-GAM), is a multifunctional cytokine. It is an 18-kDa 
protein and has 168 amino acids (Li et al., 1990). Although PTN is detectable in many organs 
including brain, prostate and testis, this lysine-rich peptide is mostly associated with the 
extracellular matrix of neuronal cells and bone cells (Li et al., 2005a). It shares nearly 55% 
sequence identity with midkine and they have similar functions including promoting cell 
survival, enhancing cellular growth and stimulating migration of embryonic neurons and 
osteoblasts (Muramatsu, 2002). These two genes are therefore referred to as the PTN family of 
developmentally regulated genes (Li et al., 1992). PTN has large basic surfaces on both of its 
structural domains (the N-terminal and C- terminal regions). The residues in the hinge segment 
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connecting the domains have significant contacts with the C-terminal domain.  The C-terminus, 




Figure 2. Pleiotrophin 3D structure; Photo adapted from NCBI website 
(www.ncbi.nlm.nih.gov) 
 
1.7 Structure and function of midkine 
Midkine (MK) is a 13 kDa heparin-binding cytokine/growth factor. It is a lysine-rich protein 
and has several common features to pleiotrophin. MK is structurally divided into two domains, 
with short tails at either ends and a connecting hinge region (Iwasaki et al., 1997). Both 
domains consist of three antiparallel beta-sheets and the two heparin-binding sites are located 
in the C-terminus. Most of the biological activities have been attributed to the C-terminal 
domain. The N-terminal domain plays a role in maintaining structural stability. Midkine cDNA 
was first isolated from a spontaneous mouse teratocarcinoma treated with retinoic acid 
(Muramatsu, 2003). Further research has shown it to be strongly expressed during 
embryogenesis especially at mid-gestation (Kadomatsu et al., 1990), during ischemia within a 
cerebral infarct (Yoshida et al., 1995) and within carcinoma tissues (Tsutsui et al., 1993). 
Therefore, this protein and its inhibitors have been identified as potential therapeutics for many 
diseases (Ergüven et al., 2012). Interestingly, MK is overexpressed in association with more 







Figure 3. Midkine 3D structure. A. N-terminal domain of midkine B. C-terminal domain of 
midkine. Photos adapted from NCBI website (www.ncbi.nlm.nih.gov) 
 
1.8 Pleiotrophin and midkine receptors 
Different receptors have been identified during studies which aimed for a better understanding 
of the functions of the PTN family. These receptors include: receptor-type protein-tyrosine 
phosphatase ζ (RPTPζ), anaplastic lymphoma kinase (ALK), integrins, neuroglycan C (NGC), 
low-Density lipoprotein (LDL) receptor related protein (LRP), syndecan (SDC) and Notch (Xu 




Figure 4. Schematic structure of number of receptors involved in PTN signalling. Image 





1.8.1 Receptor type protein tyrosine phosphatase zeta (RPTPζ) and interactions 
PTN is the most potent known natural ligand of RPTPζ and its activity is mostly attributed to 
interactions with the chondroitin sulfate (CS) proteoglycan in RPTPζ. The C-terminal tail of 
PTN is essential for maintaining stable interactions with chondroitin sulfate A, the type of CS 
commonly found on RPTPζ. This could possibly explain why truncated PTN, which lacks the 
C-terminal tail, is unable to signal through RPTPζ (Ryan et al., 2016). Similarly, the C-terminal 
half of midkine exhibits full binding activity with RPTPζ. RPTPζ to midkine binding was 
inhibited by the presence of PTN. This suggests that PTN and MK share a common binding 
site on RPTPζ (Maeda et al., 1999). 
The high affinity binding of PTN and MK to RPTPζ has been shown to result in inhibition of 
RPTPζ phosphatase activity (Kuboyama et al., 2016). RPTPζ -deficient mice displayed reduced 
bone formation and decreased trabecular bone volume. Likewise, RPTPζ –deficient osteoblasts 
had a diminished potential to form osteocyte-like cellular extension. These provide evidence 
that RPTPζ has a regulatory role in bone formation and remodelling (Schinke et al., 2008).  
RPTPζ is abundantly expressed in neural cells. A number of available studies demonstrate that 
RPTPζ is overexpressed in different cancer cells, and has functions in cell proliferation, cell 
adhesion and migration, epithelial-to-mesenchymal transition, and cancer stem cells. RPTPζ is 
involved in cell survival signalling and is a positively correlated prognostic marker for several 
tumours. It may therefore be a therapeutic target in several kinds of cancers (Xia et al., 2019). 
 
1.8.2 Anaplastic Lymphoma Kinase (ALK) receptor and interactions 
Protein kinases regulate cell cycle progression and apoptosis, differentiation, development, the 
immune response and neural system function (Manning et al., 2002). Anaplastic Lymphoma 
Kinase (ALK) is a receptor protein-kinase (RPK) of the insulin receptor super family. Like 
other RPKs, it has an extracellular ligand‐binding region, a transmembrane‐spanning domain 
and a cytoplasmic catalytic region (Pulford et al., 2004). It was initially identified because of 
its involvement in anaplastic large cell lymphoma (ALCL), a type of non-Hodgkin lymphoma 
involving T-cells (Pulford et al., 2004). ALK is mostly expressed in the embryonic nervous 
system and down-modulated after birth. It is also involved in the pathogenesis of different 
cancers (Iwahara et al., 1997; Morris et al., 1997). Currently a number of ALK inhibitors have 
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demonstrated promising results for the treatment of ALK-positive malignancies (Roskoski Jr, 
2013). 
ALK has been proposed as a receptor for PTN. A comparison of the expression of ALK mRNA 
in ten different human fetal brain cell lines with their growth in response to PTN indicated a 
growth response to PTN in the presence of ALK mRNA expression. Also, ALK-negative cells 
failed to show a growth response to PTN (Stoica et al., 2001). ALK was also identified to be a 
receptor for MK. However, MK demonstrated >5-fold lower affinity for ALK compared to 
PTN. MK binds directly to ALK and a cross-competition between MK and PTN for binding to 
ALK has been demonstrated (Stoica et al., 2002). 
Interestingly, PTN requires RPTPζ to stimulate tyrosine phosphorylation of ALK. The direct 
interaction of PTN and ALK does not induce phosphorylation of ALK, but as a consequence 
of the inactivation of RPTPζ by PTN, autophosphorylation and autoactivation of ALK rapidly 
follow (Perez-Pinera et al., 2007). PTN failed to activate ALK in those cells that do not express 
RPTPζ. So ALK is indirectly activated by PTN through the PTN/RPTPζ signalling pathway 
(Deuel, 2013). Earlier studies found MK associates with PTN/RPTPζ, suggesting the 
possibility MK also signals through RPTPζ (Maeda et al., 1999).  
 
1.8.3 Notch-2 receptor and interactions 
Notch is a highly conserved, intracellular signalling pathway controlling various cell fate 
decisions and has five ligands (Jagged-1, Jagged-2, Delta-like-1, Delta-like-3, Delta-like-4) 
and four receptors (Notch1- 4) (Youngstrom et al., 2017). The specific ligands bind to the four 
Notch receptors to induce proteolytic cleavage and release of intracellular domain, which enters 
the cell nucleus and activates specific transcription factors (Van Tetering & Vooijs, 2011). 
Notch signalling may interact with other signalling pathways such as Wnt and BMP in 
osteoblasts, osteocytes and osteoclasts during skeletal development (Regan & Long, 2013). 
MK was shown to be a ligand for Notch-2 in a yeast hybridisation assay and by co-precipitation 
of MK and Notch-2 in human keratinocytes. Both MK and MK-C (C-terminal truncated 
isoform) have strong affinity with the N-terminal region of the Notch-2 receptor (Huang et al., 
2008). There is no direct evidence for physical affinity of PTN with Notch receptors (Xu et al., 
2014). However, the Notch receptor was found to be active during PTN mediated effects on 
bone marrow and progenitor cell expansion (Himburg et al., 2010). 
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Evidence shows that both activation and inactivation of Notch pathway signalling has impacts 
on bone remodelling. Identification of Notch-2 mutations in individuals with Hajdu-Cheney 
syndrome (HCS), which presents with marked osteoporosis, has highlighted its human 
relevance (Yorgan et al., 2016). 
In vitro studies examining the relationship between the Notch pathway and osteoblast 
differentiation have provided conflicting results. Although a number of studies have shown 
that Notch-1 overexpression suppresses osteoblastogenesis (Sciaudone et al., 2003; Shindo et 
al., 2003; Deregowski et al., 2006), several other studies suggest a stimulatory effect of Notch-
1 in BMP2-induced osteoblast differentiation (Tezuka et al., 2002; Nobta et al., 2005). 
When components of the Notch-1 and Notch-2 signalling pathways were removed in mice, 
skeletogenic mesenchyme markedly increased trabecular bone mass, while the mesenchymal 
progenitors were undetectable in the bone marrow. This resulted in the development of severe 
osteopenia as the animals aged. This suggests that bone formation in vivo may be enhanced by 
short pulses of Notch inhibitors. Depletion of Notch signalling in osteoblasts also enhances 
osteoclastogenesis from bone marrow macrophage progenitors and thus increases bone 
resorption (Bai et al., 2008; Hilton et al., 2008). Overall it appears that Notch expression in 
cells of osteoblastic lineage is dependent on the maturation stage of cells. Notch expression in 
immature osteoblasts impairs osteoblast differentiation, causing osteopenia and in more mature 
cells from the osteoblast-lineage, regulates osteoclastogenesis indirectly. Notch expression in 
osteocytes however causes an initial suppression of bone resorption and an increase in 
trabecular bone mass (Hilton et al., 2008; Canalis et al., 2013b). 
Notch signalling directly or indirectly regulates angiogenesis through the VEGF receptors 
(Kofler et al., 2011). Post-traumatic bone healing is found to be positively regulated by Jagged-
1-mediated Notch signalling. Jagged-1 is a principle Notch ligand in bone and is a potent 
osteoinductive protein (Youngstrom et al., 2017). Clinical therapeutic options can be developed 
for bone regeneration by using Notch signalling and efficient coupling of osteogenesis and 
angiogenesis (Luo et al., 2019). 
 
1.9 Functions associated with pleiotrophin and midkine  
Mouse models with either PTN or MK genes knocked out, exhibit similar moderate 
abnormalities (Sakurai et al., 2001; Kaplan et al., 2003; Ezquerra et al., 2008). Mice with both 
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PTN and MK simultaneously knocked out displayed severe abnormalities such as reduced birth 
rate and female infertility (Herradon et al., 2005; Muramatsu et al., 2006; Zou et al., 2006; Sone 
et al., 2011). These results suggests that the function of PTN and MK overlap (Xu et al., 2014). 
Interestingly, PTN expression in midkine deficient mice was significantly elevated, but not vice 
versa, suggesting that PTN gene expression follows MK gene expression; and that during 
development that the absence of MK can be compensated for by increasing in PTN expression 
(Herradon et al., 2005). The functions of PTN and MK are discussed as follows. 
 
1.9.1 Role of pleiotrophin and midkine in mitogenicity and cellular survival 
Pleiotrophin was first discovered as a proliferative factor for fibroblasts, involved in the 
regulation of cell growth. Extracted bovine uterine HBGF-8 showed substantial mitogenic 
activity for fibroblasts, epithelial, and endothelial cells (Milner et al., 1989).  
Examination of MK mitogenicity on fibroblasts showed the dose of MK required for maximum 
growth was 5 times more than the dose required for PTN. MK weakly promoted growth of 
NIH/3T3 cells (cells from the Japanese Cancer Research Resource Bank), but the mode of 
cellular induction may be different to that of FGF and PTN. Moreover, MK showed no 
mitogenic activity to normal rat kidney (NRK) cells (Muramatsu & Muramatsu, 1991). 
 
1.9.2 Role of pleiotrophin and midkine in oncogenicity and angiogenesis 
As an angiogenic growth factor, PTN has an impact on physiological and pathological 
angiogenesis by inducing the proliferation and migration of endothelial cells (Papadimitriou et 
al., 2009). The main receptor for PTN’s angiogenic activity is believed to be the protein 
tyrosine phosphatase zeta (RPTPζ) transmembrane receptor (Fukada et al., 2006; Wang, 2020). 
A number of angiogenic growth factors that enhance angiogenesis in the early stages of bone 
repair have been identified. These include vascular endothelial growth factor (VEGF), 
fibroblast growth factors (FGFs), platelet derived growth factor (PDGF), bone morphogenetic 
proteins (BMPs) and transforming growth factor beta (TGF-β) (Pountos et al., 2014). 
PTN’s oncogenic role is inferred by its elevated expression in different cancer cells including 
cancer of breast, prostate, pancreas, stomach, lung, colon, ovary and glioblastoma (Wang, 
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2020). The increased expression of PTN and MK in different human malignancies, make them 
promising tumour markers and also putative targets for cancer therapy (Muramatsu, 2002). 
Higher expression levels of MK found in many tumours, have been associated with poor 
prognosis. This is the opposite to PTN where low expression is correlated with a poor prognosis 
(Kadomatsu, 2005). It is apparent that MK and PTN proteins may function quite differently in 
cancer compared with angiogenesis in healing. In particular, midkine enhances tumour 
angiogenesis, tumour growth and invasion (Kadomatsu et al., 1997), and is thus associated with 
poor outcomes.  
 
1.9.3 Role of pleiotrophin and midkine in inflammation and injury 
MK and PTN are expressed in chronic inflammatory conditions such as atherosclerosis, 
rheumatoid arthritis, models of autoimmune encephalitis and ischemia-reperfusion injury 
(Sorrelle et al., 2017). 
PTN and MK expression increases upon ischemic injury. Elevated expression of PTN 
following injury in different organs such as brain, heart, liver and bone marrow has been 
reported. PTN is also known to activate macrophages as part of the immune response (Wang, 
2020). Upon ischemic injury to blood vessels, MK recruits inflammatory leukocytes and 
neutrophil, and these cells secrete factors promoting the migration of smooth muscle cells and 
trigger the formation of neointima (Muramatsu, 2002). This activity is important in tissue repair 
and defence against infection (Takada et al., 1997). 
 
1.9.4 Role of pleiotrophin and midkine in differentiation 
Pleiotrophin has been identified as a factor promoting the growth and maturation of rat brain 
(Rauvala, 1989). Outside the brain, it is involved in morphogenesis of tissues that derived from 
mesenchymal-epithelial interactions (Vanderwinden et al., 1992; Mitsiadis et al., 1995; Sakurai 
et al., 2001). 
As a growth and differentiation factor, MK plays an important role in bone development and 
remodelling. A high bone mass phenotype has been reported in MK-deficient mice (Neunaber 
et al., 2010). MK has negative effect on the response of osteoblasts to mechanical loading and 
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it induces pro-chondrogenic, pro-angiogenic and pro-inflammatory effects (Haffner-Luntzer et 
al., 2014). 
 
1.9.5 Role of pleiotrophin and midkine in stem cells renewal 
Systemic administration of PTN to irradiated mice caused a substantial expansion of bone 
marrow stem and progenitor cells in vivo (Himburg et al., 2010). Mice with the PTN gene 
knocked out displayed a significant decrease in bone marrow hematopoietic stem cells content 
and impaired hematopoietic regeneration following myelosuppression. In agreement with this 
finding, mice lacking the RPTPζ receptor, which is inactivated by PTN, exhibited significant 
expansion of the BM HSCs in vivo. These results suggest an essential role for PTN in regulating 
hematopoietic stem cell regeneration (Himburg et al., 2012). 
MK has been shown to play a significant role in embryonic stem cells (ESC) renewal. In 
addition, the MK/RPTPζ signalling pathway maintains the pluripotency of ESCs (Yao et al., 
2010). 
 
1.10 Pleiotrophin and bone formation/repair 
Pleiotrophin plays an important role in bone formation. It has the ability to promote adhesion, 
migration, growth and differentiation of human osteoprogenitor cells (Lamprou et al., 2014). 
As such it may be a good target molecule to functionalise scaffolds for DBBM materials (Yang 
et al., 2003). Different cell types act as the source of PTN, for example chondrocytes during 
prenatal endochondral ossification, osteocytes of the lamellar bone during postnatal bone 
growth, and osteocytes of the injured bone during post-arthritic ossification. Under normal 
conditions, PTN is not expressed in adult bone (Li et al., 2005a). However, it is upregulated on 
the surface of damaged bone and the induced osteoblasts deposit new osteoid as part of the 
repair process (Imai et al., 1998). In a fracture model conducted in rats, the osteoblasts, 
endothelial cells and fibroblasts were all shown to strongly PTN positive in the newly formed, 
woven bone (Petersen et al., 2004). PTN deficient mice showed low bone formation, affecting 
mainly the weight-bearing long bones. The limitation of this growth retardation to weight-
bearing bones indicates that the osteogenic effect of PTN may be linked to mechanical stress 
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in bone. PTN was localised around osteocytes and their processes and it was suggested that 
PTN could be an osteocyte-derived factor (Imai et al., 2009). 
 An in vitro study has shown that a cDNA clone with the same sequence as PTN could be 
isolated from the murine osteoblastic cell line MC3T3-E1, in mouse calvarial osteoblast-
enriched cells, and in mouse brain tissues. This suggested that this protein (PTN) has a 
fundamental role in bone and brain function (Tezuka et al., 1990).  
In developing rat bone, pleiotrophin was found to be strongly expressed in the cartilage 
template and was localised in sites where osteoblast precursors were recruited for deposition 
of osteoid in vivo (Imai et al., 1998). While PTN over-expression in bone tissues had a moderate 
enhancing effect on bone development at the early stages, prolonged PTN over-expression 
resulted in more brittle bone later in life (Li et al., 2005a). The importance of PTN in regulation 
of fracture healing was also shown in a human study. As opposed to the relatively low serum 
level of PTN in non-injured adult, a prolonged increase in serum level of PTN during the 
process of fracture healing and remodelling was observed. This was associated with an increase 
in serum level of angiogenic cytokines which reached the peak concentration during early 
fracture healing (Weiss et al., 2009).  
 
1.11 Midkine and bone formation/repair 
Recombinant human MK has been found to promote the differentiation of osteoclasts, which 
play a key role in the aetiology of rheumatoid arthritis in vitro. Interestingly, inhibition of MK 
expression suppresses the development of antibody-induced arthritis (Yamamoto et al., 2006). 
Midkine plays a role in bone remodelling. MK-deficient mice, which show the opposite effect 
to PTN-deficient mice, display an increase in trabecular bone volume at 12 and 18 months of 
age, suggesting a role of MK as a negative regulator of osteoblast function in vivo (Neunaber 
et al., 2010). MK deficient mice, in response to mechanical load on bone, show increased 
mineralising surface, mineral apposition rate, and bone formation rate. The improved 
osteoblast function was associated with an enhancement of the response to mechanical loading 
(Liedert et al., 2011). Therefore, it is reasonable to suggest that in the future, MK antagonists 
could be used therapeutically to stimulate osteoblast activity in individuals with bone loss 
disorders such as osteoporosis (Liedert et al., 2014). When a MK-neutralising antibody was 
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used in ovariectomy-induced osteoporotic mice, it improved the bone healing by increasing 
bone formation in the fracture callus (Haffner-Luntzer et al., 2016). 
 
1.12 Laboratory techniques used in this research 
1.12.1 Immunohistochemistry (IHC) as a method to assess protein expression 
Immunohistochemistry (IHC) is a technique used to localise antigen (protein) expression 
within a tissue section. In this method, positive staining is visualised using a labelled molecule. 
The advantage of this technique over other protein detection methods is the ability to correlate 
the presence of antigen with its location in a tissue (Ramos-Vara, 2011). IHC involves fixing 
tissues to preserve cellular integrity and the IHC protocol begins with antigen retrieval. 
Different processes such as pressure cooking, proteinase treatment or heating histologic 
sections in a bath of appropriate buffers are used for unmasking the antigenic sites in formalin 
fixed tissues. Samples are subsequently incubated with primary and secondary antibodies. The 
secondary antibody is typically conjugated to biotin, horseradish peroxidase, or some other tag. 
A coloured reaction product is produced due to an enzymatic reaction at the site of the antigen, 
which is then visualised for microscopic analysis (Cregger et al., 2006). 
 
1.12.2 Introduction to qRT2-PCR  
Quantitative real time polymerase chain reaction is a powerful method for measuring relative 
gene expression. The assay is based on the detection of a fluorescent signal, which represents 
the amount of product at any given point in the amplification reaction (Bustin, 2000). The 
qRT2-PCR reaction results in data in the form of a cycle threshold (Cq) for each gene. The 
number of cycles that the fluorescence reaches to a specific threshold level of detection is 
defined as Cq value. This is inversely correlated with the amount of template mRNA present 
in the reaction (Walker, 2002).  If the mRNA level of the target gene is high, the Cq value will 
be low. The process of qRT2-PCR is divided into 2 steps: 1) Reverse transcriptase conversion 
of RNA to cDNA. 2) Real-time qualification of amplified products by PCR. The detection of 
amplification is achieved by binding of fluorescent molecules that specifically interact with 
double-stranded DNA (non-specific detection) or specific probes (specific detection). The non-
specific detection technology is the most simple and cost-effective method in real-time PCR. 
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The most widely used fluorescent molecule is SYBER Green, which is a fluorochrome that 
binds to the minor grooves of the DNA double helix. The fluorescence increases as the product 
accumulates after each amplification cycle. The real-time PCR assay is fast and efficient and 
does not require post-PCR processes and is a reproducible method for quantifying gene 
expression (Hilscher et al., 2005). 
 
1.12.2.1 Importance of using reference genes in analysis of the qPCR data  
Reference genes (housekeeping genes) refers to the genes that are constantly expressed to 
maintain cellular function (Warrington et al., 2000). The expression of reference genes may be 
constant or varying in a given situation. It has been concluded that these genes are not only 
involved in basal cell metabolism but also take part in other functions. As a result, 
housekeeping genes should be used for internal controls (Thellin et al., 1999). RNA from each 
experiment should be quantified and then analysed for the most suitable control and that 
exhibits low modulation (Suzuki et al., 2000). Variation in the amount of starting material 
between samples results in errors in the quantification of mRNA transcripts. This leads to the 
misinterpretation of the expression of the genes of interest when the samples have been 
obtained from different individuals (Lorkowski & Cullen, 2006). The accepted method to avoid 
this error is to normalise the values by using reference genes as an internal  standard (Bustin, 
2000). 
1.13 Summary 
The present research evaluated of the expression of osteogenic differentiation genes and 
pleiotrophin expression in a sheep model of tooth socket healing. The first objective of the 
research was to investigate bone healing, with and without a grafting material, following tooth 
extraction in a sheep model. This was achieved by comparing the H&E stained sections of the 
non-grafted and grafted sockets. The second objective was to investigate the role of the growth 
factor family of pleiotrophin/midkine and their receptors anaplastic lymphoma kinase (ALK), 
receptor-type tyrosine-protein phosphatase zeta (RPTPζ) and Notch-2, during osteogenesis 
with and without a grafting material, after tooth extraction in a sheep model. 
Immunohistochemistry and qRT2-PCR were used to localise pleiotrophin in tooth sockets 
healing with and without Bio-Oss®. Samples from the tooth sockets were collected 4, 8 and 16 
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week post-surgery. Immunohistochemistry was conducted using antibodies for pleiotrophin 
and midkine, and their receptors. 
This study examined bone regeneration in ungrafted and Bio-Oss® grafted tooth socket sites 
using a sheep model. This study was the first in vivo study to investigate the expression of 
pleiotrophin in association with a grafting material and bone regeneration. Pleiotrophin has 
properties consistent with being a promising growth factor to enhance bone repair and 
regeneration and this study aimed to provide the in vivo biological expression profiling which 
would underpin its development. 
 
1.14 Hypotheses 
1.  Pleiotrophin family protein ligands and receptors will be detected in alveolar tooth sockets 
with and without grafting with Bio-Oss®/Bio-Gide®, during osteogenesis in a sheep model. 
2.  Bone grafting will enhance gene expression of pleiotrophin family of cytokines in a sheep 
model of tooth socket healing 
 
1.15 Aims of the study: 
1.  To investigate bone healing with and without a grafting material following tooth extraction 
in a sheep model 





 Materials and methods 
2.1 Experimental approach and animal surgery 
2.1.1 Selection of animals 
Ethical approval was obtained from the University of Otago Animal Ethics Committee 
(75/2017). The investigators involved in the surgical component of the project attended and 
completed the necessary training sessions through the Animal Welfare Office at the University 
of Otago.  This research report conforms to the ARRIVE guidelines 2.0 for reporting animal 
research (Percie du Sert et al., 2020). This study employed 3 groups of 10 Romney-cross ewes 
(total of 30 sheep). Animals were randomly selected from a larger pool at the AgResearch 
Invermay farm (Mosgiel, Dunedin, New Zealand). Sheep were kept in approved indoor housing 
at the research facility for a minimum of 7 days prior to the planned surgery, for animal 
selection, identification and acclimatisation. The inclusion criteria consisted of female full-
mouth barren ewes with a minimum weight of 75 kg and age of 3.5 years. Animals that were 
underweight, pregnant or with lamb(s) at foot or that had foot rot or broken-mouth periodontitis 
(as shown by loss of one or more incisor tooth) were excluded. All animals used in the study 
were given a unique identifier (plastic ear tag) prior to surgery. 
 
2.1.2 Sample size  
Previous studies have shown eight sheep per group is the minimum number required to 
demonstrate statistically significant results for morphometric analysis of bone regeneration, 
where p<0.05 and CI is 95% (Liu et al., 2016). The use of 10 sheep per group is based on 
previous experience with sheep models which suggests, were for unrelated reasons, one or 
more of the animals (~10% dropout) may become ill or die (Sheftel, 2017). 
 
2.1.3 Preoperative care 
Animals were kept overnight in the Invermay holding pens before surgery. They were starved 
overnight and weighed prior to receiving general anaesthesia. Sheep were pre-medicated with 
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subcutaneous injection of antibiotics every 48 hours (15 mg/kg Betamox LA injection, 
150mg/ml, Norbrook) and analgesic once a day (4 mg/kg Carprofen, Carprieve injection 
50mg/ml, Norbrook). 
 
2.1.4 Treatment modalities and allocations 
All three mandibular premolars on the right and left side of each animal were extracted. One 
of the following treatment modalities was randomly performed for each socket using the Latin-
square design (Table 2). 
A. Bio-Oss® bone graft (small particles, Geistlich) with ovine forestomach matrix (OFM 
collagen membrane (Aroa Biosurgery) 
Not used in this study but used for a parallel study for morphometric analysis 
B. Bio-Oss® bone graft (small particles, Geistlich) with Bio-Gide® collagen membrane  
(Geistlich)  
      C.   Socket without any treatment as control site 









Group R P1 R P2 R P3 L P1 L P2 L P3 
1 597 4 week A B C* A B C 
2 437 4 week B C A B C A 
3 432 4 week C A B* C A B 
4 586 4 week A B C* A B C 
5 590 4 week B C A B C A 
6 441 4 week C A B* C A B 
7 583 4 week A B C* A B C 
8 593 4 week B C A B C A 
9 428 4 week C A B* C A B 
10 595 4 week A B C* A B C 
11 440 8 week A B C* A B C 
12 594 8 week B C A B C A 
13 589 8 week C A B* C A B 
14 434 8 week A B C* A B C 
15 591 8 week B C A B C A 
16 598 8 week C A B* C A B 
17 426 8 week A B C* A B C 
18 439 8 week B C A B C A 
19 438 8 week C A B* C A B 
20 450 8 week A B C* A B C 
21 430 16 week A B C* A B C 
22 436 16 week B C A B C A 
23 599 16 week C A B* C A B 
24 584 16 week A B C* A B C 
25 587 16 week B C A B C A 
26 585 16 week C A B* C A B 
27 442 16 week A B C* A B C 
28 592 16 week B C A B C A 
29 427 16 week C A B* C A B 
30 425 16 week A B C* A B C 
 
R: right side mandible 
L: left side mandible 
P1: first premolar 
P2: second premolar 
P3: third premolar 




Samples were harvested at 3 time points post-surgery (4, 8 and 16 weeks). At each time point 
10 animals were sacrificed. Samples were only collected from right-side for this this study.  
For gene expression analysis, the bone immediately mesial to the first right mandibular molar 
was collected using a trephine prior to euthanasia. As only sites which received treatment B or 





Figure 5. Representative diagram of the sheep mandible and treatment sites. First 
premolar (P1), second premolar (P2) and third premolar (P3) were extracted and received one 




2.1.5 Surgical protocol 
All surgery was carried out using full-scrub aseptic technique with sterile instruments in a 
dedicated animal operating theatre at Invermay AgResearch (Mosgiel, Dunedin, New 
Zealand). General anaesthesia was induced by intravenous infusion of Diazepam 0.2 mg/kg 
(Troy Laboratories, Australia, Cat no. 160545A) and Ketamine 2 mg/kg (Phoenix Xylaket 
15/5, ketamine HCl 50mg/mL, Cat no. 025975), and animals intubated orally with a stomach 
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tube. General anaesthesia was maintained using Isoflurane (2.5-3.5%) (Bayer, New Zealand, 
Cat no. NZ20609). Each sheep was placed on an operating table with their head supported with 
sand bags. After operating on one side they were moved to the opposite side. The face was 
shorn of wool and disinfected with povidone iodine 10% w/v (Betadine, Sanofi, Auckland New 
Zealand, Cat No. 297272). The oral cavity was wiped with a sterile gauze soaked with 0.2% 
chlorhexidine gluconate solution (Savacol®; Colgate-Palmolive, New Zealand) and also rinsed 
with the same solution for antisepsis using a disposable syringe. Local anaesthetic (Lignospan® 
Lignocaine Hydrochloride B.P. 2% with adrenaline 1:80,000, AstraZenica, Cat no.F0087-1) 
was infiltration administered distal to the third premolar on the buccal and lingual sides. 
 
2.1.6 Flap design and extractions 
A sulcular incision was made from the mid-buccal region of the first mandibular molar to 1 cm 
mesial to the first mandibular premolar. A full thickness mucoperiosteal flap was elevated 
buccally and lingually (Figure 6A). Subsequently a dental elevator was placed distal to each 
premolar to bridge the contact points and was gently tapped with a surgical mallet. Tooth 
removal was performed by using molar forceps to hold the tooth and by applying mesial forces 
by Coupland’s or Cryer’s elevators (Figures 6B&C). Care was taken not to damage the cortical 
bone and inter-radicular bone. Any root that fractured were retrieved using root pick elevators 
and the socket was curetted. Periapical radiographs were taken to check the complete removal 
of the tooth and record a baseline x-ray. Size 2 Kodak intra-oral x-ray film with a Rinn® holder 
for paralleling technique was used. 
 
   
 
Figure 6. A. Full thickness flap, and mandibular premolars before extraction, B. tooth retrieval using 





2.1.7 Preparing the graft site 
The depth and width of the sockets were measured using a Williams probe (Figure 7A). The 
socket depth was calculated from the crestal bone to the deepest part of the socket. The width 
was gauged from the mid-buccal to the mid-lingual point of the marginal bone. The sockets 
were standardised in size at their coronal portion using a 6.0 x 11 mm implant bur (Figure 7B; 




Figure 7. A. Measurement of the width and depth of the sockets using a Williams probe, B. 
Standardisation of coronal portion of the socket with an implant bur (6.0 x 11 mm). 
 
 
2.1.8 Grafting procedure 
On each side, one treatment modality was performed for each socket according to site 
allocation (Figure 8). Two sockets as designated for Treatments ‘A’ and ‘B’ were filled with 
Bio-Oss® graft material to the level of the marginal bone crest. This was done by aspirating 
blood from the surgical site and mixing with Bio-Oss® bone graft. The Bio-Oss® impregnated 
with blood was then placed into the socket. In the treatment ‘A’ sites, OFM collagen membrane 
was trimmed based on the size of the socket and was placed over the grafted socket. In 
treatment ‘B’ the socket was covered with a Bio-Gide® collagen membrane using the same 
technique. One socket (treatment C) was kept untreated (no bone graft or collagen membrane) 
as the control site. The buccal and lingual mucoperiosteal flap was sutured using resorbable 
3.0 Polyglycolic Acid suture (Ethicon Vicryl) and primary closure was achieved. A periapical 
radiograph was taken of the non-grafted and grafted sockets immediately after surgery on each 
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side. Local anaesthetic (Lignospan® Lignocaine Hydrochloride B.P. 2% with adrenaline 
1:80,000) was infiltration administered to control post-operative pain. 
 
   
 
Figure 8. A. Bio-Oss® bone graft impregnated with sheep blood, B. Allocated sockets filled with Bio-
Oss® bone graft, C. OFM collagen membrane (on the right socket) and Bio-Gide® (in the middle socket) 
collagen membranes trimmed to the size of the sockets and placed over allocated sockets. 
 
 
2.1.9 Postoperative care 
Starting on the day following surgery, 0.2% Chlorhexidine gluconate antiseptic solution 
(Savacol®; Colgate-Palmolive, New Zealand) was applied daily to surgical sites using a syringe 
for 3 days. All sheep were given post-operative subcutaneous injection of antibiotics every 48 
hours (15 mg/kg Betamox LA injection, 150mg/ml, Norbrook) and analgesic once daily (4 
mg/kg Carprofen, Carprieve injection 50mg/ml, Norbrook) for 3 days after surgery. They were 
monitored daily by veterinary staff to evaluate their food and hydration intake, behaviour, any 
complication to the defect sites and general wellbeing. The sheep were provided small pellets 
or muesli-type feed for 5-7 days post-operatively. They were then returned to the farm for the 
remainder of the study period. 
 
2.1.10 Tissue trephination 
At the 4, 8 and 16-week time-points, the animals were returned to the surgery and placed under 
general anaesthesia as detailed above. Sheep with treatments B or C at the right mandibular 
third premolar site were subjected to tissue trephination prior to formalin fixation (Table 2). 
For site identification, a periapical x-ray was taken of the right side. Tissue immediately mesial 
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to the right mandibular first molar was trephined. A 3 mm ø soft tissue punch (Salvin Dental 
Specialties, Inc.  Charlotte, North Carolina, U.S.A) in a handpiece was used to remove the 
overlying gingiva and a 2 mm ø trephine (Salvin Dental Specialties, Inc.  Charlotte, North 
Carolina, U.S.A) was used to drill to a depth of 10-15 mm, and remove the bone core from the 
third premolar site. The bone core was immediately placed in a labelled 1.5 ml tube containing 




Figure 9. A. Soft tissue healing before bone trephination on the date of euthanisation; the first right 





For euthanasia, the sheep were placed in a supine position with the neck slightly over-extended. 
Transcutaneous incisions were made and carotid arteries were exposed by blunt dissection 
bilaterally. On each side, two polyester sutures (Ethibond Excel, Cat no. LEP679, Ethicon) 
were placed around the carotid artery. One suture was used to ligate the artery at a site proximal 
from the heart. The other suture was used to ligate a 14 G catheter (BD Insyte Autogaurd, USA, 
Cat no. 381467) to prevent the dislodgement of cannula. The drip sets were connected to a 1 
litre bag of heparinised saline on each side. The animal was euthanised by anaesthetic 
(Isoflurane) overdose. The jugular veins were severed to allow venous outflow and 2 L sterile 
saline with heparin were perfused bilaterally through the carotid arteries. This was followed by 
2 L of 10% neutral buffered formalin (NBF; LabServ, ThermoFisher Scientific, New Zealand, 




2.1.12 Sample collection and handling 
The right and left posterior mandibles were removed using a handsaw and placed into a sealed 
labelled container of 10% NBF (LabServ, ThermoFisher Scientific, New Zealand, Cat no. 
BSP10C). Mandibular right-side samples were place at 4°C on an orbital shaker (Stuart SSM1) 
for 48 hours, then transferred to 20% alcohol (Ethanol, Emsure®, Merck, Cat no. 1.00983.2500; 
Appendix 1). Samples then refrigerated at 4°C for one week. Trephined tissue samples for 
RNA extraction were refrigerated at 4°C overnight while gently rotating on the orbit shaker 



















3 treatment modalities: 
A. Bio-Oss® bone graft with OFM collagen membrane  
      B.  Bio-Oss® bone graft with Bio-Gide® collagen membrane 
  C. Untreated (No bone substitute and no collagen membrane) 
 
Bilateral extraction 
First, second and third premolar 
Euthanasia 8 weeks 
n=10 
In each sheep 
One of the treatment modalities bilaterally 











2.2 Immunohistochemistry (IHC)  
2.2.1 Specimen preparation for H&E staining and IHC 
2.2.1.1 Decalcification 
The mandibular left side samples were used in another study and will not be discussed further 
here. 
The 30 mandibular right-side samples were radiographed with using the Elema-Schönander 
radiographic machine (Järnhs, Stockholm-Solna- Sweden). Carestream T-MAT G/RA film 
with a Lantex regular intensifying screen was used with exposure setting of 50 mA, 45 kVp, 
0.08-0.10 seconds at FFD 90 cm; these were then processed in an automatic processing 
machine. The Borders of the sockets were identified on the radiograph and matched on the 
mandibular specimens. Each socket was separated using a hand saw and placed in a labelled 
embedding cassette and submerged in 10% ethylenediaminetetraacetic acid (EDTA) in 
individual 100 mL pottles to decalcify (See Appendix 2) (Savi et al., 2017). Large socket 
samples were sectioned into two blocks to accelerate the decalcification process. Sections were 
marked with tissue marking dye (Shandon™, Thermo Fisher Scientific, Cat no. 3120127) at 
the opposite side of the cutting surface. The position of the dye was toward the bottom of the 
cassette and the cutting surface was the top surface when the cassette was opened. The 
specimens were kept at 4C rotating on the orbit shaker (Stuart SSM1). Decalcification solution 
was changed every 3 days. 
The oxalate test was used to monitor the decalcification process (Morse, 1945). The oxalate 
test was performed by taking a 5 mL sample of the EDTA solution from the pottle holding the 
sample and adding concentrated hydrochloric acid HCl (Merck, Cat no. 100317.2500) until the 
test solution reached pH 3.2-3.6 (Hydrion® Brilliant pH dip sticks, pH-range 0.0-6.0, Merck, 
Sigma-Aldrich, Cat no. Z264776). Following pH correction, 5 ml of 4% di-ammonium oxalate 
monohydrate extra pure (Merck, Cat no. 101190.1000) was added. The resultant solution was 
observed for 30 minutes for precipitate formation. The presence of any cloudiness or precipitate 
in the test solution was noted as evidence of incomplete decalcification. When no precipitate 
was formed the fluid was free of calcium ions and the sample was considered decalcified. 
Completion of the decalcification process was confirmed by x-ray using the same protocol as 
described in section 2.2.1.1. Decalcification was considered complete when no radiopaque 
tissue could be identified on the radiograph. The samples were then transferred to phosphate 
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buffer saline (PBS; GibcoTM Life Technologies, Cat no. SALB010) for 24 hours at 4C on an 
orbit shaker.  
 
2.2.1.2 Paraffin block preparation 
Specimens were transferred to the Oral Pathology laboratory, School of Dentistry, University 
of Otago, for embedding in paraffin blocks. 
The tissue samples were embedded using the ‘long cycle’ schedule of the Shandon Citadel 
1000 processor (Thermo Fisher Scientific, USA) This automatic processor takes samples 
through 12 stations with a series of graded ethanol solution (70%, 95%, 100%, 100% and 
100%), xylene and finally 56C melting point Paraplast wax (Appendix 3). Orientation of the 
specimens was confirmed and the cut surface, where the specimen was sectioned in half, was 
placed face-up for embedding, to allow sections to be taken as close to the centre of the grafted 
site as possible. The opposite side of each specimen was marked with a tissue dye (Shandon, 
Thermo Scientific, Cat no. 3120127) to confirm correct embedding alignment. When the blocks 
were paraffin-embedded, we ensured that the transverse section was parallel to the sectioning 
plane. The specimens were then embedded in molten (56C) paraffin. The paraffin blocks were 
then stored for further use. 
 
2.2.1.3 Sectioning and slide preparation 
A total of 18 paraffin-embedded specimens (six from each time-point) were randomly selected 
and serial sections at 4 µm of thickness cut in a mesio-distal plane perpendicular to the external 
surface of the mandible. A microtome (Microm HM 340E, Germany) with a S35 disposable 
feather type microtome blade was used for sectioning. All blocks were sequentially trimmed 
to the mid socket position. At this point, 41 serial sections were taken. The first 21 sections and 
the sections 40 and 41 were mounted and numbered for the experiment (Appendix 4). Sections 
were floated in a water bath at 59C before mounting on 3-aminopropyltriethoxysilane 
(APES)-coated slides (Superfrost Ultra Plus®, Thermo Scientific, Cat no. J3800AMNZ). 
Finally, the slides were dried for 15-20 minutes at 45C and then placed in an incubator 




2.2.1.4 Histomorphology staining 
Slide numbers 1, 20 and 40 were stained with haematoxylin and eosin as a histology guide by 
the Oral Pathology laboratory, School of Dentistry, University of Otago (the staining protocol 
is attached in Appendix 5). In addition, Trichrome staining was performed on slide numbers 2, 
21 and 41 which were investigated as part of another project. 
 
2.2.1.5 Imaging and histological analysis of H&E sections 
Images of the H&E slides were obtained using digital pathology slide scanner (Aperio 
ScanScope) at 20X magnification. Histological evidence of the socket healing was assessed by 
analysis of the H&E slides. 
 
 
2.2.2 Immunohistochemistry (IHC) procedure 
2.2.2.1 Development of a heat-induced antigen retrieval method  
Antigen retrieval is a technique in immunohistochemistry (IHC) for unmasking low-level or 
formalin cross-linked antigens in formalin-fixed paraffin-embedded tissues. The techniques 
used to restore the immunoreactivity of an epitope generally fall into two main categories; (1) 
enzyme-induced antigen retrieval and (2) heat-induced antigen retrieval (Shi et al., 1997; Ezaki, 
2000). The latter method was used in this research. Initial trials, found lifting or folding of the 
tissue was occurring with the heat-induced antigen retrieval method. Therefore, the following 
experiments were performed to develop a protocol to address this problem. 
The heat retrieval process was tested with three different slide brands (Über, InstrumeC; Crest, 
Matsunami, Cat no. 30740212; Trajan, Trajan Scientific, Cat no. 472042491). Two slides from 
each brand were selected and labelled. Slides were processed through 3 steps of 
deparaffinisation by placing them in xylene (Scharlau, Cat no. X100592500) for 5 min, 5 min 
and 10 min. Subsequently they were rehydration by placing in graded alcohols (100%, 90%, 




A Decloaking ChamberTM NxGen instrument (Biocare Medical) was used to perform the heat 
retrieval process. The slides were submerged in processing canister containing the antigen 
retrieval solution (220 ml; 0.1 M Tri Sodium Citrate see Appendix 5) and incubated at 110C 
for 10 min. The slides were removed after the chamber had cooled to 90C and washed twice 
in a beaker containing PBS (Gibco, Life Technologies, Cat no. SALB010) for 5 min each. 
Partially-lifted tissue from the slides were observed. Slides were stained with haematoxylin by 
adding 2 drops of filtered haematoxylin (Surgipath, Cat no. 100517) to each slide for 2 seconds. 
Slides were washed under running tap water until clear, then placed in Scott’s tap water (ACR, 
Cat no. 1871) for 1 min followed by rinsing with cold tap water. Subsequently, they were 
dehydrated in graded alcohol for 2 min (50%, 90% and 100%) each, followed by two xylene 
washes. DPX mounting solution (SIGMA, Life Science, Cat no. BCBV8243) was applied to 
each slide and coverslips applied (Labserv, Cat no. 031215-9). Microscope assessment of the 
sections showed tissue folding as a result of lifting from the slides. They were not assessed as 
being sufficiently adherent to be of analytical value and the use of a different method was 
indicated. 
 
The impact of the pre-heating protocol was assessed by placing two slides (Superfrost Ultra 
Plus®, Cat no. J3800AMNZ) in an incubator at 50C overnight, while two other slides were 
kept on the bench at room temperature. In addition, slides were also processed at a different 
temperature in the Decloacking Chamber (95C at 10 min). The heat retrieval process was 
performed as outlined above. The same problem with tissue lifting and folding was observed. 
 
A further experiment was conducted where the heat retrieval process was performed for two 
slides (Superfrost Ultra Plus®, Cat no. J3800AMNZ) in the Decloaking chamber at 80C for 
15 min while two other slides were processed in a water bath. In the later process, a beaker 
containing antigen retrieval solution (Appendix 6) was placed in the water bath. When the 
temperature in the beaker reached 95C, slides were transferred to the beaker which was held 
at 95C for 10 min. During processing of the slides using these two methods of heat retrieval, 
no tissue lifting was observed and the final slides were of sufficiently good quality for 
microscopic assessment.  
The final method used included the Decloaking Chamber set at 80C for 15 mins. 
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2.2.2.2 Antibody titrations 
Several concentrations of antibody were trialled to optimise detection of immunopositive 
protein staining while minimising the background stain with the final concentration determined 
by visual inspection of trial sections.  
 
 
2.2.2.3 Negative controls 
To confirm the validity of positive antibody staining, all samples were also processed with 
matched IgG at the same concentration as the primary antibody as a negative control. Control 
IgG for each antibody differed according to the species that the original antibody was raised 
in.  
 
2.2.2.4 Pleiotrophin antibody  
An anti-PTN mouse monoclonal, anti-human IgG isotype (Santa Cruz, Cat no. SC74443) 
antibody was used at a final concentration of 4 μg/ml. Blocking was conducted with 20% rabbit 
serum (Sigma, R9133) in 1%BSA/PBS (Sigma Aldrich, Cat no. 120M1145V/Gibco, Life 
Technologies, Cat no. SALB010). The secondary antibody was a biotinylated rabbit anti-
mouse antibody (Abcam, Cat no. ab5761) at a final concentration of 1.25 μg/ml (1:400 
dilution). The control IHC staining was performed with mouse IgG (Santa Cruz, Cat no. 
SC2025) at a concentration of 4 μg/ml (1:100 dilution). 
 
2.2.2.5 Midkine antibody  
An anti-MK rabbit monoclonal, anti-human IgG isotype (Abcam, Cat no. AB52637) antibody 
was used at a final concentration of 2.1 μg/ml (1:50 dilution). Blocking was conducted with 
20% goat serum (Sigma, G9023) in 1%BSA/PBS (Sigma Aldrich, Cat no. 120M1145V/ Gibco, 
Life Technologies, Cat no. SALB010). The secondary antibody was a biotinylated goat anti-
rabbit antibody (Abcam, Cat no. ab6012) at a final concentration of 5 μg/ml (1:200 dilution). 
The control IHC staining was performed with a rabbit IgG (Dako-X0936,) at 2 μg/ml 




2.2.2.6 Receptor type protein tyrosine phosphatase zeta (RPTPζ) antibody  
An anti-RPTPζ rabbit polyclonal, anti-human IgG isotype antibody (Resolving Images, Cat no. 
MBS2034104) was used at a final concentration of 5 μg/ml (1:40 dilution). The secondary 
antibody application was with a Ventana “universal” cocktail that includes goat anti-mouse 
IgG, goat anti-rabbit IgG, and goat anti-mouse IgM. This cocktail recognises a broad range of 
primary antibody types. The control IHC staining was performed with rabbit IgG (Dako, Cat 
no. X0936) at 2 μg/ml concentration (1:200 dilution). 
2.2.2.7 Anaplastic Lymphoma Kinase (ALK) antibody 
An anti-ALK rabbit polyclonal, anti-human IgG isotype (Assay Matrix, Cat no. PA1741) 
antibody was used at a concentration of 2 μg/ml (1:250 dilution). Blocking was conducted with 
20% goat serum (Sigma, G9023) in 1%BSA/PBS (Sigma Aldrich, Cat no. 120M1145V/ Gibco, 
Life Technologies, Cat no. SALB010). The secondary antibody was a biotinylated goat anti-
rabbit antibody (Abcam, Cat no. ab6012) which was used at 5 μg/ml (1:200 dilution). The 
control IHC staining was performed with rabbit IgG (Dako, Cat no. W0936) at a concentration 
of 2 μg/ml (1:500 dilution). 
 
2.2.2.8 Notch-2 antibody 
The primary antibody was an anti-Notch-2 rabbit polyclonal, anti-human IgG isotype (Abcam, 
Cat no. AB8929) antibody used at 1:500 dilution. Blocking utilised 20% goat serum (Sigma, 
G9023) in 1%BSA/PBS (Sigma Aldrich, Cat no. 120M1145V/ Gibco, Life Technologies, Cat 
no. SALB010). The secondary antibody was a biotinylated goat anti-rabbit antibody (Abcam, 
Cat no. ab6012) which was used at 5 μg/ml (1:200 dilution). The matched IHC staining was 
performed with rabbit IgG isotype (Dako, Cat no. X0936) at a concentration of 2 μg/ml (1:500 
dilution). 
 
2.2.2.9 Immunohistochemistry protocols for different proteins 
IHC was conducted using the primary and secondary antibodies as outlined in sections 2.2.2.4 
to 2.2.2.8. The RPTPζ IHC was conducted using a Benchmark XT automated slide stainer 
(Ventana Medical System, INC. AZ, USA). The machine performs deparaffination, cell 
conditioning, primary antibody incubation, and 3,3’-diaminobenzidine (DAB) application 
using an indirect biotin-streptavidin system with washing between each step. Antibody titration 
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was performed manually (Appendix 7). PTN, MK, ALK and Notch-2 antibodies were 
incubated on the sections overnight at 4C and then were detected with a biotinylated secondary 
antibody. Peroxidase labelling and amplification were undertaken for 30 min using a 
VECTASTAIN Elite ABC system and developed with diaminobenzidine (DAB) which was 
visualised as a brown stain (Appendix 8). All slides were mounted manually with DPX 
mounting medium (Sigma-Aldrich, Cat no. BCBv8243) in the fume cupboard. 
 
2.2.3 Imaging and histological analysis of immunohistochemistry sections 
IHC slides were assessed under the EVOS M5000 light microscope with the expression 
positive staining for each of the proteins of interest assessed. The location of the protein 
associated cells and tissue staining was reported for coronal and apical regions of the socket. 
Semi-quantitative analysis was conducted using the following scores for the presence of protein 
of interest: 0 = no positive cells; 1 = occasional lightly coloured positive cells; 2 = moderately 




2.3 Gene expression 
2.3.1 Experimental aims for the gene expression analysis 
To examine the role of pleiotrophin in osteogenesis the gene expression analysis was performed 
to: (1) validate a suitable sheep gene for the normalisation of input qRT2-PCR cDNA.(2) 
determine the mRNA expression levels of the sheep osteogenesis-associated genes 
pleiotrophin, midkine and their receptors Notch-2, ALK, RPTPζ (3) compare the expression 
levels for each of the genes in tissue recovered following tooth extraction from an empty socket 
(control) and a socket which contained Bio-Oss® and Bio-Gide® membrane (test). Samples 
were collected at 4 wks, 8 wks and 16 wks post-surgery Quantitative real-time reverse 
transcriptase polymerase chain reaction (qRT2-PCR) assays were used for the gene expression 
analysis. 
 
2.3.2 Sample collection 
Samples were collected immediately prior to euthanasia as described in section 2.1.10, placed 
in a 1.5 ml tube containing RNAlater solution (Qiagen, Cat. No. 76104) and stored at -80C 
until required. Tissue samples were collected from seven sheep at each time-point with a total 
of 21 samples (Table. 3). This included one control sample for each time-point sample which 





































* Samples used for protocol development.  
B. Bio-Oss® bone graft (small particles, Geistlich) with Bio-Gide® collagen membrane  
(Geistlich)  










1 597 4-week C 
2 432 4-week B 
3 586 4-week C 
4 441 4-week B 
5   *583 4-week C 
6 428 4-week B 
7 595 4-week C 
8 440 8-week C 
9 589 8-week B 
10   *434 8-week C 
11 598 8-week B 
12 426 8-week C 
13 438 8-week B 
14 450 8-week C 
15 430 16-week C 
16 599 16-week B 
17 584 16-week C 
18 585 16-week B 
19   *442 16-week C 
20 427 16-week B 
21 425 16-week C 
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2.3.3 Tissue homogenisation for RNA extraction 
It is critical to obtain RNA of high quality for efficient qRT2-PCR analysis. RNA is readily 
degraded by RNase. It is therefore important that all equipment is RNase-free before the 
process of RNA purification is undertaken. The tissue grinding process was carried out at very 
low temperature to reduce RNA degradation.  
A Cryogenic Grinding (SPEX SamplePrep, Freezer/Miller 6770) mill was initially used, 
however it was found the grinding vial was too large making the recovery of the tissue 
homogenate impossible. A Precelleys® Evolution homogeniser (Bertin instruments) which uses 
small microvials and beads was therefore employed. This utilised a dry ice-based cooling 
system preventing thermo-sensitive samples from heat degradation during the homogenisation 
process. Tweezers were cleaned with RNase Away® Reagent (Ambion by Life Technologies, 
Cat No. 10328-011) and used to transfer the defrosted samples submerged in RNAlater to the 
Precelleys® 2 ml lysing tube (Hard tissue grinding MK28-R, Cat No. P000917-LYSKO-A). A 
two-step process was used, each with three cycles. Firstly, three-cycles of grinding were 
performed as follows: 30 seconds grinding, 30 seconds pause, speed at 6000 rpm at 4C. This 
was followed by a second grinding step which included three cycles of grinding for 30 seconds, 
20 seconds pause, speed at 7200 rpm at 4C. The lysis tube containing the ground tissue was 
then placed on ice and TRIzol® Reagent (250 µl; Ambion, Life Technologies, Cat No. 
15596026) added and mixed well before being transferred to a to 2 ml microfuge tube. A 
second aliquot of TRIzol® Reagent (250 µl) was used to recover all of the homogenised tissue 













2.3.4 RNA isolation  
Total RNA was purified from the tissue homogenate using a PureLink TM RNA Mini Kit 
(Invitrogen, Thermo Fisher Scientific, Cat no. 12185-010), which included an on-column 
DNaseI treatment step (PureLink DNase Set; Invitrogen, Thermo Fisher Scientific, Cat no. 
12185-010). 
 
2.3.5 PureLinkTM Spin column RNA purification 
RNA purification with PureLinkTM RNA Mini Kit includes a number of steps which consists 
of phase separation, binding the RNA to a spin column, a wash step and finally elution of the 
RNA. Prior to use, 60 mL of 100% AR ethanol (Lab Supply, Cat no. 3887) was added to Wash 
Buffer II and mixed thoroughly. The homogenised sample previously stored in 500 µL TRIzol® 
Reagent at -80C was defrosted on ice. 500 µL TRIzol® was added to the sample and the 
contents of the tube were transferred to a pre-spun PhasemakerTM tube (Invitrogen, Cat no. 
A33248) and incubated at room temperature (RT) for 5 mins. Chloroform (200 µL; Merck, Cat 
no. 1.02445.2500) was added and mixed with vigorous shaking by hand for 15 secs and then 
incubated at RT for 2 mins. After centrifuging for 5 minutes at 14,000 g at 4C, approximately 
500 µL of the colourless upper aqueous phase containing the RNA was transferred to new 1.5 
mL microfuge tube. An equal volume of 70% ethanol (500 µL) was added and mixed well by 
vortexing before being transferred to a spin column inserted into a collection tube. Following 
centrifugation at 12,000 g for 20 secs, the flow-through was discarded and the spin column 
were reinserted into the same collection tube.  
 
2.3.6 On-column PureLinkTM DNase treatment 
PureLinkTM DNase was utilised to eliminate the unwanted genomic DNA from the purified 
RNA. Prior to first use, PureLinkTM DNase was reconstituted by dissolving the lyophilised 
DNase in 550 µL RNase-free water (Ambion, Cat no. AM 9937). A DNase master mix (80 µL 
per sample) was prepared for on-column treatment. The master mix contained 10x DNase I 
reaction buffer (8 µL), resuspended DNase (~3U/μL; 10 μL) and RNase-free water (62 µL).   
Wash Buffer I (350 µL) was added to the spin cartridge and centrifuged at 12,000 g for 15 secs 
at RT. The flow-through was discarded and the spin cartridges reinserted into a new collection 
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tube. The DNase mixture (80 µL) was added directly onto the surface of the spin cartridge 
membrane and was incubated at room temperature for 15 minutes. Wash Buffer I (350 µL) was 
again added to the spin cartridge and centrifuged at 12,000 g for 15 secs at RT. The flow-
through was discarded and the spin cartridge reinserted into a new collection tube. Wash Buffer 
II (500 µL, with ethanol pre-added) was added and centrifuged at 12,000 g for 15 secs at RT. 
The flow-through was discarded and the Wash Buffer II process was repeated once. The spin 
cartridge was then centrifuged at 12,000 g for 1 minute to dry the membrane. The collection 
tube was discarded and the spin cartridge was then inserted into a new recovery tube. The 
membrane-bound RNA was eluted with 50 µL RNase-free water (Ambion, Cat no. AM 9937) 
following 1 min incubation at RT and centrifugation at 12,000 g for 1 min. The purified total 
RNA samples were stored at -80C. 
 
2.3.7 RNA quality and quantitation 
Spectrophotometry is an standard method for determination of RNA concentration and purity 
(Joseph, 2016). RNA can be quantified by measuring the absorption at 260 nm, where 1 
absorbance unit is equal to 40 μg/ml, at pH 7.5. The ratio of absorbance at 260 nm and 280 nm 
(A260:A280 ratio) is frequently used to assess the purity of RNA preparations. It should range 
from 1.8 to 2.0 for the high purity RNA for the qualitative and quantitative analysis (Glasel, 
1995). Each of the 21 RNA samples were spectrometrically assessed using a Nanophotometer 
(Implen P360). RNase-free water was used as a blank (Ambion, Cat no. AM 9937). 
 
2.3.8 RNA concentration 
RNA samples which were < 10 ng/µL, were concentrated using the GeneJET RNA Cleanup 
and Concentration Micro Kit (Thermo Scientific, Cat no. K0841) according to manufacturer’s 








2.3.9 Reverse transcription of mRNA to cDNA 
Purified total RNA (300 ng) was utilised for the synthesis of complementary DNA (cDNA) 
using SuperScriptTM IV VILOTM Master Mix with an ezDNase enzyme kit (Invitrogen, Thermo 
Fisher Scientific, Cat no. 00691163). The kit contains reverse transcriptase, nucleotides and 
buffers to synthetise cDNA from the RNA. A no-RT control was conducted which included all 
the components of the SuperScriptTM IV VILOTM Master Mix except the reverse transcriptase 
enzyme. It is used to verify the absence of genomic DNA (gDNA) contamination in the RNA 
sample. All the kit components and the samples were allowed to thaw on ice prior to use. For 
each sample, 10 µL gDNA digestion reaction mix was prepared which contained 10X ezDNase 
buffer (1 µL), ezDNase enzyme (1 µL), RNA template (≤8 µL) and nuclease-free water (to 10 
µL). The mixture was incubated at 37C for 2 mins, and was placed on ice after a brief 
centrifugation. SuperScriptTM IV VILOTM Master Mix (4 µL) and nuclease-free water (6 µL) 
were added to the 10 µL reaction mix before being placed in the thermal cycler (PTC-100TM 
Programmable Thermal Controller, MJ Research, Inc). The cDNA was synthesised with 
incubation at 25C for 10 mins, 50C for 10 mins and 85C for 5 mins. The no RT control 
reaction was performed by substituting the SuperScriptTM IV VILOTM Master Mix with the 
SuperScriptTM IV VILOTM No RT Control.  No RT Control reactions were only conducted for 
3 tissue samples (control group; one for each time-point). The cDNA (15 ng/µL) samples were 















2.3.10 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) assay 
Fast SYBR Green gene expression assays were used for the determination of mRNA 
expression.  
 
2.3.10.1 SYBR Green primer design 
cDNA input reference genes are required to be constitutively expressed (Panina et al., 2018). 
The expression profile of five candidate reference genes GAPDH, ACTB, RPL19, B2M and 
YWHAZ were evaluated for their suitability to act as reference genes for the normalisation of 
input cDNA (Table 4). The primer sequences for the five sheep reference genes were retrieved 
from the literature (Schulze et al., 2017). Primers for pleiotrophin, midkine, ALK, Notch-2, 
RPTPζ however, have not been previously published so these were specifically designed for 
the study. mRNA sequences were retrieved from the NCBI database and Primer Premier 5.0 
software used to select pairs of primers which spanned exons and would produce amplicons 
<150 bp in length (Appendix 9). All pleiotrophin, midkine, Notch-2, ALK and RPTPζ primers 
were custom made (Table 5; Sigma-Aldrich). 
 
2.3.10.2 SYBR Green RT2-qPCR assay 
The qPCR assay was set up in a laminar flow hood to prevent contamination. Fast SYBRTM 
Green Master Mix (Applied Biosystems, Thermo Fisher Scientific, Cat no.4385612) and the 
synthetised cDNA were allowed to thaw on ice. cDNA was diluted to 1 ng/µL using RNase-
free water (Ambion, Cat no. AM 9937). A qPCR master mix was made which included Fast 
SYBR Green Master Mix (5 µL), GOI or reference gene forward and reverse primers (20 µM; 
0.2 µL each) and 1.6 µL RNase-free water.  The master mix (7 ul) was dispensed into each 
well of the 96-well plate along with each cDNA sample (3 ng; 3 µL). All samples were run in 
duplicate and RNase-free water was used as a negative control. Amplification was performed 
using the QuantStudio 6 Flex machine (Applied Biosystems, Life Technologies). Cycling 
parameters were as follows: DNA polymerase UP activation at 95C 20 sec, denaturation at 40 
cycles of 95C 3 sec with annealing at 40 cycles of 60C 30 sec. A melting curve was also run 
at the completion of each run.
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Table 4.  Candidate sheep reference genes; forward and reverse primers and amplicon size. 
 
Gene Gene product Primer sequence Amplicon 
ACTB Beta-actin 
F:5’ GCAGATGTGGATCAGCAAGC 3′ 
95 bp 
R:5’ GGGTGTAACGCAGCTAACAG 3’ 
RPL19 Ribosomal protein L19 
F:5’ AGCCTGTGACTGTCCATTCC 3′ 
126 bp 
R:5’ ACGTTACCTTCTCGGGCATT 3 
B2M Beta-2 microglobulin 
F:5’ CCTTGGTCCTTCTCGGGCTG 3′ 
91 bp 




activation protein, zeta 
F:5’ GATGAAGCCATTGCTGAACTTGA 3′ 
124 bp 




F:5’ ACAGTCAAGGCAGAGAACGG 3′ 
98 bp 









    Table 5. Pleiotrophin family genes and their receptors; forward and reverse sheep primers and amplicon size.  
 
Gene Primer sequence Amplicon Reference 
Pleiotrophin 
F:5’ ACTGGGAGCCTGAAGCGAGC 3′ 
140 bp This study (Appendix 10) 
R:5’ CTTCTTCTTAGATTCTGCTTGAGGT 3′ 
Midkine 
F:5’ GGGTGCCCTGTAACTGGAA 3′ 
162 bp This study (Appendix 11) 
R:5’ GCTTGGTCACTCGGATGGT 3′ 
Notch-2 
F:5’ CAGACCACTACGAAGACAACCAC 3′ 
131bp (Jing et al., 2017) 
R:5’ CATCAGCACCACAATGACGAG 3′ 
ALK 
F:5’ GAGAAGAACGTTCATGGT 3′ 
126 bp 
Modified from (Chen et al., 2009) 
(Appendix 12) 
 R:5’ CCAACCAGAGCTGAGTCCAT 3′ 
RPTPζ 
F:5’ GCCATGAGTCTCGTATTGGTCTA 3′ 
158 bp This study (Appendix 13) 







2.3.11 Data analysis  
Following amplification Cq values were determined using the QuantStudioTM 6 and 7 Flex 
Real-Time PCR System Software v1.0 (Life technologies, CA, USA). In order to select the 
most stable reference gene for normalisation, a panel of five reference genes (GAPDH, ACTB, 
RPL19, B2M and YWHAZ) was evaluated. The expression profiles for each of the five 
reference genes were compared using Normfinder software. Data analysis was performed using 
GraphPad Prism software v8 (GraphPad Software Inc, San Diego, USA). 
 
The Cq value is inversely proportional to the amount of target nucleic acid in the sample. Gene 
expression levels are expressed as 2-Cq as the product doubles exponentially following each 
cycle. The relative quantity of the gene of interest is expressed as 2-ΔCq  were ΔCq = Cq gene 
of interest – Cq reference gene (Schmittgen & Livak, 2008). The difference between each 
group was analysed using the parametric unpaired t-test and one-way ANOVA and were 













 3 Results 
3.1  Surgery 
All animals survived surgery and the post-operative healing period. At euthanasia, three 
animals were observed as having swelling over the left side sockets. As previously mentioned, 
left side samples were analysed as part of another research project. There was no evidence of 
infection on the right side of the mandible which was used for this research. 
 
3.2 H&E and immunohistochemistry 
3.2.1 Decalcification process 
The time taken for decalcification of the 4-week group samples was 112-135 days. Completion 
of decalcification took longer in the 8-week and 16-week groups, both ranged 139-287 days. 
 
3.2.2 Harvesting samples 
Three extraction socket sites were harvested from each experimental animal and in total 90 
sites had sections stained with H&E and trichrome stain.  
 
3.2.3 Gross histological observation of the haematoxylin and eosin stained sections 
H&E staining was performed for all control and test samples (Appendices 14-16). All sockets 
showed epithelial healing with varying degrees of new bone formation. Infilling with woven 
bone was observed from the socket margin with trabecular bone radiating toward the centre of 
the socket. This was more noticeable in the test group compared to the control group. 
Representative images are shown at 4, 8, and 16 week time points with control (no Bio-Oss®/ 
no membrane) and test (Bio-Oss® + Bio-Gide®); where n=3 animals (6 socket sites) were 




3.2.3.1 Histology of 4-week control and test groups 
Small amounts of woven bone formed at the edge of the socket in the control samples. In the 
test group the socket outline was surrounded with more newly formed bone compared to the 
control group (Figure 11). The connective tissue of the non-grafted sockets, as well as the 
grafted sockets, was densely packed and more extensive at 4-weeks compared to the samples 
in 8-week and 16-week (Figures 12 & 13). No obvious sign of residual Bio-Gide® membrane 










Figure 11. Photomicrographs illustrating decalcified tissue with haematoxylin and eosin 
staining of the extraction sockets at 4-weeks. A. Control sample; B. Test sample; C. Magnified 
socket outline shown in A; D. Magnified socket outline shown in B. Note the densely packed 
connective tissue fibers and cells in both groups and more newly formed bone in the test group. 
Connective tissue (CT); woven bone (WB); lamellar bone (LB). Scale bars: 2 mm.
 
 
3.2.3.2 Histology of 8-week control and test groups 
More woven bone was detected at the edge of the socket in both control and test samples when 
compared to 4-week groups. In the test group the socket outline was surrounded with more new 
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bone when compared to the control group (Figure. 12). The provisional bone matrix contained 




Figure 12. Photomicrographs illustrating decalcified tissue with haematoxylin and eosin 
staining of the extraction sockets at 8-weeks. A. Control sample; B. Test sample; C. Magnified 
socket outline shown in A; D. Magnified socket outline shown in B. Note the more newly 
formed bone in the test group. Connective tissue (CT); woven bone (WB); lamellar bone (LB). 




3.2.3.3 Histology of 16-week control and test groups 
In both control and test groups a newly formed hard tissue bridge, mainly composed of woven 
bone, was seen separating the marginal mucosa from the extraction socket (Figure 13). At the 
edge of the socket, more woven bone was evident compared to the 4-week time-point. In the 
test group the socket outline was consistently surrounded with more newly formed bone 
compared to the control group. The connective tissue appeared less cellular compared to the 









Figure 13. Photomicrograph illustrating decalcified tissue with haematoxylin and eosin 
staining of the extraction sockets at 16-weeks. A. Control sample; B. Test sample; C. 
Magnified socket outline shown in A; D. Magnified socket outline shown in B. Note the loosely 
packed connective tissue fibers and cells in both groups and more newly formed bone in the 








3.2.4  Immunohistochemistry (IHC)  
3.2.5 Immunohistochemical detection of the pleiotrophin family ligands and receptors 
during healing of tooth sockets in sheep 
Immunohistochemistry was used to detect the pleiotrophin family of proteins in control and 
test samples. The margin of coronal and apical parts of the sockets were presented so as to 
provide an overview of the staining pattern, with photomicrographs taken for each group at all 
three time-points. Results shown below are representative of observations made in three 
replicates of each group/time-point. 
 
 




3.2.6 Pleiotrophin detection by immunohistochemistry 
3.2.6.1 Pleiotrophin, 4-week group, control and test 
Positive staining of cells resembling osteoblasts lining the edge of the newly formed woven 
bone was observed in the test group. Also, positive granules (brown staining) were observed 
on the surface of the bone trabeculae and on the edge of the newly formed bone in both control 




Figure 15. Representative photomicrographs of 4-week non-grafted and grafted sockets 
subjected to immunohistochemistry for pleiotrophin detection and counterstained with 
haematoxylin A. Control sample, coronal part of the socket; B. Control sample, apical part of 
the socket; C. Test sample, coronal part of the socket; D. Test sample, apical part of the socket. 
Osteoblasts (black arrows) lining the edge of the newly formed woven bone (WB); positive 
granules (blue arrows) can be observed on the surface of the bone trabeculae and on the edge 





3.2.6.2 Pleiotrophin, 8-week group, control and test 
Strong positive staining (brown) was observed on the surface of the bone trabeculae associated 
with new bone and the loose connective tissue in test and control groups. Cells resembling 
osteoblast, observed at the edge of the newly formed woven bone were positively stained in 
some test group samples (Figure 16, Table 6). 
 
Figure 16. Representative photomicrographs of 8-week non-grafted and grafted sockets 
subjected to immunohistochemistry for pleiotrophin detection and counterstained with 
haematoxylin A. Control sample, coronal part of the socket; B. Control sample, apical part of 
the socket; C. Test sample, coronal part of the socket; D. Test sample, apical part of the socket. 
Osteoblasts (black arrows) lining the edge of the newly formed woven bone (WB); positive 





3.2.6.3 Pleiotrophin, 16-week group, control and test 
Positive pleiotrophin staining (brown) was observed on the surface of the bone trabeculae. 
However, the intensity was less than in the 4 and 8-week samples. Cells resembling osteoblasts 
observed lining at the edge of the newly formed bone but were stained lightly. (Figure 17, 
Table 6). 
 
Figure 17. Representative photomicrographs of 16-week non-grafted and grafted sockets 
subjected to immunohistochemistry for pleiotrophin detection and counterstained with 
haematoxylin A. Control sample, coronal part of the socket; B. Control sample, apical part of 
the socket; C. Test sample, coronal part of the socket; D. Test sample, apical part of the socket. 
Osteoblasts (black arrows) lining the edge of the newly formed woven bone (WB); positive 






3.2.7 Midkine detection by immunohistochemistry 
Immunohistochemisty for midkine protein in all control and test samples was conducted. 
Photomicrographs of the samples from coronal and apical parts of the sockets are presented for 
each group. 
 
3.2.7.1 Midkine, 4-week group, control and test 
The socket wall, the newly formed woven bone, and the osteocytes showed positive staining 
for midkine in both non-grafted and grafted sockets. Midkine was not detected in the loose 
connective tissue or the cells resembling osteoblasts (Figure 18, Table 6). 
 
Figure 18. Representative photomicrographs illustrating 4-week non-grafted and grafted 
sockets subjected to immunohistochemistry for midkine detection (brown) and counterstained 
with haematoxylin A. Control sample, coronal part of the socket; B. Control sample, apical 
part of the socket; C. Test sample, coronal part of the socket; D. Test sample, apical part of the 
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socket. Positive staining could be observed on the surface of the new bone trabeculae and 
osteocytes (black arrow). Scale bar: 100 µm. 
 
3.2.7.2 Midkine, 8-week group, control and test 
Staining was similar to the 4-week group. The socket wall, the newly formed woven bone and 
the osteocytes showed positive staining for midkine in both non-grafted and grafted sockets. 
No midkine was detected in the loose connective tissue or the cells resembling osteoblasts 
(Figure 19, Table 6). 
 
Figure 19. Representative photomicrographs illustrating 8-week non-grafted and grafted 
sockets subjected to immunohistochemistry for midkine detection and counterstained with 
haematoxylin A. Control sample, coronal part of the socket; B. Control sample, apical part of 
the socket; C. Test sample, coronal part of the socket; D. Test sample, apical part of the socket. 
Positive staining was observed on the surface of the bone trabeculae and osteocytes (black 
arrow). Scale bar: 100 µm.  
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3.2.7.3 Midkine, 16-week group, control and test 
The socket walls with the newly formed bone and entrapped osteocytes showed positive 
staining for midkine in both non-grafted and grafted sockets. However, midkine was not 
detected in the loose connective tissues and the cells resembling osteoblasts (Figure 20, Table 
6). 
 
Figure 20. Representative photomicrographs illustrating 16-week non-grafted and grafted 
sockets subjected to immunohistochemistry for midkine detection and counterstained with 
haematoxylin A. Control sample, coronal part of the socket; B. Control sample, apical part of 
the socket; C. Test sample, coronal part of the socket; D. Test sample, apical part of the socket. 
Positive staining can be observed on the surface of the bone trabeculae and osteocytes (black 





3.2.8 Notch-2 detection by immunohistochemistry 
Immunohistochemistry for Notch-2 was examined in all control and test samples. 
Photomicrographs of the samples from coronal and apical parts of the sockets are presented for 
each group. 
 
3.2.8.1 Notch-2, 4-week group, control and test 
Cell resembling osteoblasts and osteocytes showed positive staining for Notch-2 in both non-
grafted and grafted sockets. Also, a strong positive staining was observed in the loose 
connective tissue cells in both test and control groups (Figure 21, Table 6). 
 
Figure 21. Representative photomicrographs of 4-week non-grafted and grafted sockets after 
immunohistochemistry for Notch-2 protein and counterstained with haematoxylin A. Control 
sample, coronal part of the socket; B. Control sample, apical part of the socket; C. Test sample, 
coronal part of the socket; D. Test sample, apical part of the socket. Staining of osteoblasts 
(black arrow), osteocytes (blue arrow) and the loose connective tissue. Scale bar: 100 µm 
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3.2.8.2 Notch-2, 8-week group, control and test 
While cells resembling osteoblasts were positively stained for Notch-2 protein in the grafted 
sockets, osteocytes showed positive staining in both non-grafted and grafted sockets. Also, a 
strong positive staining was observed in the loose connective tissue region in both test and 
control groups (Figure 22, Table 6). 
 
Figure 22. Representative photomicrographs of 8-week non-grafted and grafted sockets after 
immunohistochemistry for Notch-2 protein and counterstained with haematoxylin A. Control 
sample, coronal part of the socket; B. Control sample, apical part of the socket; C. Test sample, 
coronal part of the socket; D. Test sample, apical part of the socket. Osteoblasts (black arrow), 





3.2.8.3 Notch-2, 16-week group, control and test 
Osteocytes showed positive staining for Notch-2 in both non-grafted and grafted sockets. 
Positive staining was observed in the loose connective tissue in both test and control group. 
However, staining was not as strong as 4-week and 8-week samples (Figure 23, Table 6). 
 
Figure 23. Representative photomicrographs of 16-week non-grafted and grafted sockets after 
immunohistochemistry for Notch-2 protein and counterstained with haematoxylin A. Control 
sample, coronal part of the socket; B. Control sample, apical part of the socket; C. Test sample, 
coronal part of the socket; D. Test sample, apical part of the socket. Brown staining was found 







3.2.9 ALK detection by immunohistochemistry 
Immunohistochemistry for ALK protein in control and test samples. Photomicrographs of the 
coronal and apical parts of the sockets are presented for each group. 
 
3.2.9.1 ALK, 4-week group, control and test 
ALK was expressed intracellularly at similar levels in the control and test groups. The cells 
resembling osteoblast cells aligning the new bone and the superficial osteocytes most obviously 
showed positive brown staining for ALK in both non-grafted and grafted sockets (Figure 24, 
Table 6). 
 
Figure 24. Representative photomicrographs of 4-week non-grafted and grafted sockets with 
immunohistochemical detection of ALK protein. A. Control sample, coronal part of the socket; 
B. Control sample, apical part of the socket; C. Test sample, coronal part of the socket; D. Test 
sample, apical part of the socket. Intracellular staining (brown) of the osteoblasts (black arrow) 
and some osteocytes (blue arrow). Scale bar: 100 µm.  
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3.2.9.2 ALK, 8-week group, control and test 
Osteoblasts, some osteocytes and some loose connective tissue cells showed positive brown 
staining for ALK in the test group. However, only cells resembling osteoblasts and osteocytes 
were positively stained for ALK in the control group (Figure 25, Table 6). 
 
Figure 25. Representative photomicrographs of 8-week non-grafted and grafted sockets with 
immunohistochemical detection of ALK protein. A. Control sample, coronal part of the socket; 
B. Control sample, apical part of the socket; C. Test sample, coronal part of the socket; D. Test 
sample, apical part of the socket. Intracellular staining (brown) of the osteoblasts (black arrow) 







3.2.9.3 ALK, 16-week group, control and test 
ALK was expressed at similar levels in the control and test groups. The cells resembling 
osteoblasts, some osteocytes and some connective tissue cells showed positive brown staining 
for ALK in both non-grafted and grafted sockets (Figure 26, Table 6). 
 
Figure 26. Representative photomicrographs of 16-week non-grafted and grafted sockets with 
immunohistochemical detection of ALK protein. A. Control sample, coronal part of the socket; 
B. Control sample, apical part of the socket; C. Test sample, coronal part of the socket; D. Test 
sample, apical part of the socket. Intracellular staining (brown) of the osteoblasts (black arrow) 







3.2.10 RPTPζ detection by immunohistochemistry 
Immunohistochemistry for RPTPζ was visualised in all test and control samples. 
Photomicrographs of the samples from coronal and apical parts of the sockets are presented for 
each group. 
 
3.2.10.1 RPTPζ, 4-week group, control and test 
RPTPζ was expressed at similar levels in the control and test groups. The cells resembling 
osteoblasts showed strong positive brown staining for RPTPζ in both non-grafted and grafted 
sockets (Figure 27, Table 6). 
 
Figure 27. Representative photomicrographs of 4-week non-grafted and grafted sockets with 
immunohistochemistry for RPTPζ protein. A. Control sample, coronal part of the socket; B. 
Control sample, apical part of the socket; C. Test sample, coronal part of the socket; D. Test 
sample, apical part of the socket. Osteoblasts stained darkly (black arrow) and osteocytes (blue 
arrow). Scale bar: 100 µm.  
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3.2.10.2 RPTPζ, 8-week group, control and test 
The cells resembling osteoblasts showed strong positive brown staining for RPTPζ in the test 
group only. Osteocytes were positively stained in both non-grafted and grafted sockets (Figure 
28, Table 6). 
 
Figure 28. Representative photomicrographs of 8-week non-grafted and grafted sockets with 
immunohistochemistry for RPTPζ protein. A. Control sample, coronal part of the socket; B. 
Control sample, apical part of the socket; C. Test sample, coronal part of the socket; D. Test 
sample, apical part of the socket. Osteoblasts stained darkly (black arrow) and osteocytes (blue 







3.2.10.3 RPTPζ, 16-week group, control and test 
RPTPζ was similarly expressed in the control and test groups but at lower levels than other 
time points examined (Figure 29, Table 6). 
 
Figure 29. Representative photomicrographs of 16-week non-grafted and grafted sockets with 
immunohistochemistry for RPTPζ protein. A. Control sample, coronal part of the socket; B. 
Control sample, apical part of the socket; C. Test sample, coronal part of the socket; D. Test 
sample, apical part of the socket. Osteoblasts stained (black arrow) and osteocytes (blue arrow). 




Table 6. Immunostaining localisation and intensity at three time-points 
 
0 = no positive cells; 1 = occasional lightly coloured positive cells; 2 = moderately positive 




4 weeks 8 weeks 16 weeks 
Control Test Control Test Control Test 
New bone 3 3 3 3 2 2 
Osteoblasts 2 2 2 2 2 2 
Osteocytes 0 0 0 0 0 0 
Connective tissue 1 1 2 2 1 1 
Midkine staining 
4 weeks 8 weeks 16 weeks 
Control Test Control Test Control Test 
New bone 3 3 3 3 3 3 
Osteoblasts 0 0 0 0 0 0 
Osteocytes 3 3 3 3 3 3 
Connective tissue 0 0 0 0 0 0 
Notch-2 staining 
4 weeks 8 weeks 16 weeks 
Control Test Control Test Control Test 
New bone 1 1 1 1 1 1 
Osteoblasts 2 2 2 2 2 2 
Osteocytes 2 2 2 2 2 2 
Connective tissue 3 3 3 3 2 2 
ALK staining 
4 weeks 8 weeks 16 weeks 
Control Test Control Test Control Test 
New bone 0 0 0 0 0 0 
Osteoblasts 2 2 2 2 2 2 
Osteocytes 2 2 2 2 2 2 
Connective tissue 1 1 0 1 1 1 
RPTPζ staining 
4 weeks 8 weeks 16 weeks 
Control Test Control Test Control Test 
New bone 0 0 0 0 0 0 
Osteoblasts 3 3 3 3 3 3 
Osteocytes 3 3 3 3 2 2 
Connective tissue 2 2 2 2 1 1 
78 
 
3.2.11 Mouse IgG isotype negative controls with immunohistochemistry 
Immunohistochemical staining with mouse IgG isotype matched negative controls. 
Photomicrographs of the coronal and apical parts of the sockets are presented for each group. 
 
3.2.11.1 Mouse IgG, 4-week group, control and test 
Staining (brown) was not observed in the mouse IgG isotype negative control slides. This was 
true for both control and test groups (Figure 30). 
 
Figure 30. Representative photomicrographs of 4-week non-grafted and grafted sockets 
subjected to immunohistochemistry for mouse IgG isotype negative control and counterstained 
with haematoxylin A. Control sample, coronal part of the socket; B. Control sample, apical 
part of the socket; C. Test sample, coronal part of the socket; D. Test sample, apical part of the 




3.2.11.2 Mouse IgG, 8-week group, control and test 
Staining (brown) was not observed in the mouse IgG isotype negative control slides. This was 
true for both control and test groups (Figure 31). 
 
Figure 31. Representative photomicrographs of 8-week non-grafted and grafted sockets 
subjected to immunohistochemistry for mouse IgG isotype negative control and counterstained 
with haematoxylin A. Control sample, coronal part of the socket; B. Control sample, apical 
part of the socket; C. Test sample, coronal part of the socket; D. Test sample, apical part of the 








3.2.11.3 Mouse IgG, 16-week group, control and test 
Staining (brown) was not observed in the mouse IgG isotype negative control slides. This was 
true for both control and test groups (Figure 32). 
 
Figure 32. Representative photomicrographs of 16-week non-grafted and grafted sockets 
subjected to immunohistochemistry for mouse IgG isotype negative control and counterstained 
with haematoxylin A. Control sample, coronal part of the socket; B. Control sample, apical 
part of the socket; C. Test sample, coronal part of the socket; D. Test sample, apical part of the 








3.2.12 Rabbit IgG negative controls with immunohistochemistry 
Immunohistochemical staining with rabbit IgG isotype matched negative controls. 
Photomicrographs of the coronal and apical parts of the sockets are presented for each group. 
 
3.2.12.1 Rabbit IgG, 4-week group, control and test 
In the rabbit IgG isotype negative control slides only light intra-vascular staining was observed. 
This was true for both control and test groups (Figure 33). 
 
Figure 33. Representative photomicrographs of 4-week non-grafted and grafted sockets 
subjected to immunohistochemistry for rabbit IgG isotype negative control and counterstained 
with haematoxylin A. Control sample, coronal part of the socket; B. Control sample, apical 
part of the socket; C. Test sample, coronal part of the socket; D. Test sample, apical part of the 
socket. Scale bar: 100 µm.  
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3.2.12.2 Rabbit IgG, 8-week group, control and test 
Staining (brown) was not observed in the rabbit IgG isotype negative control slides. This was 
true for both control and test groups (Figure 34). 
 
Figure 34. Representative photomicrographs of 8-week non-grafted and grafted sockets 
subjected to immunohistochemistry for rabbit IgG isotype negative control and counterstained 
with haematoxylin A. Control sample, coronal part of the socket; B. Control sample, apical 
part of the socket; C. Test sample, coronal part of the socket; D. Test sample, apical part of the 
socket. Scale bar: 100 µm.  
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3.2.12.3 Rabbit IgG, 16-week group, control and test 
Only light background staining (brown) was observed in the rabbit IgG isotype negative control 
slides at 16 weeks. This was true for both control and test groups (Figure 35). 
 
Figure 35. Representative photomicrographs of 16-week non-grafted and grafted sockets 
subjected to immunohistochemistry for rabbit IgG isotype negative control and counterstained 
with haematoxylin A. Control sample, coronal part of the socket; B. Control sample, apical 
part of the socket; C. Test sample, coronal part of the socket; D. Test sample, apical part of the 









3.3 Gene expression and analysis 
3.3.1 Quantitation and quality RNA 
The RNA recovered from each of the 21 samples ranged in quality from 1.55 – 1.88 and the 
total RNA ranged from 560 – 6450 ng. Six of the RNA samples were concentrated due to their 
low yield (Table 7). 
 


















* Samples used for protocol development.  










Group A260 A260/ A280 
Concentration 
of RNA (ng/µl) 
Total 
RNA (ng) 
1 †597 4 week C 0.045 1.704 18.4 920 
2 432 4 week B 0.198 1.756 60.4 3020 
3 586 4 week C 0.320 1.899 128.0 6400 
4 441 4 week B 0.149 1.886 59.6 2980 
5 †*583 4 week C 0.028 1.556 11.2 560 
6 428 4 week B 0.091 1.820 36.4 1820 
7 595 4 week C 0.081 1.745 32.8 1640 
8 †440 8 week C 0.047 1.750 19.6 980 
9 589 8 week B 0.085 1.771 34.0 1700 
10 *434 8 week C 0.031 1.833 13.2 660 
11 †598 8 week B 0.035 1.667 14.0 700 
12 426 8 week C 0.152 1.831 60.8 3040 
13 438 8 week B 0.158 1.847 62.8 3140 
14 450 8 week C 0.169 1.888 67.2 3360 
15 430 16 week C 0.324 1.878 129.0 6450 
16 599 16 week B 0.096 1.846 38.4 1920 
17 584 16 week C 0.119 1.872 47.2 2360 
18 †585 16 week B 0.061 1.848 24.4 1220 
19 *442 16 week C 0.053 1.828 21.2 1060 
20 †427 16 week B 0.048 1.778 19.2 960 
21 425 16 week C 0.095 1.843 37.6 1880 
85 
 
3.3.2 Reference gene validation 
The mRNA expression level of the candidate reference genes GAPDH, ACTB, RPL19, B2M 
and YWHAZ was determined. A tissue sample from each time-point with and without reverse 
transcriptase was analysed. qRT2-PCR amplification products for each of the five candidate 
reference genes was achieved with Cq values ranging between 19.9 to 22. (Figure 36). 
Following NormFinder analysis B2M and RPL19 with the stability value of 0.014 were found 
to be the most consistently expressed (Table 8). Melting curve analysis confirmed the selection 
of B2M which was consistent across the three samples (Figure. 37A - E). A negative result for 
the reverse transcription-minus control samples (RT-) confirmed the elimination of the 
genomic DNA for B2M.  
 
B2M was selected as the most stable reference gene and was used for cDNA input 
normalisation. B2M Cq values and primer melting temperatures for all 18 samples can be found 
in Appendix 17. 
 
Table 8. Expression stability values of the reference genes calculated by NormFinder 
algorithm. 



















Figure 36. Reference mRNA expression. Three study samples were used to validate a reference 
gene. Reverse transcription (RT+) and reverse transcription- minus (RT-) are compared. UD: 














Figure 37. Reference melting curve analysis. Three study samples were used to validate a 
reference gene. Reverse transcription (RT+) and reverse transcription- minus (RT-) samples 











3.3.3 mRNA transcript analysis  
Pleiotrophin mRNA expression was found in all 18 samples analysed. No significant difference 
was seen between the control and test groups. When the control group gene expression was 
compared across the 3 time-points, it peaked at 8-week then decreased. However, in test group 
it was expressed at the highest level at 4-wks decreasing by 8-wk with a small but not 
significant increase by 16-wks. No significant changes were observed within the groups or 
between the controls and tests at matched time points (Figure 38, Table 9, Appendix 18). 
Midkine resembled a similar gene expression pattern to pleiotrophin and was detected in all 
samples. Midkine mRNA expression was found in all the samples analysed. No significant 
difference was seen between the control and test groups at 4-wks, 8-wks and 16-wks (P-value 
0.112, 0.136 and 0.155 respectively, Table 9). When the control group gene expression was 
compared across the 3 time-points, it peaked at 8-week then decreased. However, in test group 
it was expressed at the highest level at 4-wks decreasing by 8-wk and 16-wk. The P-value was 




Figure 38. Pleiotrophin (PTN) and midkine mRNA expression. mRNA expression 
normalised to the B2M reference gene are shown. Data (2∆-Cq) represented by floating bar (min 
to max) control (grey) and test (blue). The dotted line indicates the limit of detection; UD = 





mRNA expression of pleiotrophin family receptor genes were found in all 18 samples analysed 
(Appendix 20-22). From the analysis, the relative expression of pleiotrophin family receptor 
genes Notch-2, ALK, and RPTPζ did not reveal any statistically significant difference (P < 
0.05) at the three time-points between test and control group. 
Notch-2 was expressed at the highest level of three receptors and with small, but not significant, 
increase in expression over time (Figure 39, Table 9, Appendix 20). 
ALK mRNA expression was found in all the samples analysed. No significant difference was 
seen between the control and test groups (Table 9). When the control group gene expression is 
compared across the 3 time-points, it peaked at 8-week then decreased. However, in the test 
group it was expressed at the highest level at 4-wks, decreased at week 8 with then increased 
at 16-wks. This gene expression pattern was similar to mRNA expression in pleiotrophin. A 
high variability was observed in both control and test groups in ALK mRNA expression in 16-
wks (Figure 39). 
RPTPζ gene was expressed at the lowest level compared to ALK and Notch-2. No significant 
difference was seen between the control and test groups (Table 9). Although the RPTPζ gene 
was expressed, some values were undetectable (Cq >40). Therefore, differences in mRNA 




















Figure 39. Notch-2, ALK, RPTPζ mRNA expression. mRNA expression normalised to the 
B2M reference gene are shown. Data (2∆-Cq) represented by floating bar (min to max) control 
(grey) and test (blue). The dotted line indicates the limit of detection; UD = undetected. N = 3 
for each time point.
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Table 9. mRNA gene expression for test and control groups at each of 3 time-points  
 
Gene expression 
Pleiotrophin Midkine Notch-2 ALK RPTPζ 
P value P value P value P value P value 
*4-wk C vs 4-wk T 0.192 0.112 0.560 0.259 0.851 
*8-wk C vs 8-wk T 0.133 0.136 0.256 0.308 0.085 
*16-wk C vs 16-wk T 0.643 0.155 0.168 0.874 0.406 
†4-wk C vs 8-wk C vs 16-wk C 0.117 0.128 0.227 0.376 0.304 
†4-wk T vs 8-wk T vs 16-wk T 0.304 0.144 0.113 0.607 0.435 
 
Control (C); test (T); significant difference in relative gene expression at P < 0.05 
*Analysed using the parametric unpaired t-test 








  Discussion 
Bone resorption following tooth extraction may result in inadequate alveolar bone volume and 
unfavourable bone architecture for restorative treatment, particularly when implant is planned. 
To tackle this problem, bone replacement grafting materials (e.g. Bio-Oss®), secured with 
collagen membranes are commonly used to regenerate bone and to reduce bone resorption. The 
success of grafting is dependent on multiple factors including the presence of osteogenic 
growth factors and cytokines (Soltan et al., 2009). Previous researchers have detected 
pleiotrophin in osteoprogenitor cells during bone healing (Petersen et al., 2004; Li et al., 
2005b). Pleiotrophin is a multifunctional cytokine involved in osteogenesis. It has the ability 
to promote adhesion, migration, growth and differentiation of human osteoprogenitor cells 
(Lamprou et al., 2014). Therefore, it may be a good target molecule to functionalise scaffolds 
for bone graft materials (Yang et al., 2003). 
The aim of this study was to investigate the role of pleiotrophin family of cytokines and their 
receptors, during osteogenesis with and without a grafting material, after tooth extraction in a 
sheep model. To do this, we characterised the gene and protein expression of pleiotrophin 
(PTN), midkine (MK) and three of their receptors, receptor-type protein-tyrosine phosphatase 
ζ (RPTPζ), anaplastic lymphoma kinase (ALK) and Notch-2. We used a sheep tooth-socket 
model of bone regeneration, treated using a widely-accepted bovine xenograft (Bio-Oss®) and 
resorbable porcine collagen membrane (Bio-Gide®). We examined healing after three time 
points (four, eight and 16 weeks) using immunohistochemistry (IHC) of demineralised, 
paraffin-embedded sections, as well as investigating gene expression using quantitative real-
time reverse transcriptase polymerase chain reaction techniques  (qRT2-PCR). To the best of 
our knowledge, this is the first in vivo study to attempt the localisation and expression analysis 
of the PTN family of cytokines in association with grafting material and bone regeneration. 
Our first hypothesis was that pleiotrophin family protein ligands and receptors would be 
detected in alveolar tooth sockets with and without grafting with Bio-Oss®/Bio-Gide®, during 
osteogenesis in a sheep model. This hypothesis was correct, as we did localise PTN, MK and 
receptors in the healing tooth sockets. The second hypothesis was that bone grafting would 
enhance gene expression of pleiotrophin family of cytokines in a sheep model of tooth socket 




We found an increase in woven bone formation in tooth socket healing when grafted with Bio-
Oss® and Bio-Gide®. IHC illustrated similar expression of PTN, MK and their receptors in both 
non-grafted and grafted sockets. The PTN and MK proteins were detected in association with 
new bone formation. Notch-2 was detected in the connective tissue, and both RPTPζ and ALK 
were located in the nuclei of cuboidal osteoblasts involved in bone formation. Consistent with 
this finding, PTN and MK gene expression was detected in all control and test tooth sockets 
and showed a similar expression pattern during socket healing. The relative expressions of the 
PTN family receptor genes RPTPζ, ALK and Notch-2 were not statistically different at the 
three time-points and between test and control groups (p>0.05). 
Sheep have been shown to be a suitable model for periodontal research (Danesh-Meyer et al., 
1995; Duncan, 2005; Smith, 2011; Baharuddin et al., 2015; Lander, 2016). They are considered 
to have a comparable bone healing rate to that of humans (Den Boer et al., 1999). The 
similarities in size, weight and general physiology with humans make this animal a valuable 
model for research (Newman et al., 1995). Sheep premolars vary in size and apart from the first 
premolar, vary greatly compared to premolars in humans. We found extraction of second and 
third premolars challenging due to their long, slender roots and the higher density of the bone 
(Nafei et al., 2000). A full thickness periosteal flap was elevated for the tooth extractions. This 
was to ensure adequate access and better visibility as well as achieving primary closure to 
enclose the graft material and collagen membrane. To control the differences in size between 
tooth sockets, the sockets were standardised with an implant drill to prepare the premolar tooth 
sockets. Using the tooth sockets in sheep to investigate bone healing with and without bone 
grafts, as opposed to creating defects in long bones (Ignatius et al., 2001), has the advantage of 
assessing intramembranous bone healing under a physiologic mechanical load similar to 
clinical conditions for dental application.  
Mandibular bone remodelling in sheep reaches a peak during the period of maximal growth, 
which is at 1 year and 2 months. The remodelling also increases slightly at 2 ½ years and 3 ½ 
years and thereafter a decrease occurs with minimal bone remodelling activity at 3 ½ years  
(Atkinson et al., 1982). In our research, animals were selected from the same flock and age-
matched (average 3.5 years). We did this to minimise the influence of variations in healing 
physiology. In New Zealand, the use of sheep for animal studies is common and economical 
as these animals are available in large numbers. They are part of the food chain and more 
ethically acceptable for application in studies compared to companion animals such as dogs 
(Pearce et al., 2007) 
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In the present study 10% neutral buffered formalin (NBF), which is the most common fixative 
used in diagnostic pathology, was used to fix the samples. It preserves peptide-protein bonds 
and the general structure of cellular organelles. (Bancroft & Gamble, 2008). The EDTA 
decalcification for the samples took sixteen to forty-one weeks to achieve which was longer 
than other studies using EDTA for similar purposes on sheep samples (Baharuddin et al., 2015). 
This was due to the large size of the blocks, as the entire tooth socket was required for the 
investigation. 
Light microscopy was used to analyse the H&E stained sections and this indicated varying 
degrees of bone healing in all control and test samples at the three time-points. This was a 
credible finding, as a previous study in the sheep model indicated the initiation of bone 
formation and osteogenesis at six days post-defect formation (Harrison, 1943). This compares 
to humans where osteogenesis of the tooth socket is evident at an average time of 12 days 
(Amler, 1969).  
The highest quantity of provisional bone matrix containing connective tissue with 
mesenchymal cells was observed in the 4-week group. Formation of woven bone with 
projections of mineralised tissue were identified, which progressively extended from the walls 
of the socket to the centre of the wound. This observation has also been previously described 
by others as the “proliferative phase” of tooth socket healing (Amler, 1969; Broughton et al., 
2006; Trombelli et al., 2008) . The histological findings in the 8-week and 16-week groups 
resembled the “modelling and remodelling” phase of socket healing, with formation of more 
woven bone and replacement by lamellar bone (de Sousa Gomes et al., 2019). We found a 
marginal hard tissue bridge covering the socket entrance in the 8-week and 16-week samples, 
which was similar to that observed at 60 days (around eight weeks) and 120 days (around 16 
weeks) in the dog model (Cardaropoli et al., 2003). In our study, bone formation in the apical 
and lateral portions of the socket was noted earlier than the central and marginal regions. This 
finding was similar to the finding in grafted sockets with Bio-Oss Collagen® in the dog model 
(Araújo et al., 2010). 
We found plexiform bone structures which comprised of woven and lamellar bone with a 
vascular plexus, which was consistent with the age of the sheep in the study (about 3.5 years). 
Haversian systems were not detected, as has been observed in sheep aged 7-9 years (Newman 
et al., 1995).  
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Our histological analysis suggested that there was more newly formed bone (osteoid) in grafted 
sockets compared to non-grafted sockets at each-time point. A quantitative histomorphometric 
analysis comparing the total volume of the newly formed bone in each group was conducted 
as part of another study and not reported here. 
Bio-Oss® demonstrated good osteoconductivity with healing showing increased formation of 
the woven bone. Trabecular bone formation in the healing sockets was seen radiating from the 
peripheral bone toward the centre of the socket. 
No difference was seen in the gene expression for PTN, MK and their receptors in sites grafted 
with Bio-Oss® and Bio-Gide® compared to the non-grafted sites at matched time points in this 
study. Little known about the regulation of PTN and MK in socket healing. However, study 
showed that PTN increases tyrosine phosphorylation of beta- catenin, an essential upstream 
regulator of bone formation (Meng et al., 2000). Osteoconductive bone materials, despite their 
apparently inert osseous phenotype, have been described as biologically active substances 
(Klein et al., 2020). Furthermore, it has been shown that membranes not only act as a passive 
barrier but also play a bioactive role in modulating the cellular and molecular activities during 
bone regeneration (Omar et al., 2019). However, our study found no evidence of a direct 
regulatory effect by the bone graft and membrane for the PTN family of cytokines and 
receptors. 
As part of this research project, we developed a protocol for heat-induced antigen retrieval for 
IHC analysis. We found methodological errors, with tissue samples lifting and folding, when 
the Decloaking ChamberTM NxGen (Biocare Medical) was used at the recommended 
temperature of 110C for 10 min. We investigated a number of different microscope slides with 
different adhesion technology and different heat-induced antigen retrieval protocols with both 
the pressure cooker and water bath. We achieved the best results in terms of tissue stability on 
glass slides and immunostaining outcomes when Superfrost Ultra Plus® (Cat no. J3800AMNZ) 
glass slides was used and antigen retrieval was performed with Decloaking ChamberTM at 80C 
for 15 min. All antibodies were optimised to achieve satisfactory results with high intensity 
staining and with minimum tissue background staining. Negative IgG controls were used to 
reveal non-specific binding and false positive results. Qualitative analysis of IHC slides was 
performed to assess the expression of the protein of interest in the sockets. Semi-quantification 
analysis was not used as it was shown to be subjective in interpretation (Rizzardi et al., 2012). 
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Using IHC, PTN protein was detected in osteoblasts and the newly formed bone in all control 
and test samples at all time-points. This suggests that PTN has a fundamental role in 
osteoblastic activity (Li et al., 2005a). Upregulation of PTN on the surface of damaged bone is 
thought to play an important role in osteoblasts recruitment and  new osteoid deposition during 
bone repair (Imai et al., 1998). 
Notch-2 protein was observed in osteoblasts, osteocytes and the connective tissue in test and 
control samples at 4-week. However, osteoblasts were not positively stained in the later stages 
of socket healing. Notch activation in osteocytes leads to suppression of bone resorption and 
enhancement of bone formation in cortical bone (Canalis et al., 2013a). Others have also 
reported the high expression of the Notch-2 receptor during healing, and found it localised in 
mesenchymal cells during bone healing (Dishowitz et al., 2012). This is consistent with the 
localisation of Notch-2 protein in the connective tissue in this study. 
ALK and RPTPζ, proteins were found in association with osteocytes and cuboidal osteoblasts 
involved in bone formation. RPTPζ, is a marker for differentiated osteoblasts which negatively 
regulates proliferation in vitro and regulates the tyrosine phosphorylation of proteins affecting 
growth factor activation (Baldauf et al., 2015). Little is known of the role of ALK in 
osteogenesis, however in other systems it has been associated with activation of anti-apoptotic 
signalling in hematopoietic cells thus enhances cell survival (Zamo et al., 2002) 
All the proteins of interest were detected in all control and test sockets at the three time-points 
however we found that these had different spatial and cellular localisations. The respective 
genes of interest were also expressed. The expression of proteins of interest were similar in the 
test and control group at three time-points. This was consistent with the expression of the genes 
of interest, which showed no statistically significant differences between the test and control 
groups. Other studies that evaluated the concordance between protein and mRNA expression 
level found wide variability (Pascal et al., 2008). It has been demonstrated that protein 
concentrations correlate with the corresponding mRNA levels by only 20 – 40%. The 
discrepancy between protein and mRNA expression are most likely a result of the biology of 
gene expression rather than measurement errors. This emphasises the importance of post-
transcriptional regulatory mechanisms (Tian et al., 2004). Therefore, mRNA levels are only a 
weak surrogate for corresponding protein concentration (Nie et al., 2006). 
97 
 
Quantitative analysis of the expression of the genes of interest were investigated using qRT2-
PCR. We are the first to report PTN family gene expression in alveolar bone.  This confirmed 
our IHC observations showing high expression of PTN, MK, Notch-2 and ALK in both grafted 
and non-grafted sites at all time-points. RPTPζ RNA was expressed at low levels however the 
receptor protein was found to be present by immunohistochemistry. This can be explained by 
the mechanism for regulation of RPTPζ activity. RPTPζ is distributed on cell membranes and 
both PTN and MK bind to extracellular region of RPTPζ (Maeda et al., 1996; Maeda et al., 
1999). This binding induces the clustering of RPTPζ on the cell surface and subsequently 
inactivates RPTPζ (Fukada et al., 2006). 
The similarity and relatively high gene expression for PTN and MK is plausible as they are 
from the same family gene group with 55% structural homology and have similar sequence 
identity (Muramatsu, 2014).  
The current investigated time frames do not allow a full assessment of whether Bio-Oss® and 
Bio-Gide® promoted PTN and MK gene expression, or what aspect of the regeneration process 
or the hypoxic wound environment might play in inducing the levels seen by 4-weeks (Antoine 
et al., 2005). The expression of PTN and MK were high at 4 weeks and ideally a study to 
investigate earlier time-point would be recommended. In another study, the grafting of murine 
sockets with bovine bone graft promoted osteoblasts and osteoclasts after seven days (Klein et 
al., 2020). In a similar model when intracranial defects were covered with a non-resorbable 
membrane, osteogenesis-associated growth and differentiation factors and transcriptional 
regulators of osteoblast function were up-regulated at day 14 (Ivanovski et al., 2011). Turri and 
co-workers demonstrated an increase in expression of bone formation gene markers at day six 
and day 28 when a collagen membrane was used in the defects created in rat femurs. The results 
of their study provided structural, cellular and molecular evidence suggesting that the 
membrane creates a bioactive compartment (Turri et al., 2016). The rabbit calvaria model 
grafted with bovine bone and collagen membrane revealed an increased expression of genes 
related to the early stages of bone formation, bone remodelling and preosteoclast development 
after one week (Suleimenova et al., 2017). Although the size of the defects in other studies are 
different, the increased expression of the bone formation markers prior to 4 weeks suggests the 
possibility that PTN and MK expression might have been initiated earlier than 4 weeks. This 
can be supported by the fact that the blood clot serves to concentrate the elaborated cytokines 
and growth factors during the haemostasis and inflammation phase of socket healing (from 
immediately after extraction through day four to day six) (de Sousa Gomes et al., 2019).  
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Comparing the grafted and non-grafted groups, the expression level of PTN and MK switched 
at 8-week, where the test group revealed lower gene expression compared with the control 
group, although no statistically-significant differences were detected. In the later stages of 
socket healing at 16-week, the greater variability of gene expression in the test group could be 
explained by heterogeneity in the study samples. The small sample size (3 samples in each 
time-point) could also increase the inter-sample differences (Rusticus & Lovato, 2014). 
Tooth extraction leads to microvascular damage and blood extravasation that are controlled by 
vasoconstriction of the vascular smooth muscles (Broughton et al., 2006) . This is only 
temporarily effective until acidosis and hypoxia develop within the microenvironment and lead 
to passive vascular relaxation (Monroe & Hoffman, 2012). We believe this temporary hypoxia 
may induce PTN gene transcription. The effect of hypoxia on PTN upregulation has been 
demonstrated in rat hepatic stellate cells (Antoine et al., 2005). MK has a HIF-1α- (hypoxia‐
inducible factor 1α) responsive gene element and is induced under low oxygen conditions 
(Reynolds et al., 2004). Therefore, we conclude that PTN and MK expression was initiated at 
the early stages of the socket healing and the impact of hypoxia needs further investigation. 
Of the three receptors examined in this study, Notch-2 was expressed at the highest level with 
a small but not significant increase in the expression over time. The Notch intercellular 
signalling pathway is highly conserved and regulates cell proliferation, differentiation, and 
determines cell fate decisions (Luo et al., 2019). It regulates osteoblast and chondrocyte 
behaviour and also regulates angiogenesis, which is critical for bone healing. Upregulation of 
Notch signalling during bone fracture healing has been previously reported (Dishowitz et al., 
2013). Overexpression of Notch signalling in osteocytes resulted in suppressed bone resorption 
and increased bone volume; promotion of bone repair via regulation of Notch signalling has 
been shown in several studies  (Luo et al., 2019). It has been noted that hypoxia promotes 
Notch expression and activates Notch signalling (Xu et al., 2013). This supports the finding in 
our research that Notch-2 expression was upregulated within the defect site in the early stage 
of wound healing and was then consistently expressed during osteogenesis. 
The ALK gene was also highly expressed and the pattern of expression was similar to that of 
PTN. However, RPTPβ/ζ was expressed at low levels. This could be a result of crosstalk 
between ALK and RPTPβ/ζ. Tyrosine phosphatase activity of RPTPβ/ζ and 
autophosphorylation and activation of ALK are balanced. PTN inactivates RPTPβ/ζ through 
dimerisation of the membrane receptors, resulting unbalanced autophosphorylation of ALK 
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and therefore autoactivation of ALK occurs. Thus the PTN/RPTPβ/ζ signalling pathway 
regulates the activity of ALK and tyrosine phosphorylation levels of ALK downstream target 
proteins (Deuel, 2013).  
A number of important limitations in the current study need to be considered. First, migration 
of the graft material to the adjacent socket may have occurred. The use of all three premolar 
sockets were required for another study, thus this study design was inevitable. Secondly, three 
dimensional radiographic imaging (either computerised tomography CT or cone-beam 
computerised tomography CBCT) was not available at the time of surgery. Therefore, the only 
reliable reference after extraction of the premolars was the first molar, which was used as a 
reference for the bone trephination. This resulted in a small number of samples for gene 
analysis (N=3 per group at each time-point). Thirdly, tooth sockets were not monitored during 
healing as this required placing the animals under a general anaesthetic for access. The sheep 
were placed on a soft diet, therefore the chance of damaging the flap and losing the bone graft 
was low although it was not impossible. Finally, blinding of the investigators at the time of 
surgery was impossible to achieve. However, investigators were blinded during sample 
analysis. 
Pleiotrophin is a small, stable molecule that has been found to be involved in both the activation 
of osteogenic progenitor cells and the maturation of bone and as such is an important regulator 
of bone formation. We found PTN, MK and their receptors are expressed during bone 
regeneration in this model. Advances in tissue engineering techniques might provide bioactive 
materials for enhanced bone formation that improve clinical outcomes. The potential 
therapeutic application of these cytokines require investigations that examine the presence of 
receptor/ligand interactions important to natural osteogenesis. Modulation of PTN and its 





The present study investigated bone healing and the role of the PTN family in osteogenesis 
with and without a grafting material following tooth extraction in a sheep model during tooth 
socket healing. 
Within the limitations of this study, it can be concluded that the grafted tooth sockets 
demonstrated undisturbed wound healing and better histological outcomes in terms of bone 
formation at 4, 8 and 16 weeks when compared to the negative (ungrafted) control group. 
The pleiotrophin family of ligands and receptors were expressed in both non-grafted and 
grafted sockets during osteogenesis in a sheep model of alveolar bone regeneration, however 
bone grafting did not enhance the expression of these cytokines. This demonstration of the 
importance of the pleiotrophin/midkine family during alveolar bone regeneration is novel and 
opens up new avenues of research. Therapeutic supplementation of tooth sockets using 
pleiotrophin and or midkine in an appropriate matrix / carrier may be an approach to enhance 
regeneration or to facilitate healing where this is delayed. The activation of Notch-2 and RPTPζ 
receptors were identified as important during bone regeneration in vivo. RPTPζ as a receptor is 
known to act as a key molecular switch as it allows activation of other tyrosine kinase receptors 
such as ALK to go unchecked without negative feedback from this tyrosine-protein 
phosphatase. As such it may be critical in bone tissues requiring enhanced regeneration. Notch-
2 is known to be critical to cell fate during differentiation as it suppresses osteoclastogenesis 
and aids recruitment of osteoblasts. Future research into modulating the expression of the PTN 










4.2 Future directions 
The following experiments are suggested to expand the findings presented here. 
 In our experimental model, we had a challenge in defining the socket outline when 
separating the sockets. The application of 3-D radiographic imaging such as CT or 
CBCT may help define the location of the different surgical sites and thus provide more 
consistency in histological imaging. 
 In our study, we detected an increase in the gene expression of the PTN family of 
cytokines and their receptors. However, this difference was not statistically significant. 
This could be due to the small sample size (N=3 for each group, at each time-point). 
Therefore, we recommend using a larger sample size for future studies. 
 In this research, expression of the PTN family genes was investigated in grafted and 
non-grafted sockets at 4, 8 and 16 weeks. We suggest that gene modulation using 
siRNA (small interfering RNA) during the first four weeks be investigated in future 
research as a potential therapeutic approach to post-tooth extraction alveolar ridge 
preservation. 
 The tooth sockets were standardised using an implant drill in this experiment. However, 
for more accurate results and to decrease the variability, it is recommended creating 
defects where the same amount of bone graft could be applied. Thus, this research 
should also be investigated in standardised critical size defect models such as the 
cranial, scapular, iliac or long bone segmental defect models in sheep (Gosain et al., 
2004; Li et al., 2015; Ferguson et al., 2018; McGovern et al., 2018) 
 It would be worthwhile evaluating the PTN family gene expression in bone healing 
when only a membrane is applied to the tooth socket. This would establish whether the 
changes in the gene transcription are induced by bone graft, membrane or both. 
 Detection of PTN and MK during the socket healing is an interesting finding. Future 
research could be conducted stimulating of the production of these cytokines by using 
gene therapy.  
 The presence of the PTN family receptors during bone healing suggests the potential to 
target these for tissue engineering therapies. Performing studies on the impact of 
activation of these receptors during rapid bone regeneration or initiation of healing in 
cases with delayed healing, are recommended. 
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 A feasibility study introducing the use of PTN and/or MK as a biological regenerative 
device (e.g.: PTN and or MK absorbed in a collagen sponge) for bone healing after 
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Appendix 1. 20% alcohol preparation 
 
Reagents and equipment 
 Ethanol (absolute for analysis), (Emsure®, Merck, Cat no. 1.00983.2511) 
 Double distilled water (dd H2O) 
 Graduated cylinder 
 Glass Bottle with cap 
 
Preparation 
Measure 200 ml volume of ethanol and 800 ml volume of dd H2O with separate graduated 











Appendix 2. 10% EDTA preparation 
Requirements: 
● Reagents 
 EDTA powder (ethylene dinitrilotetraacetic acid disodium salt dehydrate) (Titriplex® 
III, Merck, Cat no.1.08418.1000) 
 Sodium Hydroxide (Emsure®, Merck, Cat no.1.06498.0500) 
 Double distilled water (dd H2O) 
 Milli-Q water (MQ H2O) 
● Equipment 
 Beaker 
 Graduated Conical flask 
 Digital scale 
 Magnetic stirrer 
 pH meter 
 Autoclavable glass bottle with cap 
 Autoclave 
 
Preparation of 750 ml 10% EDTA 
Weigh out 75 g of EDTA. Gently place the magnetic stir bar in the beaker and add 500 mL dd 
H2O. After calibrating the pH meter, add sodium hydroxide pellets to adjust the pH to 7.4 and 
wait until it completely dissolves. Adjust the volume to 750 mL by adding dd H2O. Adjust the 
pH by adding sodium hydroxide pellets if required. Transfer the solution to graduated conical 
flask to measure 750 mL of the solution. Adjust the volume by adding more dd H2O if required. 





Appendix 3. Paraffin embedding process for decalcified specimens 
Automatic Processing machine, Shandon Citadel 1000 (England, UK) 
Use program ‘A’-Long Cycle 
Station Reagent Time (hours) 
1 70% Ethanol 2.00 
2 95% Ethanol 1.30 
3 100% Ethanol 1.30 
4 100% Ethanol 2.00 
5 100% Ethanol 1.50 
6 Ethanol/ Xylene 0.30 
7 100% Xylene 1.30 
8 100% Xylene 1.45 
9 100% Xylene 1.45 
10 Paraplast wax 1.40 
11 Paraplast wax 1.30 
12 Paraplast wax 1.40 
 Total Time 19.10  
 
















Appendix 4. Slide numbers after sequential sectioning of the paraffin-embedded blocks and the designated experiment for each slide 
* Slide used for immunohistochemistry experiment in this study
Slide cut 
No  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 40 41 
     
  Block 
 




















































































































 4-week                        
1 441 R1B           * * * * * * * *      
2 441 R3           * * * * * * * *      
3 586 R2           * * * * * * * *      
4 586 R3           * * * * * * * *      
5 597 R2           * * * * * * * *      
6 597 R3           * * * * * * * *      
 8-week                        
7 594 R1 B           * * * * * * * *      
8 594 R2 A           * * * * * * * *      
9 438 R1           * * * * * * * *      
10 438 R3           * * * * * * * *      
11 598 R1           * * * * * * * *      
12 598 R3 A           * * * * * * * *      
 16-week                        
13 430 R2 A           * * * * * * * *      
14 430 R3           * * * * * * * *      
15 427 R1           * * * * * * * *      
16 427 R3 B           * * * * * * * *      
17 592 R1           * * * * * * * *      
18 592 R2           * * * * * * * *      
128 
 
Appendix 5. Haematoxylin and eosin (H&E) staining 
 
Reagents 
 Haematoxylin Gill II (Leica, Surgipath, Cat no. 060419)                         
 Eosin (Leica, Surgipath, Cat no. 042919) 
 Ethanol (Fisher Chemical, Cat no. 1909933) 
 Xylene (Ajax Finechem, Cat no. 1910294390) 
 Scott’s water (Amber Scientific, Cat no. A190323) 
 DPX mounting agent (Entellan, Merck, Cat no. HX90503161) 
 Cover slip (Trajan, Cat no. 471112450M) 
Procedure 
Place the slides in a metal staining rack and immerse sections in Haematoxylin for 10 
seconds 
Rinse slides under running tap water until clear 
Immerse sections in Eosin stain for about 30 seconds 
Rinse slides under running tap water until clear 
Place slides in the following solutions: 
50% alcohol for 2 min 
90% alcohol for 2 min 
100% alcohol for 2 min 
Xylene 2 x 5 min 











Appendix 6. Preparing antigen retrieval solution 
 
Reagents 
 Tri- Sodium citrate dihydrate (Merck KGaA, Germany, M: 294.10g/mol, Cat no. 
1.06448.05000) 
 Concentrated HCl 
 Double distilled water (dd H2O) 
 Milli-Q water (MQ H2O) 
 
Equipment 
 Nalgene filtration product (Apogent Technologies, Cat no. 8-0000-22 0301) 
 Sterile filter unit with Durapore®PVDF membrane (Millex®- HV, 0.45 µm, Merck, 
Cat no. SLHU033RS0) 
 Digital scale 
 Beaker 
 Digital scale 
 Magnetic stirrer 
 pH meter 
 Glass bottle with cap 
 
Preparing 0.1 M tri- sodium citrate buffer 
- Weigh out 29.4 g of tri- sodium citrate dihydrate 
- Gently place the magnetic stir bar in the beaker and add 900 mL dd H2O 
- After calibrating the pH meter, add 10 M concentrated HCl to adjust the pH to 6.0  
- Adjust to 1 litre with dd H2O 
- Filter the 10X stock solution through a 0.45 µm button filter into an autoclaved bottle 




Appendix 7. Benchmark XT Immunohistochemistry  
Outline of the automated IHC procedure for RPTPζ on the Ventana benchmark 
machine (Ventana Medical System, INC. AZ, USA) 
 








Isotype IgG (Santa Cruz, 
Cat no. SC74443) 
5 μg/ml (1:40 dilution) 
 
Rabbit IgG, solid phase 
absorbed (Dako, Cat no. 
X0936) 




1. Select the protocol (standard CC1). 
2. Print and apply slide barcode label for the planned antibody protocol. 
3. Place the reagent tray on the automated slide stainer. 
4. Check bulk fluids and waste. 
5. Load the slides onto the automated slide stainer and start the staining process. 
Machine commences deparaffination followed by cell conditioning. 
6. Gently open the staining tray once the machine indicates the time for manual 
titration of the antibody. 
7. Dispense 100 µl of diluted antibody in the centre of the slide and close the 
tray. Press start to continue the automated procedure with antibody incubation 
and DAB detection. 
8. At the completion of the run, remove the slides from the automated slide 
stainer. 
9. Wash the slides under running water for 5 min. 
10. Dehydrate the slides in ascending alcohol (50%, 90%, 100%) (5 min x 3), 
ending in xylene (2 min x 2). 











Appendix 8. Immunohistochemistry protocol for antibody incubation on bench 
 
Reagents 
 Primary and secondary antibodies  









 Anti-PTN, mouse 
monoclonial, anti-human, 
Isotype IgG (Santa Cruz, 
Cat no. SC74443) 
4 μg/ml (1:50 dilution) 
 
Mouse IgG, solid phase 
absorbed (Santa Cruz, Cat 
no. SC2025) 
4 μg/ml (1:100 dilution) 
Biotin rabbit anti-mouse 
(IgG), (Abcam, Cat no. 
ab6761) 








Isotype IgG (Abcam, Cat 
no. ab52637) 
2.1 μg/ml (1:250 dilution) 
 
Rabbit IgG, solid phase 
absorbed (Dako, Cat no. 
X0936) 
2 μg/ml (1:500 dilution) 
Biotin goat anti-rabbit 
(IgG), (Abcam, Cat no. 
ab6012) 













Rabbit IgG, solid phase 
absorbed (Dako, Cat no. 
X0936) 
2 μg/ml (1:500 dilution) 
Biotin goat anti-rabbit 
(IgG), (Abcam, Cat no. 
ab6012) 







Isotype IgG (Assay 
Matrix, Cat no. PA1741) 
2 μg/ml (1:250 dilution) 
 
Rabbit IgG, solid phase 
absorbed (Dako, Cat no. 
X0936) 
2 μg/ml (1:500 dilution) 
Biotin goat anti-rabbit 
(IgG), (Abcam, Cat no. 
ab6012) 
5 μg/ml (1:200 dilution) 
 
 Blocking serums 
Pleiotrophin Midkine Notch-2 ALK 
20% rabbit serum 
(Sigma, Cat no. 
R9133) 
20% goat serum 
(Sigma, Cat no. 
G9023) 
20% goat serum 
(Sigma, Cat no. 
G9023) 
20% goat serum 
(Sigma, Cat no. 
G9023) 
 
 BSA (Albumin from Bovine Serum) (Sigma Aldrich, Cat no. 120M1145V) 
 PBS (Phosphate Buffer Saline) (Gibco, Life Technologies, Cat no. SALB010) 
 Xylene (Scharlu, Cat no. X100592500) 
 Ethanol (Lab Supply, Cat no. CHE2292.1) 
 dH2O (distilled water) 
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 Antigen retrieval solution (see appendix 4) 
 WB graded filter paper 
 Non-fat milk powder (Pams) 
 Tween 20 (BIO-RAD, Cat no. 170-6513) 
 Methanol (Merck, Cat no.1230) 
 Hydrogen peroxide 30% (Scharlau, Cat no. HI01361000) 
 Vectastatin ABC Kit (Elite PK-6100, Vector Laboratories, Cat no. ZD0413) 
 3, 3’- Diaminobenzidine (DAB) enhanced DAB liquid substance system 
tetrahydrochloride (Sigma, Cat no. SLBQ85341V) 
 Haematoxilin Gill II (Surgipath, Cat no. 100517) 
 Scott’s Tap Water Substitute (ACR Laboratory Reagent, Cat no, 1871) 
 DPX mounting solution (SIGMA, Life Science, Cat no. BCBV8243) 
 Cover slips (Labserv. Cat no. 031215-9) 
Equipment 
 Slide rack 
 Decloaking Chamber (BioCare medical, Cat no. DC12-220-0255) 
 Slide staining jar 
 Wax pen (Deko, Denmark, Cat no. 00088518) 
 Orbital shaker (IKA-SCHÜTTLER MTS4) 
 Incubation box 
 
This procedure was performed over two days 
Day 1. 
1. Clearly label the slides with the experimental slide number, target antigen/negative 
control plus the experimental date using a HB pencil. 
2. Prepare 1% BSA/PBS required for day 1 and day 2. BSA acts as a carrier protein and 
helps minimise background staining. When mixing BSA in the PBS, do not shake it 
rather agitate gently while on ice until it dissolves. 
3. Place the slides in a rack and immerse in xylene for deparaffinisation in 3 steps of 5 
mins, 5 mins and 10 mins (xylene should always be used under fume cupboard). 
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4. Place the slides in the descending graded ethanol series (100%, 90%, 70%, 50%) for 5 
mins each. 
5. Slides washed with distilled water (dH2O) twice for 5 min. After dH2O, all the slides 
can be kept in PBS, which is better for long-time storing and subsequent steps. 
6.  Antigen heat retrieval: Add 500 ml dH2O to the Decloaking Chamber NxGen metal 
water chamber; 220 ml dH2O to the two outside metal slide canisters; to the inside 
canister with the slides inside it add 220 ml antigen retrieval solution. Select the 
program: 80C for 15 mins. After completion of the run, wait until the machine has 
cooled down to 70C and remove the metal slide canister and wash the slides 2 x 5 min 
in a slide staining jar with 300 ml PBS (on orbital shaker).  
7. Draw a closed circle with a wax pen around the tissue on the slide. The WB graded 
filter paper can be used to remove excess liquid. In all steps should be conducted 
quickly so that the tissue does not dry out. 
8. Prepare 20% blocking serum by mixing the animal serum with 1% BSA/PBS. Calculate 
the required blocking serum based on using 150 µl blocking serum per slide. Store the 
blocking serum on ice before use. 
9. Immunohistochemical staining: incubate the blocking serum on all slides (150 µl per 
slide) in a humidified chamber for 30 mins at room temperature. 
10.  Prepare antibody diluent of 5% animal serum (goat or rabbit) diluted in 1% BSA/PBS. 
Store on ice before use. Make enough for diluting both the primary and secondary 
antibodies. 
11. Drain slides on tissue paper for a few seconds (do not rinse - never wash between 
blocking and 1st antibody incubation) and wipe around the sections with filter paper 
a) Apply diluted primary antibody (150 µl per slide) on target antigen slides. 
b) Apply diluted isotype matched control (150 µl per slide) on negative control slides. 
12. Incubate overnight at 4°C in the incubation box with PBS to humidify environment. 
13. Prepare Wash Buffer (0.1% Tween-20 and 0.5% milk powder in PBS). To 320 ml of 








14. Remove all the slides from the incubation box and put them into a small glass container 
with 100 ml wash buffer, 3 washes for 5 mins, 20 mins and 20 mins, while on orbital 
shaker. 
15. Prepare and apply diluted secondary antibody on all slides (150 µl per slide). 
16. Incubate for 1 hour in a humidified chamber at room temperature (lid on). 
17. Wash with 3 changes of PBS for 5 mins, 10 mins and 10 mins. 
During the washing, start to make the ABC mixture for step 21. 
18. Prepare endogenous peroxidase blocking just before working. Add 1 ml of 30% 
hydrogen peroxide in 100 ml methanol and mix.  
19. Incubate slides in 0.3% H2O2 in methanol for 10 mins (shaking is not required). 
20. Wash with 3 changes of PBS for 5 mins each time. 
21. Prepare Vectastain Elite ABC Kit Strep HRP. Add 40 µl of the A solution to 2000 µl 
PBS and mix it. Then, add 40 µl of the B solution to the mixture and mix. Wait 30 mins 
before use. 
22. Add the per-prepared Strep HRP onto the tissues, 150 µL per slide. 
23. Incubate all slides for 30 mins at room temperature in a humidified environment. 
24. Wash with 3 changes of PBS for 5 mins, 10 mins and 10 mins. 
25. Prepare DAB Chromogen by adding 2 drops of DAB (solution B) to 2 ml of buffer 
(solution A). The DAB mixture should be prepared no more than 10 mins before use. 
26. Apply 150 µl onto slides for a maximum of 3 mins each slide. Three slides in one batch. 
Tip excess through funnel into DAB waste flask. 
27. Wash with 3 changes of dH2O for 5 mins each time. 
28. Haematoxylin staining by using 2 drops of haematoxylin solution for 2 seconds.* 
29. Rinse slides under running tap water until clear.* 
30. Place the slides in Scott’s tap water for 1 min.* 
31. Rinse slides under running cold tap water.* 
32. Place the slides in ascending graded alcohol for 2 mins for dehydration of the tissues 
(50%, 90% and 100% accordingly). 
33. Place the slides in xylene in 2 steps for 5 mins each. 
34. Retrieve one of the slides from the metal rack in the xylene 2 container and leave the 
others in the xylene container. Wipe the excess liquid beneath the slide on the tissue 
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papers. Apply DPX on the slide/tissue and place a coverslip on the centre of the tissues 
inside the lab fume cupboard. 
* Skip these steps if haematoxylin counterstaining is not planned. In the present study, 
haematoxylin counterstaining was performed for PTN, MK and Notch-2 and it was not 
conducted for ALK and RPTPζ where the staining was nuclear and would be masked by 
haematoxylin staining. 
 












Appendix 9. Important features of primer design requirements 
 Primers are better designed within a conservative region of cDNA. 
 Length of primers are typically between 18 and 24 bp. 
 Content of GC% should be between 40% and 60% (45% to 55% is the best range), and 
both primers should be similar. 
 The 3’ end of primers should not be “A”, which has the highest chance of giving false 
priming. Instead, “T” is the best choice, or “G”,”C”, “CG”, “GC”. 
 At the 3’ end of a primer it is better to avoid the third position of codon because of its 
lower conservation. 
 Better to not to have three continuous G or C nucleotides at the 3’ end in case of GC 
enrichment. 
 Dimers or cross dimers should be avoided. If this cannot be avoided, it is better to keep 
their ΔG values less than 4.5 kcal/mol. Otherwise, dimers will decrease the effective 
concentrations of primers. 
 ΔG values of 5’ end and internal area should be relatively higher than that of 3’ end. 
This can increase the stability of primers. 
 After primers are designed a BLAST should be conducted to check their specificity, i.e. 
primers only recognise the target of interest.   
 The Tm should be between 55 and 65 degrees, and the Tm values of forward and reverse 
primers should be similar. The difference should be within 2 degrees. 
 The products length should be between 60 and 150 bp. 
 Primers must span an exon-exon junction to avoid genome contaminations. 
 Better to design the target fragment of primers closer to the poly(A) tail of the template. 
This is because normally cDNA synthesis is initiated from the poly(A) tail using 
poly(T) oligonucleotide primers. This means the sequence closer to the poly(A) tail 
may be more enriched during reverse transcription. 
 The best way is to use Primer 5.0 to design the primers without setting exons positions. 
Then check if the primers from the top span the exons one-by-one until getting the best 
primers pair or doing some minor adjustments before BLAST. 
 If no optimal primers can be found, instead of eliminating dimers, false priming can be 
excluded. If this is done it is important to ensure the fragment length of false priming 
is much longer than the length of target of interest, meaning that the fragment of false 
priming will not be effectively synthesised.   
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 If it is not possible to span an exon-exon junction, design forward and reverse primers 
inside exons which are across at least 1 or 2 different exon boundaries. This means that 




























Appendix 10. Pleiotrophin gene line up 
Primer sites marked in yellow.  
Exon boundaries marked in bold. 
 
CLUSTAL O(1.2.4) multiple sequence alignment 
Human (EXON MAP based on this)BOLD 
Bovine 
Sheep                                                                                             
lcl|X52946.1_cds_CAA37121.1_1      AGGGAAGAAAGAGAAACCAGAAAAAAAAGTGAAGAAGTCTGACTGTGGAGAATGGCAGTG 155 
lcl|X52945.1_cds_CAA37120.1_1      AGGAAAGAAAGAGAAACCAGAAAAGAAGGTGAAGAAGTCTGACTGTGGAGAATGGCAGTG 155 
lcl|XM_004008093.3_gene_1          AGGAAAGAAAGAGAAACCAGAAAAGAAGGTGAAGAAGTCTGACTGTGGAGAATGGCAGTG 600 
                                   *** ******************** ** ******************************** 
 
lcl|X52946.1_cds_CAA37121.1_1      GAGTGTGTGTGTGCCCACCAGTGGAGACTGTGGGCTGGGCACACGGGAGGGCACTCGGAC 215 
lcl|X52945.1_cds_CAA37120.1_1      GAGTGTGTGTGTACCCACCAGTGGGGACTGTGGGCTGGGCACCCGCGAGGGCACCCGTAC 215 
lcl|XM_004008093.3_gene_1          GAGTGTGTGTGTACCCACCAGTGGGGACTGTGGGCTGGGCACCCGTGAGGGCACCCGTAC 660 
                                   ************ *********** ***************** ** ******** ** ** 
 
lcl|X52946.1_cds_CAA37121.1_1      TGGAGCTGAGTGCAAGCAAACCATGAAGACCCAGAGATGTAAGATCCCCTGCAACTGGAA 275 
lcl|X52945.1_cds_CAA37120.1_1      CGGAGCTGAGTGTAAACAAACCATGAAGACCCAGAGATGTAAGATCCCCTGCAACTGGAA 275 
lcl|XM_004008093.3_gene_1          CGGAGCTGAGTGTAAACAAACCATGAAGACCCAGAGATGTAAGATCCCCTGCAACTGGAA 720 




lcl|X52946.1_cds_CAA37121.1_1      GAAGCAATTTGGCGCGGAGTGCAAATACCAGTTCCAGGCCTGGGGAGAATGTGACCTGAA 335 
lcl|X52945.1_cds_CAA37120.1_1      AAAGCAATTTGGAGCGGAGTGCAAATACCAGTTCCAGGCCTGGGGAGAATGTGATCTGAA 335 
lcl|XM_004008093.3_gene_1          AAAGCAATTTGGCGCGGAGTGCAAATACCAGTTCCAGGCCTGGGGAGAATGTGATCTGAA 780 
                                    *********** ***************************************** ***** 
 
lcl|X52946.1_cds_CAA37121.1_1      CACAGCCCTGAAGACCAGAACTGGAAGTCTGAAGCGAGCCCTGCACAATGCCGAATGCCA 395 
lcl|X52945.1_cds_CAA37120.1_1      CACGGCTCTGAAGACCCGAACTGGGAGCCTGAAGCGAGCCCTCCACAACGCCGACTGCCA 395 
lcl|XM_004008093.3_gene_1          CACGGCTCTGAAGACCCGAACTGGGAGCCTGAAGCGAGCCCTCCACAACGCTGACTGCCA 840 
                                   *** ** ********* ******* ** ************** ***** ** ** ***** 
 
lcl|X52946.1_cds_CAA37121.1_1      GAAGACTGTCACCATCTCCAAGCCCTGTGGCAAACTGACCAAGCCCAAACCTCAAGCAGA 455 
lcl|X52945.1_cds_CAA37120.1_1      GAAGACAGTCACCATCTCCAAGCCCTGTGGCAAGCTGACCAAGTCCAAACCTCAAGCAGA 455 
lcl|XM_004008093.3_gene_1          GAAGACAGTCACCATCTCCAAGCCCTGTGGCAAGCTGACCAAGTCCAAACCTCAAGCAGA 900 
                                   ****** ************************** ********* **************** 
 
lcl|X52946.1_cds_CAA37121.1_1      ATCTAAGAAGAAGAAAAAGGAAGGCAAGAAACAGGAGAAGATGCTGGATTAA-------- 507 
lcl|X52945.1_cds_CAA37120.1_1      ATCTAAGAAGAAGAAAAAGGAAGGCAAGAAACAGGAGAAGATGCTGGACTAA-------- 507 
lcl|XM_004008093.3_gene_1          ATCTAAGAAGAAGAAAAAGGAAGGCAAGAAACAGGAGAAGATGCTGGACTAAAAGCCGCC 960 
                                   ************************************************ ***         
Forward: 5’ ACTGGGAGCCTGAAGCGAGC 3’ 





Appendix 11. Midkine gene line up 
 
Primer sites marked in yellow.  





lcl|M69148.1_cds_AAA58478.1_1                CTCGCCCTGCTGGCGCTCACCTCCGCGGTCGCCAAAAAGAAAGATAAGGTGAAGAAGGGC 93 
lcl|AB036426.1_cds_BAA98139.1_1              CTCGCCTTGCTGGCGCTCACCTCCGCGGTGGCCAAAAAGAAAGACAAAATGAAGAAGGGA 93 
lcl|XM_004016437.4_cds_XP_004016486.3_1      CTCGCCCTGCTGGCTCTCACCTCCGCGGTGGCCAAAAAGAAAGACAAAGTGAAGAAGGGA 120 
                                             ****** ******* ************** ************** **  **********  
 
lcl|M69148.1_cds_AAA58478.1_1                GGCCCGGGGAGCGAGTGCGCTGAGTGGGCCTGGGGGCCCTGCACCCCCAGCAGCAAGGAT 153 
lcl|AB036426.1_cds_BAA98139.1_1              GGCCCAGGGAGCGAGTGTGCCGAGTGGACCTGGGGGCCCTGCACCCCCAGCAGCAAGGAC 153 
lcl|XM_004016437.4_cds_XP_004016486.3_1      GGCCTGGGGAGCGAGTGTGCCGAGTGGACCTGGGGGCCCTGCACCCCCAGCAGCAAGGAC 180 
                                             ****  *********** ** ****** *******************************  
 
lcl|M69148.1_cds_AAA58478.1_1                TGCGGCGTGGGTTTCCGCGAGGGCACCTGCGGGGCCCAGACCCAGCGCATCCGGTGCAGG 213 
lcl|AB036426.1_cds_BAA98139.1_1              TGCGGCGTGGGATTCCGCGAGGGCACCTGCGGGGCCCAGACGCAGCGCATCCGGTGCCGG 213 
lcl|XM_004016437.4_cds_XP_004016486.3_1      TGCGGCGTGGGATTCCGCGAGGGCACCTGCGGGGCCCAGACGCAGCGCATCCGCTGCCGG 240 
                                             *********** ***************************** *********** *** ** 
 
lcl|M69148.1_cds_AAA58478.1_1                GTGCCCTGCAACTGGAAGAAGGAGTTTGGAGCCGACTGCAAGTACAAGTTTGAGAACTGG 273 
lcl|AB036426.1_cds_BAA98139.1_1              GTGCCCTGTAACTGGAAGAAGGAGTTTGGAGCCGACTGCAAGTACAAGTTTGAGACCTGG 273 
lcl|XM_004016437.4_cds_XP_004016486.3_1      GTGCCCTGTAACTGGAAGAAGGAGTTCGGAGCCGACTGCAAGTACAAGTTTGAGACCTGG 300 
                                             ******** ***************** **************************** **** 
 
lcl|M69148.1_cds_AAA58478.1_1                GGTGCGTGTGATGGGGGCACAGGCACCAAAGTCCGCCAAGGCACCCTGAAGAAGGCGCGC 333 
lcl|AB036426.1_cds_BAA98139.1_1              GGGGCGTGTGATGGGGGCACAGGCACCAAAGCCCGCCAAGGGACCCTGAAGAAGGCGCGA 333 
lcl|XM_004016437.4_cds_XP_004016486.3_1      GGGGCGTGTGATGGGGGCACAGGCACCAAAGCCCGCCAAGGGACCCTGAAGAAGGCGCGA 360 
                                             ** **************************** ********* *****************  
 
lcl|M69148.1_cds_AAA58478.1_1                TACAATGCTCAGTGCCAGGAGACCATCCGCGTCACCAAGCCCTGCACCCCCAAGACCAAA 393 
lcl|AB036426.1_cds_BAA98139.1_1              TACAATGCCCAGTGCCAGGAGACCATCCGAGTGACCAAGCCCTGCAGCCCCAAGACCAAA 393 
lcl|XM_004016437.4_cds_XP_004016486.3_1      TACAATGCCCAGTGCCAGGAGACCATCCGAGTGACCAAGCCCTGCAGCCCCAAGACCAAA 420 




lcl|M69148.1_cds_AAA58478.1_1                GCAAAGGCCAAAGCCAAGAAAGGGAAGGGAAAGGACTAG 432 
lcl|AB036426.1_cds_BAA98139.1_1              GCCAAGGCCAAAGCTAAGAAAGGGAAGGAAAAGGACTAG 432 
lcl|XM_004016437.4_cds_XP_004016486.3_1      GCCAAGGCCAAAGCCAAGAAAGGGAAGGAAAAGGACTAG 459 




Forward: 5’ GGGTGCCCTGTAACTGGAA 3′ 






Appendix 12. ALK-5 or TGFBR1 bovine gene line up 
Primer sites marked in yellow.  
Exon boundaries marked in bold. 





CLUSTAL O(1.2.4) multiple sequence alignment 
 
lcl|AF317296.1_cds_AAQ14586.1_1              ---------------------------------------------GAGACCACAGACAAA 15 
lcl|NM_174621.2_cds_NP_777046.1_1            AATTTTACTTGTGTCACAGATGGGCTTTGCTTTGTTTCTGTCACAGAGACCACAGACAAA 180 
lcl|XM_012120354.3_cds_XP_011975744.1_1      AATTTTACTTGTGTCACAGATGGGCTTTGCTTTGTCTCTGTCACAGAGACCACAGACAAA 180 
                                                                                          *************** 
 
lcl|AF317296.1_cds_AAQ14586.1_1              GTTATACACAATAGCATGTGTATAGCTGAAATTGACCTAATTCCGCGAGACAGGCCATTT 75 
lcl|NM_174621.2_cds_NP_777046.1_1            GTTATACATAATAGCATGTGTATAGCTGAAATTGACCTAATTCCACGAGACAGGCCATTT 240 
lcl|XM_012120354.3_cds_XP_011975744.1_1      GTTATACATAACAGCATGTGTATAGCTGAAATTGACCTAATTCCACGAGACAGGCCATTT 240 
                                             ******** ** ******************************** *************** 
 
lcl|AF317296.1_cds_AAQ14586.1_1              GTATGTGCACCTTCTTCAAAAACTGGGTCTGTTACTACAACATATTGCTGCAATCAGGAC 135 
lcl|NM_174621.2_cds_NP_777046.1_1            GTATGTGCACCATCTTCAAAAACTGGGTCTATAACTACAACATATTGCTGCAACCAGGAC 300 
lcl|XM_012120354.3_cds_XP_011975744.1_1      GTATGTGCACCATCTTCAAAAACTGGGTCTACA------ACATATTGCTGCAACCAGGAC 294 
143 
 
                                             *********** ******************         ************** ****** 
 
lcl|AF317296.1_cds_AAQ14586.1_1              CATTGCAATAAAATAGAACTCCCAACTGTTGGTCCTTTTCCAGGAAAGCCACCATCTGGC 195 
lcl|NM_174621.2_cds_NP_777046.1_1            CACTGCAATAAAATAGAACTTCCAACTG------------TTGGAAAGCCATCATCTGGC 348 
lcl|XM_012120354.3_cds_XP_011975744.1_1      CACTGCAATAAAATAGAACTTCCAACTGTCGGCCCTTTTACAGGAAAGCCGTCATCTGGC 354 
                                             ** ***************** *******              ********  ******** 
 
lcl|AF317296.1_cds_AAQ14586.1_1              CTTGGTCCTGTTGAACTGGCAGCTGTCATTGCTGGACCAGTCTGCTTTGTCTGCATCTCA 255 
lcl|NM_174621.2_cds_NP_777046.1_1            CTTGGTCCTGTTGAACTGGCAGCTGTCATTGCTGGACCAGTCTGCTTTGTCTGTATCTCA 408 
lcl|XM_012120354.3_cds_XP_011975744.1_1      CTCGGTCCTGTTGAACTGGCAGCTGTCATTGCTGGACCAGTCTGCTTTGTCTGTATCTCA 414 
                                             ** ************************************************** ****** 
 
lcl|AF317296.1_cds_AAQ14586.1_1              CTCATGTTGATGGTCTATATCTGCCATAACCGTACAGTCATTCACCATCGAGTGCCAAAT 315 
lcl|NM_174621.2_cds_NP_777046.1_1            CTCATGTTGATGGTCTATATTTGCCATAACCGCACTGTCATTCACCATCGAGTGCCAAAT 468 
lcl|XM_012120354.3_cds_XP_011975744.1_1      CTCATGTTGATGGTCTATATCTGCCATAACCGCACTGTCATTCACCATCGAGTGCCAAAT 474 
                                             ******************** *********** ** ************************ 
 
lcl|AF317296.1_cds_AAQ14586.1_1              GAGGAGGATCCTTCATTAGATCGCCCTTTTATTTCAGAGGGTACTACATTAAAAGATTTA 375 
lcl|NM_174621.2_cds_NP_777046.1_1            GAAGAGGATCCCTCGTTAGATCGCCCTTTTATTTCAGAGGGTACAACGTTAAAAGATTTA 528 
lcl|XM_012120354.3_cds_XP_011975744.1_1      GAAGAGGATCCCTCGTTAGATCGCCCTTTTATTTCAGAGGGTACAACGTTAAAAGATTTA 534 




lcl|AF317296.1_cds_AAQ14586.1_1              ATTTATGATATGACAACATCAGGTTCTGGATCAGGTTTACCATTGCTTGTTCAGAGAACA 435 
lcl|NM_174621.2_cds_NP_777046.1_1            ATTTACGACATGACAACATCAGGTTCTGGATCAGGTTTACCATTGCTTGTTCAGAGAACA 588 
lcl|XM_012120354.3_cds_XP_011975744.1_1      ATTTACGACATGACAACATCAGGTTCTGGATCAGGTTTACCATTGCTTGTTCAGAGAACA 594 
                                             ***** ** *************************************************** 
 
lcl|AF317296.1_cds_AAQ14586.1_1              ATTGCAAGAACTATTGTGCTACAAGAAAGTATTGGCAAAGGTCGATTTGGAGAGGTTTGG 495 
lcl|NM_174621.2_cds_NP_777046.1_1            ATTGCGAGAACTATTGTGTTACAAGAAAGTATTGGCAAAGGTCGTTTTGGAGAAGTTTGG 648 
lcl|XM_012120354.3_cds_XP_011975744.1_1      ATTGCGAGAACTATTGTGTTACAAGAAAGTATTGGCAAAGGTCGTTTTGGAGAAGTTTGG 654 
                                             ***** ************ ************************* ******** ****** 
 
lcl|AF317296.1_cds_AAQ14586.1_1              CGAGGAAAATGGAGAAGAGAGGAAGTTGCTGTTAAAATATTCTCCTCCAGGGAAGAACGT 555 
lcl|NM_174621.2_cds_NP_777046.1_1            CGAGGAAAATGGAGAGGAGAAGAAGTTGCTGTTAAAATATTCTCCTCTAGAGAAGAACGT 708 
lcl|XM_012120354.3_cds_XP_011975744.1_1      CGAGGAAAATGGAGAGGAGAAGAAGTTGCTGTTAAAATATTCTCCTCTAGAGAAGAACGT 714 
                                             *************** **** ************************** ** ********* 
 
lcl|AF317296.1_cds_AAQ14586.1_1              TCATGGTTCCGTGAGGCAGAGATTTATCAGACTGTTATGTTACGTCATGAAAACATCTTG 615 
lcl|NM_174621.2_cds_NP_777046.1_1            TCATGGTTCCGTGAAGCAGAGATTTATCAGACTGTCATGTTACGTCACGAAAACATCTTG 768 
lcl|XM_012120354.3_cds_XP_011975744.1_1      TCATGGTTCCGTGAAGCAGAGATTTATCAGACTGTCATGTTACGTCACGAAAACATCTTA 774 
                                             ************** ******************** *********** ***********  
 
lcl|AF317296.1_cds_AAQ14586.1_1              GGATTTATAGCAGCAGACAATAAAGATAATGGTACATGGACTCAGCTTTGGTTGGTGTCA 675 
lcl|NM_174621.2_cds_NP_777046.1_1            GGATTTATAGCAGCAGACAATAAAGACAATGGCACATGGACTCAGCTCTGGTTGGTGTCA 828 
145 
 
lcl|XM_012120354.3_cds_XP_011975744.1_1      GGATTTATAGCAGCGGACAACAAAGACAATGGCACATGGACTCAGCTCTGGTTGGTGTCA 834 
                                             ************** ***** ***** ***** ************** ************ 
 
lcl|AF317296.1_cds_AAQ14586.1_1              GATTATCATGAACATGGATCCCTTTTTGATTACTTGAATAGATACACAGTTACTGTGGAA 735 
lcl|NM_174621.2_cds_NP_777046.1_1            GATTATCATGAGCACGGATCCCTTTTTGATTATTTGAACAGATACACAGTTACTGTGGAA 888 
lcl|XM_012120354.3_cds_XP_011975744.1_1      GATTATCATGAGCACGGATCCCTTTTTGATTATTTGAACAGATACACAGTTACTGTGGAA 894 
                                             *********** ** ***************** ***** ********************* 
 
lcl|AF317296.1_cds_AAQ14586.1_1              GGAATGATAAAACTTGCTCTGTCCACAGCAAGTGGACTTGCCCATCTTCACATGGAGATA 795 
lcl|NM_174621.2_cds_NP_777046.1_1            GGAATGATAAAACTTGCTCTGTCCACAGCAAGTGGACTTGCCCATCTTCACATGGAGATA 948 
lcl|XM_012120354.3_cds_XP_011975744.1_1      GGAATGATAAAACTTGCTCTGTCCACAGCAAGTGGACTTGCCCATCTTCACATGGAGATA 954 
                                             ************************************************************ 
 
lcl|AF317296.1_cds_AAQ14586.1_1              GTTGGTACCCAAGGAAAACCAGCTATTGCTCATAGAGATTTGAAATCAAAGAATATCTTG 855 
lcl|NM_174621.2_cds_NP_777046.1_1            GTTGGTACCCAAGGAAAACCAGCCATAGCTCATAGGGATTTGAAATCAAAGAATATCTTG 1008 
lcl|XM_012120354.3_cds_XP_011975744.1_1      GTTGGTACCCAAGGAAAACCAGCCATAGCTCATAGGGATTTGAAATCAAAGAATATCTTG 1014 
                                             *********************** ** ******** ************************ 
 
lcl|AF317296.1_cds_AAQ14586.1_1              GTAAAAAAGAATGGAACTTGCTGTATTGCAGACTTAGGACTGGCAGTAAGACATGATTCA 915 
lcl|NM_174621.2_cds_NP_777046.1_1            GTAAAGAAGAATGGAACTTGCTGTATTGCAGACTTAGGATTGGCAGTAAGGCATGATTCG 1068 
lcl|XM_012120354.3_cds_XP_011975744.1_1      GTAAAGAAGAATGGAACTTGCTGTATTGCAGACTTAGGACTGGCAGTAAGGCATGATTCG 1074 




lcl|AF317296.1_cds_AAQ14586.1_1              GCCACAGATACAATTGATATTGCTCCAAACCACAGAGTGGGAACAAAAAGGTACATGGCC 975 
lcl|NM_174621.2_cds_NP_777046.1_1            GCCACGGATACAATTGACATTGCTCCAAACCACAGAGTGGGAACAAAAAGGTACATGGCC 1128 
lcl|XM_012120354.3_cds_XP_011975744.1_1      GCCACAGATACAATTGACATTGCTCCAAACCACAGAGTGGGAACAAAAAGGTACATGGCC 1134 
                                             ***** *********** ****************************************** 
 
lcl|AF317296.1_cds_AAQ14586.1_1              CCTGAAGTTCTAGATGATTCCATAAATATGAAACACTTTGAATCCTTCAAACGTGCTGAC 1035 
lcl|NM_174621.2_cds_NP_777046.1_1            CCTGAAGTTCTAGATGATTCCATAAATATGAAACACTTTGAATCCTTCAAACGTGCTGAC 1188 
lcl|XM_012120354.3_cds_XP_011975744.1_1      CCTGAAGTTCTAGATGATTCCATAAATATGAAACACTTTGAATCCTTCAAACGTGCTGAC 1194 
                                             ************************************************************ 
 
lcl|AF317296.1_cds_AAQ14586.1_1              ATCTATGCGATGGGCTTAGTATTCTGGGAAATAGCTCGACGATGTTCCATTGGTGGAATT 1095 
lcl|NM_174621.2_cds_NP_777046.1_1            ATCTATGCAATGGGACTAGTATTCTGGGAAGTAGCTCGACGATGTTCCATTGGTGGAATA 1248 
lcl|XM_012120354.3_cds_XP_011975744.1_1      ATCTATGCAATGGGACTAGTATTCTGGGAAGTAGCTCGACGATGTTCCATCGGCGGAATT 1254 
                                             ******** *****  ************** ******************* ** *****  
 
lcl|AF317296.1_cds_AAQ14586.1_1              CATGAAGATTACCAGCTGCCTTATTATGATCTTGTACCTTCTG----------------- 1138 
lcl|NM_174621.2_cds_NP_777046.1_1            CATGAAGATTACCAGCTGCCTTATTATGATCTTGTACCTTCCGATCCATCAGTTGAAGAA 1308 
lcl|XM_012120354.3_cds_XP_011975744.1_1      CATGAAGATTACCAGTTGCCTTATTATGATCTTGTACCTTCCGATCCATCAGTTGAAGAA 1314 
                                             *************** ************************* *                  
Forward: 5’ GAGAAGAACGTTCATGGT 3′ 
Reverse: 5’ CCAACCAGAGCTGAGTCCAT 3′  
147 
 
Appendix 13. RPTPζ gene line up  
Primer sites marked in yellow.  
Exon boundaries marked in bold. Exons only marked in regions of interest. 
 




lcl|M93426.1_cds_AAA60225.1_1          ATGCGAATCCTAAAGCGTTTCCTCGCTTGCATTCAGCTCCTCTGTGTTTGCCGCCTGGAT 60 
lcl|BC151071.1_cds_AAI51072.1_1        ATGCGAATCCTGCAGAGCTTCCTCGCGTGCGTTCAGCTCCTGTGCCTGTGTCGCCTGGAC 60 
lcl|NM_013080.2_cds_NP_037212.2_1      ATGCGAATCCTGCAGAGCTTCCTCGCGTGCGTTCAGCTACTGTGCGTGTGTCGCCTGGAC 60 
                                       ***********  ** * ******** *** ******* ** **  * ** ********  
 
lcl|M93426.1_cds_AAA60225.1_1          TGGGCTAATGGATACTACAGACAACAGAGAAAACTTGTTGAAGAGATTGGCTGGTCCTAT 120 
lcl|BC151071.1_cds_AAI51072.1_1        TGGGCTTATGGATACTACAGACAACAGAGGAAACTTGTTGAAGAGATTGGCTGGTCCTAC 120 
lcl|NM_013080.2_cds_NP_037212.2_1      TGGGCTTATGGATACTACAGACAACAGAGAAAACTTGTTGAAGAGATTGGCTGGTCCTAT 120 
                                       ****** ********************** *****************************  
 
lcl|M93426.1_cds_AAA60225.1_1          ACAGGAGCACTGAATCAAAAAAATTGGGGAAAGAAATATCCAACATGTAATAGCCCAAAA 180 
lcl|BC151071.1_cds_AAI51072.1_1        ACAGGAGCACTAAATCAAAAAAATTGGGGAAAGAAATATCCAATATGTAATAGCCCAAAG 180 
lcl|NM_013080.2_cds_NP_037212.2_1      ACAGGAGCACTAAATCAAAAAAATTGGGGAAAGAAATATCCAATATGTAATAGCCCAAAG 180 




lcl|M93426.1_cds_AAA60225.1_1          CAATCTCCTATCAATATTGATGAAGATCTTACACAAGTAAATGTGAATCTTAAGAAACTT 240 
lcl|BC151071.1_cds_AAI51072.1_1        CAGTCTCCTATTAATATTGATGAAGATCTTACACAAGTCAATGTGAATCTTAAGAAACTG 240 
lcl|NM_013080.2_cds_NP_037212.2_1      CAGTCTCCTATTAATATTGATGAAGATCTTACACAAGTAAATGTGAATCTTAAGAAACTG 240 
                                       ** ******** ************************** ********************  
 
lcl|M93426.1_cds_AAA60225.1_1          AAATTTCAGGGTTGGGATAAAACATCATTGGAAAACACATTCATTCATAACACTGGGAAA 300 
lcl|BC151071.1_cds_AAI51072.1_1        AAATTTCAGGGTTGGGAAAAAGCGTCCTTGGAAAACACGTTCATTCACAACACTGGGAAA 300 
lcl|NM_013080.2_cds_NP_037212.2_1      AAATTTCAGGGTTGGGAAAAACCATCCTTGGAAAACACGTTTATTCACAACACTGGGAAA 300 
                                       ***************** *** * ** *********** ** ***** ************ 
 
lcl|M93426.1_cds_AAA60225.1_1          ACAGTGGAAATTAATCTCACTAATGACTACCGTGTCAGCGGAGGAGTTTCAGAAATGGTG 360 
lcl|BC151071.1_cds_AAI51072.1_1        ACAGTGGAAATAAATCTCACTAATGACTACTATCTCAGTGGAGGACTTTCAGAAAAGGTC 360 
lcl|NM_013080.2_cds_NP_037212.2_1      ACAGTGGAAATAAATCTCACCAATGACTACTATCTCAGTGGAGGACTTTCAGAAAAGGTC 360 
                                       *********** ******** *********  * **** ****** ********* ***  
 
lcl|M93426.1_cds_AAA60225.1_1          TTTAAAGCAAGCAAGATAACTTTTCACTGGGGAAAATGCAATATGTCATCTGATGGATCA 420 
lcl|BC151071.1_cds_AAI51072.1_1        TTCAAGGCAAGCAAGATAACTTTCCACTGGGGAAAATGCAATGTGTCATCTGAAGGATCG 420 
lcl|NM_013080.2_cds_NP_037212.2_1      TTCAAGGCAAGCAAAATGACTTTTCACTGGGGGAAATGCAATGTGTCATCGGAAGGATCG 420 
                                       ** ** ******** ** ***** ******** ********* ******* ** *****  
 
lcl|M93426.1_cds_AAA60225.1_1          GAGCATAGTTTAGAAGGACAAAAATTTCCACTTGAGATGCAAATCTACTGCTTTGATGCG 480 
149 
 
lcl|BC151071.1_cds_AAI51072.1_1        GAACATAGCTTAGAAGGACAGAAGTTCCCACTGGAGATGCAAGTCTACTGCTTTGATGCG 480 
lcl|NM_013080.2_cds_NP_037212.2_1      GAACACAGCTTAGAAGGGCAGAAGTTTCCACTCGAGATGCAAATCTACTGCTTCGATGCG 480 
                                       ** ** ** ******** ** ** ** ***** ********* ********** ****** 
 
lcl|M93426.1_cds_AAA60225.1_1          GACCGATTTTCAAGTTTTGAGGAAGCAGTCAAAGGAAAAGGGAAGTTAAGAGCTTTATCC 540 
lcl|BC151071.1_cds_AAI51072.1_1        GACAGATTTTCCAGTTTTGAGGAAGCAGTTAAAGGAAAAGGAAGATTAAGGGCTTTATCC 540 
lcl|NM_013080.2_cds_NP_037212.2_1      GACCGATTTTCAAGTTTTGAGGAAACAGTTAAAGGAAAAGGAAGGTTAAGGGCTCTATCC 540 
                                       *** ******* ************ **** *********** *  ***** *** ***** 
 
lcl|M93426.1_cds_AAA60225.1_1          ATTTTGTTTGAGGTTGGGACAGAAGAAAATTTGGATTTCAAAGCGATTATTGATGGAGTC 600 
lcl|BC151071.1_cds_AAI51072.1_1        ATTTTATTTGAGGTTGGAGTTGAAGAAAATTTGGATTACAAAGCCATTATTGATGGAACT 600 
lcl|NM_013080.2_cds_NP_037212.2_1      ATTTTATTTGAGATTGGAGTTGAAGAAAATTTGGATTACAAAGCCATTATTGATGGGACT 600 
                                       ***** ****** ****    **************** ****** ***********     
 
lcl|M93426.1_cds_AAA60225.1_1          GAAAGTGTTAGTCGTTTTGGGAAGCAGGCTGCTTTAGATCCATTCATACTGTTGAACCTT 660 
lcl|BC151071.1_cds_AAI51072.1_1        GAGAGTGTTAGTCGTTTTGGAAAGCAGGCTGCTTTAGATCCATTCGTCTTGCAGAACCTC 660 
lcl|NM_013080.2_cds_NP_037212.2_1      GAAAGTGTTAGTCGTTTTGGAAAGCAGGCTGCCTTAGATCCGTTCATCTTGCAGAACCTC 660 
                                       ** ***************** *********** ******** *** *  **  ******  
 
lcl|M93426.1_cds_AAA60225.1_1          CTGCCAAACTCAACTGACAAGTATTACATTTACAATGGCTCATTGACATCTCCTCCCTGC 720 
lcl|BC151071.1_cds_AAI51072.1_1        CTGCCAAACTCCACTGACAAGTATTACATTTACAATGGATCATTGACATCCCCTCCCTGC 720 
lcl|NM_013080.2_cds_NP_037212.2_1      CTGCCAAACTCCACTGACAAGTACTACATTTACAACGGATCACTGACATCCCCTCCCTGC 720 
150 
 
                                       *********** *********** *********** ** *** ******* ********* 
 
lcl|M93426.1_cds_AAA60225.1_1          ACAGACACAGTTGACTGGATTGTTTTTAAAGATACAGTTAGCATCTCTGAAAGCCAGTTG 780 
lcl|BC151071.1_cds_AAI51072.1_1        ACAGACACCGTGGAATGGATTGTTTTTAAGGATACAGTTAGCATCTCTGAAAGCCAGCTG 780 
lcl|NM_013080.2_cds_NP_037212.2_1      ACAGACACCGTCGAATGGATTGTTTTTAAGGATACAGTTAGCATCTCTGAAAGCCAGCTG 780 
                                       ******** ** ** ************** *************************** ** 
 
lcl|M93426.1_cds_AAA60225.1_1          GCTGTTTTTTGTGAAGTTCTTACAATGCAACAATCTGGTTATGTCATGCTGATGGACTAC 840 
lcl|BC151071.1_cds_AAI51072.1_1        GCTGTATTTTGTGAAGTTCTCACAATGCAACAGTCTGGGTATGTCATGTTGATGGATTAC 840 
lcl|NM_013080.2_cds_NP_037212.2_1      GCTGTATTTTGTGAAGTTCTCACAATGCAACAGTCCGGGTATGTCATGTTGATGGATTAC 840 
                                       ***** ************** *********** ** ** ********* ******* *** 
 
lcl|M93426.1_cds_AAA60225.1_1          TTACAAAACAATTTTCGAGAGCAACAGTACAAGTTCTCTAGACAGGTGTTTTCCTCATAC 900 
lcl|BC151071.1_cds_AAI51072.1_1        TTACAAAACAATTTCCGAGAACAACAGTACAAGTTTTCCAGGCAGGTGTTTTCCTCATAT 900 
lcl|NM_013080.2_cds_NP_037212.2_1      TTACAAAACAATTTCCGAGAACAACAGTACAAGTTTTCCAGGCAGGTGTTTTCTTCGTAC 900 
                                       ************** ***** ************** ** ** *********** ** **  
 
lcl|M93426.1_cds_AAA60225.1_1          ACTGGAAAGGAAGAGATTCATGAAGCAGTTTGTAGTTCAGAACCAGAAAATGTTCAGGCT 960 
lcl|BC151071.1_cds_AAI51072.1_1        ACTGGAAAGGAAGAGATCCACGAAGTAGTGTGTAGTTCAGAACCAGAAAATGTGCAAGCT 960 
lcl|NM_013080.2_cds_NP_037212.2_1      ACTGGGAAGGAAGAGATTCATGAAGCAGTGTGCAGTTCAGAACCAGAAAATGTGCAAGCT 960 




lcl|M93426.1_cds_AAA60225.1_1          GACCCAGAGAATTATACCAGCCTTCTTGTTACATGGGAAAGACCTCGAGTCGTTTATGAT 1020 
lcl|BC151071.1_cds_AAI51072.1_1        GACCCTGAGAATTACACCAGCCTTCTGGTCACATGGGAAAGACCTCGGGTCGTTTATGAC 1020 
lcl|NM_013080.2_cds_NP_037212.2_1      GACCCTGAGAATTACACCAGCCTTCTGATCACATGGGAAAGGCCTCGGGTTGTTTATGAC 1020 
                                       ***** ******** ***********  * *********** ***** ** ********  
 
lcl|M93426.1_cds_AAA60225.1_1          ACCATGATTGAGAAGTTTGCAGTTTTGTACCAGCAGTTGGATGGAGAGGACCAAACCAAG 1080 
lcl|BC151071.1_cds_AAI51072.1_1        GCCATGATTGAGAAGTTTGCAGTTCTGTACCAGCCACTGGCGGGAAATGACCAAGCCAAG 1080 
lcl|NM_013080.2_cds_NP_037212.2_1      ACAATGATTGAGAAGTTTGCGGTTCTGTACCAGCCACTGGAGGGAAACGACCAAACCAAG 1080 
                                        * ***************** *** *********   ***  *** * ****** ***** 
 
lcl|M93426.1_cds_AAA60225.1_1          CATGAATTTTTGACAGATGGCTATCAAGACTTGGGTGCTATTCTCAATAATTTGCTACCC 1140 
lcl|BC151071.1_cds_AAI51072.1_1        CATGAGTTCTTAACAGATGGCTATCAGGACTTGGGTGCCATTCTCAATAATTTACTACCT 1140 
lcl|NM_013080.2_cds_NP_037212.2_1      CATGAGTTTTTAACAGATGGCTATCAGGACTTGGGTGCCATTCTCAATAACTTAATACCT 1140 
                                       ***** ** ** ************** *********** *********** **  ****  
 
lcl|M93426.1_cds_AAA60225.1_1          AATATGAGTTATGTTCTTCAGATAGTAGCCATATGCACTAATGGCTTATATGGAAAATAC 1200 
lcl|BC151071.1_cds_AAI51072.1_1        AACATGAGTTACGTTCTTCAAATAGTGGCCGTATGCTCTAATGGTTTATATGGAAAGTAC 1200 
lcl|NM_013080.2_cds_NP_037212.2_1      AACATGAGTTATGTGCTCCAAATAGTGGCCATATGCTCTAATGGCCTTTATGGAAAGTAC 1200 
                                       ** ******** ** ** ** ***** *** ***** *******  * ******** *** 
 
lcl|M93426.1_cds_AAA60225.1_1          AGCGACCAACTGATTGTCGACATGCCTACTGATAATCCTGAACTTGATCTTTTCCCTGAA 1260 
lcl|BC151071.1_cds_AAI51072.1_1        AGTGACCAACTGATAGTGGACATGCCCACTGAAGATGCCGAACTTGACCTTTTTCCTGAA 1260 
152 
 
lcl|NM_013080.2_cds_NP_037212.2_1      AGTGACCAATTGATAGTCGACATGCCTACTGAGGATGCTGAACTTGACCTCTTTCCTGAA 1260 
                                       ** ****** **** ** ******** *****  ** * ******** ** ** ****** 
 
lcl|M93426.1_cds_AAA60225.1_1          TTAATTGGAACTGAAGAAATAATCAAGGAGGAGGAAGAGGGAAAAGACATTGAAGAAGGC 1320 
lcl|BC151071.1_cds_AAI51072.1_1        TTAATTGGGACTGAAGAAATAATCAAGGAGGAAGAATATGGAAAAGACAATGAAGAAGAC 1320 
lcl|NM_013080.2_cds_NP_037212.2_1      TTAATTGGAACTGAAGAAATAATCAAGGAGGAAGACTATGGAAAAGGCAATGAAGAAGAC 1320 
                                       ******** *********************** **  * ******* ** ******** * 
 
lcl|M93426.1_cds_AAA60225.1_1          GCTATTGTGAATCCTGGTAGAGACAGTGCTACAAACCAAATCAGGAAAAAGGAACCCCAG 1380 
lcl|BC151071.1_cds_AAI51072.1_1        ACTGGCTTGAATCCTGGTAGAGACAGTGTCACAAACCAAATAAGGAAAAAGGAACCCCAG 1380 
lcl|NM_013080.2_cds_NP_037212.2_1      ACTGGCTTGAATCCCGGTAGAGACAGTGCCACAAACCAAATAAGGAAAAAGGAACCCCAG 1380 
                                        **    ******* *************  *********** ****************** 
 
lcl|M93426.1_cds_AAA60225.1_1          ATTTCTACCACAACACACTACAATCGCATAGGGACGAAATACAATGAAGCCAAGACTAAC 1440 
lcl|BC151071.1_cds_AAI51072.1_1        GTTTCTACCACGACTCACTATAATCACATGGGGACTAAATACAATGAAGCCAAGACTAAC 1440 
lcl|NM_013080.2_cds_NP_037212.2_1      GTTTCTACCACAACTCACTATAATCACATGGGGACTAAATATAATGAAGCCAAGACTAAC 1440 
                                        ********** ** ***** **** *** ***** ***** ****************** 
 
lcl|M93426.1_cds_AAA60225.1_1          CGATCCCCAACAAGAGGAAGTGAATTCTCTGGAAAGGGTGATGTTCCCAATACATCTTTA 1500 
lcl|BC151071.1_cds_AAI51072.1_1        CGATCTCCAACAAGAGGATCTGAATTCTCTGGAAAGAGTGATGTTCCCAACACTTCCCCG 1500 
lcl|NM_013080.2_cds_NP_037212.2_1      CGATCTCCAACGAAAGGATCTGAATTCTCTGGAAAGAGTGATGTTCTCAACACATCCCTG 1500 




lcl|M93426.1_cds_AAA60225.1_1          AATTCCACTTCCCAACCAGTCACTAAATTAGCCACAGAAAAAGATATTTCCTTGACTTCT 1560 
lcl|BC151071.1_cds_AAI51072.1_1        AATTCTACTTCCCAACATGTTGCTGAATTCGAAACAGAAAGAGGAATTTCCTTGCCTTCT 1560 
lcl|NM_013080.2_cds_NP_037212.2_1      AATCCTACTTCCCAACAGGTTGCTGAATTCAATCCAGAAAGAGAAATGTCCTTGCCTTCT 1560 
                                       *** * **********  **  ** ****     ****** **  ** ****** ***** 
 
lcl|M93426.1_cds_AAA60225.1_1          CAGACTGTGACTGAACTGCCACCTCACACTGTGGAAGGTACTTCAGCCTCTTTAAATGAT 1620 
lcl|BC151071.1_cds_AAI51072.1_1        CAGACTGGAACTAACCTGCCACCACACAATGTGGAAGGCACTTCAGCCTCCTTAAACAGT 1620 
lcl|NM_013080.2_cds_NP_037212.2_1      CAGATTGGAACTAACCTGCCACCACACAGTGTGGAAGGCACCTCAGCCTCCTTAAACAGT 1620 
                                       **** **  *** * ******** **** ********* ** ******** *****   * 
 
lcl|M93426.1_cds_AAA60225.1_1          GGCTCTAAAACTGTTCTTAGATCTCCACATATGAACTTGTCGGGGACTGCAGAATCCTTA 1680 
lcl|BC151071.1_cds_AAI51072.1_1        GGCTCTAAAACTCTCTTTATCTTCCCACAGATGAACTTGTCTGGGACTGCAGAATCCTTA 1680 
lcl|NM_013080.2_cds_NP_037212.2_1      GGCTCTAAAACTCTCCTTGTCTTCCCACAGATGAACTTGTCTGGGACTGCAGAATCCTTA 1680 
                                       ************ *  **   *  ***** *********** ****************** 
 
lcl|M93426.1_cds_AAA60225.1_1          AATACAGTTTCTATAACAGAATAT------------------------GAGGAGGAGAGT 1716 
lcl|BC151071.1_cds_AAI51072.1_1        AATACGGTTCCCATAACAGAGTACAAAGAGGTTTCTGCTGACGTCAGTGAGGAAGAAAAC 1740 
lcl|NM_013080.2_cds_NP_037212.2_1      AATATGGTTTCCATAACAGAGTACAAAGAGGTGTCTGCTGACCTCAGTGAGGAAGAAAAC 1740 
                                       ****  *** * ******** **                         ***** ** *   
 
lcl|M93426.1_cds_AAA60225.1_1          TTATTGACCAGTTTCAAGCTTGATACTGGAGCTGAAGATTCTTCAGGCTCCAGTCCCGCA 1776 
154 
 
lcl|BC151071.1_cds_AAI51072.1_1        TTCCTGACTGATTTCAAGCTCGATACGGGAGCCGATGACTCTTCAGGCTCCAGCCCCTCA 1800 
lcl|NM_013080.2_cds_NP_037212.2_1      TTACTGACTGATTTCAAGCTCGATAGTGGAGCAGATGATTCGTCAGGCTCTAGCCCTGCG 1800 
                                       **  ****   ********* ****  ***** ** ** ** ******** ** **  *  
 
lcl|M93426.1_cds_AAA60225.1_1          ACTTCTGCTATCCCATTCATCTCTGAGAACATATCCCAAGGGTATATATTTTCCTCCGAA 1836 
lcl|BC151071.1_cds_AAI51072.1_1        ACCTCCACTGTCCCCTTTTCCTCAGATAATCTATCCCATGGATACATAACTTCTTCAGAC 1860 
lcl|NM_013080.2_cds_NP_037212.2_1      TCCTCCACTGTCCCCTTTTCCACAGATAATCTATCCCATGGATATACATCTTCTTCAGAT 1860 
                                        * **  ** **** **   * * ** **  ******* ** ** * *  *** ** **  
 
lcl|M93426.1_cds_AAA60225.1_1          AACCCAGAGACAATAACATATGATGTCCTTATACCAGAATCTGCTAGAAATGCTTCCGAA 1896 
lcl|BC151071.1_cds_AAI51072.1_1        ATGCCCGAGGCTATCACGTATGATGTCCTTAAGCCAGGATCTACAAGAAATGCCCCAGAG 1920 
lcl|NM_013080.2_cds_NP_037212.2_1      ACGCCCGAGGCGGTCACGTATGATGTCCTTAGGCCAGAATCTACGAGAAATGCTCTAGAG 1920 
                                       *  ** *** *  * ** *************  **** **** * ********    **  
 
lcl|M93426.1_cds_AAA60225.1_1          GATTCAACTTCATCAGGTTCAGAAGAATCACTAAAGGATCCTTCTATGGAGGGAAATGTG 1956 
lcl|BC151071.1_cds_AAI51072.1_1        GATTCAGCTCCATCAGGTTCAGAGGAATCACTAAAGGATCCATCTCTTGAAGGGAGTGTA 1980 
lcl|NM_013080.2_cds_NP_037212.2_1      GATTCGGCTCCATCAGGTTCAGAAGAATCACTAAAGGATCCCTCTCTTGAAGGGAGTGTG 1980 
                                       *****  ** ************* ***************** *** * ** ** * ***  
 
lcl|M93426.1_cds_AAA60225.1_1          TGGTTTCCTAGCTCTACAGACATAACAGCACAGCCCGATGTTGGATCAGGCAGAGAGAGC 2016 
lcl|BC151071.1_cds_AAI51072.1_1        TGGTTTCCTGGCTCCACAGACCTAACAACGCAGTCTGAGACTGGATCCGGCCGAGAGAGC 2040 
lcl|NM_013080.2_cds_NP_037212.2_1      TGGTTCCCTGGATCCACAGACCTAACAACACAGTCTGAGACTGGATCTGGGAGAGAGGGC 2040 
155 
 
                                       ***** *** * ** ****** ***** * *** * **   ****** **  ***** ** 
 
lcl|M93426.1_cds_AAA60225.1_1          TTTCTCCAGACTAATTACACTGAGATACGTGTTGATGAATCTGAGAAGACAACCAAGTCC 2076 
lcl|BC151071.1_cds_AAI51072.1_1        TTTCTCCAGGTTAACTCCACAGACATACAAATTGATGAATCGAGGGAGACAACCGAGTCG 2100 
lcl|NM_013080.2_cds_NP_037212.2_1      TTTCTCCAAGTTAACTCCACGGACTTCCAAGTTGATGAATCGAGGGAGACAACTGAGACA 2100 
                                       ********   *** * *** **  * *   **********   * *******  ** *  
 
lcl|M93426.1_cds_AAA60225.1_1          TTTTCTGCAGGCCCAGTGATGTCACAGGGTCCCTCAGTTACAGATCTGGAAATGCCACAT 2136 
lcl|BC151071.1_cds_AAI51072.1_1        TTTTCTCCAGATGCTACCGTGTCACAGGATCCTTCAGTCACAGACATGGGAATGCCACAT 2160 
lcl|NM_013080.2_cds_NP_037212.2_1      TTTTCTCCAGATGCTACCGCGTCCCGGGGTCCTTCGGTCACAGATATGGAAATGCCACAT 2160 
                                       ****** ***   *      *** * ** *** ** ** *****  *** ********** 
 
lcl|M93426.1_cds_AAA60225.1_1          TATTCTACCTTTGCCTACTTCCCAACTGAGGTAACACCTCATGCTTTTACCCCATCCTCC 2196 
lcl|BC151071.1_cds_AAI51072.1_1        TATTCTACCTTTGCCTACCTCCCAACCGAAGTGACACCACAGGCTTTCACTCCATCCTCC 2220 
lcl|NM_013080.2_cds_NP_037212.2_1      TATTCTACCTTTGCCTACCCCCCGACTGAAGTAACACCACATGCTTTCACTCCATCCTCC 2220 
                                       ******************  *** ** ** ** ***** ** ***** ** ********* 
 
lcl|M93426.1_cds_AAA60225.1_1          AGACAACAGGATTTGGTCTCCACGGTCAACGTGGTATACTCGCAGACAACCCAACCGGTA 2256 
lcl|BC151071.1_cds_AAI51072.1_1        AGACCACTTGATTTGGCTCCTACTATCAACATCCTCCATTCGCAGACGACTCAACCAGTA 2280 
lcl|NM_013080.2_cds_NP_037212.2_1      AGACCACTTGATTTGGCTCCCACTAGCAACATCCTCCATTCGCAGACAACTCAACCAGTA 2280 




lcl|M93426.1_cds_AAA60225.1_1          TACAATGGTGAGACACCTCTTCAACCTTCCTACAGTAGTGAAGTCTTTCCTCTAGTCACC 2316 
lcl|BC151071.1_cds_AAI51072.1_1        TACAATGGTGAGACACCTCTTCAACCTTCCTACAGTAGTGAAGTCTTTCCTCTAGCCACC 2340 
lcl|NM_013080.2_cds_NP_037212.2_1      TACAATGGTGAGACACCTCTTCAACCTTCCTACAGTAGTGAAGTCTTTCCTCTAGTCACC 2340 
                                       ******************************************************* **** 
 
lcl|M93426.1_cds_AAA60225.1_1          CCTTTGTTGCTTGACAATCAGATCCTCAACACTACCCCTGCTGCTTCAAGTAGTGATTCG 2376 
lcl|BC151071.1_cds_AAI51072.1_1        CCTTTGTTGCTTGACAATCAGACCCTCAACACTACCCCTGCTGCTTCAAGTAGTGATTCG 2400 
lcl|NM_013080.2_cds_NP_037212.2_1      CCTTTGTTGCTTGACAATCAGACCCTCAACACTACCCCTGCTGCTTCAAGTAGTGATTCG 2400 
                                       ********************** ************************************* 
 
lcl|M93426.1_cds_AAA60225.1_1          GCCTTGCATGCTACGCCTGTATTTCCCAGTGTCGATGTGTCATTTGAATCCATCCTGTCT 2436 
lcl|BC151071.1_cds_AAI51072.1_1        GCCTTGCATGCTACGCCTGTATCCCCCAGTGTTGGTGTGTCATTTGAATCCATCCTGTCT 2460 
lcl|NM_013080.2_cds_NP_037212.2_1      GCCTTGCATGCTACGCCTGTATTCCCCAGTGTTGGTGTGTCATTTGACTCCATCCTGTCT 2460 
                                       **********************  ******** * ************ ************ 
 
lcl|M93426.1_cds_AAA60225.1_1          TCCTATGATGGTGCACCTTTGCTTCCATTTTCCTCTGCTTCCTTCAGTAGTGAATTGTTT 2496 
lcl|BC151071.1_cds_AAI51072.1_1        TCCTATGATGATGCACCTCTGCTCCCATTTTCCTCTGCTTCCTTCAGTAGTGAAATGTTT 2520 
lcl|NM_013080.2_cds_NP_037212.2_1      TCCTATGATGATGCACCTCTGCTCCCATTTTCCTCTGCTTCCTTCAGTAGTGACTTGTTT 2520 
                                       ********** ******* **** *****************************  ***** 
 
lcl|M93426.1_cds_AAA60225.1_1          CGCCATCTGCATACAGTTTCTCAAATCCTTCCACAAGTTACTTCAGCTACCGAGAGTGAT 2556 
lcl|BC151071.1_cds_AAI51072.1_1        CGCCATCTGCATACGGTTTCTCAAACCCTTCCGCAAGTCACTTCAGCTGCTGAGAGGGAT 2580 
157 
 
lcl|NM_013080.2_cds_NP_037212.2_1      CACCATCTGCATACGGTTTCTCAAACCCTTCCGCAAGTTACTTCAGCTGCTGAGAGGGAT 2580 
                                       * ************ ********** ****** ***** ********* * ***** *** 
 
lcl|M93426.1_cds_AAA60225.1_1          AAGGTGCCCTTGCATGCTTCTCTGCCAGTGGCTGGGGGTGATTTGCTATTAGAGCCCAGC 2616 
lcl|BC151071.1_cds_AAI51072.1_1        GAGCTGTCTTTGCATGCTTCTCTGCTGGTGGCTAGGGGTGATTTGCTGTTAGAACCCAGC 2640 
lcl|NM_013080.2_cds_NP_037212.2_1      GAGCTGTCTTTGCATGCTTCTCTGCTGGTGGCTGGGGGTGATTTGCTGTTAGAGCCCAGC 2640 
                                        ** ** * ****************  ****** ************* ***** ****** 
 
lcl|M93426.1_cds_AAA60225.1_1          CTTGCTCAGTATTCTGATGTGCTGT---------CCACTACTCATGCTGCTTCAGAGACG 2667 
lcl|BC151071.1_cds_AAI51072.1_1        CTTGTTCAGTATTCTGATGTGGCGTCACATCAGGCCACTACTCGTGCTGCTTCGGACACA 2700 
lcl|NM_013080.2_cds_NP_037212.2_1      CTTGTTCAGTATTCTGATGTGATGTCACATCAGGTCACTATTCATGCTGCTTCGGACACA 2700 
                                       **** ****************  **          ***** ** ********* ** **  
 
lcl|M93426.1_cds_AAA60225.1_1          CTGGAATTTGGTAGTGAATCTGGTGTTCTTTATAAAACGCTTATGTTTTCTCAAGTTGAA 2727 
lcl|BC151071.1_cds_AAI51072.1_1        TTGGGATTTGGTAGTGAGTCTGCTGTCTTTTATAAAACGTCCATGGTTTCTCAGATTGAA 2760 
lcl|NM_013080.2_cds_NP_037212.2_1      TTGGAATTTGGTAGTGAGTCTGCTGTCCTTTATAAAACGTCTATGGTTTCTCAAATCGAA 2760 
                                        *** ************ **** ***  ***********   *** *******  * *** 
 
lcl|M93426.1_cds_AAA60225.1_1          CCACCCAGCAGTGATGCCATGATGCATGCACGTTCTTCAGGGCCTGAACCTTCTTATGCC 2787 
lcl|BC151071.1_cds_AAI51072.1_1        TCACCCAGAAGTGATGTTGTTATGCATGCATACTCTTCGGGGCCTGAACCTTCTTATACC 2820 
lcl|NM_013080.2_cds_NP_037212.2_1      TCACCCAGCAGTGATGTCGTTATGCATGCATATTCGTCAGGGCCTGAAACTTCTTATGCC 2820 




lcl|M93426.1_cds_AAA60225.1_1          TTGTCTGATAATGAGGGCTCCCAACACATCTTCACTGTTTCTTACAGTTCTGCAATACCT 2847 
lcl|BC151071.1_cds_AAI51072.1_1        G---------TTGAGGGCTCCCACCACGTACCCACTGTTTCTTACAGTTCTGCAATGCCT 2871 
lcl|NM_013080.2_cds_NP_037212.2_1      A---------TTGAGGGCTCCCACCACGTGCTCACTGTTTCTTCCAGTTCTGCAATACCT 2871 
                                                  ************ *** *   *********** ************ *** 
 
lcl|M93426.1_cds_AAA60225.1_1          GTGCATGATTCTGTGGGTGTAACTTATCAGGGTTCCTTATTTAGCGGCCCTAGCCATATA 2907 
lcl|BC151071.1_cds_AAI51072.1_1        CTGCATGGTTCTGTCGATGTATCTGATCAGGGGTCCTTACTTATCAATCCTAGCCATATA 2931 
lcl|NM_013080.2_cds_NP_037212.2_1      GTGCATGATTCTATTGGTGTAGCTGATCAGGGGTCCTTACTTATCAATCCTAGCCATATA 2931 
                                        ****** **** * * **** ** ******* ****** *** *   ************ 
 
lcl|M93426.1_cds_AAA60225.1_1          CCAATACCTAAGTCTTCGTTAATAACCCCAACTGCATCATTACTGCAGCCTACTCATGCC 2967 
lcl|BC151071.1_cds_AAI51072.1_1        TCAATGCCTGAGTCCTCCTTTATTACTCCAACTGCATCATTACTGCAGCCTCCTCCAGCC 2991 
lcl|NM_013080.2_cds_NP_037212.2_1      TCACTGCCTGAGTCCTCATTTATTACTCCAACTGCATCATTACTGCAGCTTCCTCCTGCC 2991 
                                        ** * *** **** ** ** ** ** ********************** * ***  *** 
 
lcl|M93426.1_cds_AAA60225.1_1          CTCTCTGGTGATGGGGAATGGTCTGGAGCCTCTTCTGATAGTGAATTTCTTTTACCTGAC 3027 
lcl|BC151071.1_cds_AAI51072.1_1        CTCTCTGGTGATGGGGAATGGTCTGGAGCCTCCTCTGATAGTGAATTGCTTTTACCTGAC 3051 
lcl|NM_013080.2_cds_NP_037212.2_1      CTCTCTGGTGATGGGGAGTGGTCTGGAGCCTCCTCTGATAGTGAATTGCTTTTACCTGAC 3051 
                                       ***************** ************** ************** ************ 
 
lcl|M93426.1_cds_AAA60225.1_1          ACAGATGGGCTGACAGCCCTTAACATTTCTTCACCTGTTTCTGTAGCTGAATTTACATAT 3087 
159 
 
lcl|BC151071.1_cds_AAI51072.1_1        GCAGATGGGCTGAGAACTCTTAACATTTCTTCACCTGTTTCCGTAGCTGAATTTACATAT 3111 
lcl|NM_013080.2_cds_NP_037212.2_1      ACAGATGGGCTGAGAACTCTTAACATGTCTTCACCTGTTTCTGTAGCTGATTTTACATAC 3111 
                                        ************ * * ******** ************** ******** ********  
 
lcl|M93426.1_cds_AAA60225.1_1          ACAACATCTGTGTTTGGTGATGATAATAAGGCGCTTTCTAAAAGTGAAATAATATATGGA 3147 
lcl|BC151071.1_cds_AAI51072.1_1        ACGACATCTGTGTTTGCTGATGGTATTAAGCCGCTCTCTAAAAGTGAAATGATGTATGGA 3171 
lcl|NM_013080.2_cds_NP_037212.2_1      ACGACATCTGTGTCTGGCGATGATATTAAGCCGCTTTCTAAAGGTGAAATGATGTATGGA 3171 
                                       ** ********** **  **** ** **** **** ****** ******* ** ****** 
 
lcl|M93426.1_cds_AAA60225.1_1          AATGAGACTGAACTGCAAATTCCTTCTTTCAATGAGATGGTTTACCCTTCTGAAAGCACA 3207 
lcl|BC151071.1_cds_AAI51072.1_1        AATGAGACTGAACTGAAAATGTCTTCTTTCAGTGACATGGCATACCCTTCTAAAAGCACA 3231 
lcl|NM_013080.2_cds_NP_037212.2_1      AATGAGACTGAACTGAAAATGTCTTCTTTCAGTGACATGGCATACCCTTCTAAAAGCACA 3231 
                                       *************** ****  ********* *** ****  ********* ******** 
 
lcl|M93426.1_cds_AAA60225.1_1          GTCATGCCCAACATGTATGATAATGTAAATAAGTTGAATGCGTCTTTACAAGAAACCTCT 3267 
lcl|BC151071.1_cds_AAI51072.1_1        GTTGTGCCAAAGATGTCAGATGTTGTACATAAGTGGAGTGAATCTTTAAAAGAAACCTCT 3291 
lcl|NM_013080.2_cds_NP_037212.2_1      GTCGTGCCAAAGATGTCTGATATTGTAAATAAGTGGAGTGAATCTTTAAAAGAAACCTCT 3291 
                                       **  **** ** ****  ***  **** ****** ** **  ****** *********** 
 
lcl|M93426.1_cds_AAA60225.1_1          GTTTCCATTTCTAGCACCAAGGGCATGTTTCCAGGGTCCCTTGCTCATACCACCACTAAG 3327 
lcl|BC151071.1_cds_AAI51072.1_1        GTTTCTATTTCTAGCATGAAGAGTGTGTTTCCAGAGTCTCTTGTTTATCCCACAACTAAG 3351 
lcl|NM_013080.2_cds_NP_037212.2_1      GTTTCCGTATCTAGCATAAACAGCGTGTTTACAGAGTCTCTGGTTTATCCCATAACTAAG 3351 
160 
 
                                       *****  * *******  **  *  ***** *** *** ** * * ** ***  ****** 
 
lcl|M93426.1_cds_AAA60225.1_1          GTTTTTGATCATGAGATTAGTCAAGTTCCAGAAAATAACTTTTCAGTTCAACCTACACAT 3387 
lcl|BC151071.1_cds_AAI51072.1_1        GGTTTTGAACAGGGGGTTAGTCACGTTCCAGAAATTATCTTCCCAGTTCAACCTACACAC 3411 
lcl|NM_013080.2_cds_NP_037212.2_1      GTTTTTGATCAGGAGATTAGTCGAGTTCCAGAGATTATCTTCCCAGTTAAACCTACACAC 3411 
                                       * ****** ** * * ******  ******** * ** ***  ***** **********  
 
lcl|M93426.1_cds_AAA60225.1_1          ACTGTCTCTCAAGCATCTGGTGACACTTCGCTTAAACCTGTGCTTAGTGCAAACTCAGAG 3447 
lcl|BC151071.1_cds_AAI51072.1_1        ACTGCATCTCAAGCATCTGGGGACACTTGGCTTAAACCCGGGCTTAGCGCAAACTCAGAG 3471 
lcl|NM_013080.2_cds_NP_037212.2_1      ACAGCATCTCAAGCATCTGGTGACACTTGGCTTAAACCCGGGCTTAGCACAAACTCAGAG 3471 
                                       ** *  ************** ******* ********* * ******  *********** 
 
lcl|M93426.1_cds_AAA60225.1_1          CCAGCATCCTCTGACCCTGCTTCTAGTGAAATGTTATCTCCTTCAACTCAGCTCTTATTT 3507 
lcl|BC151071.1_cds_AAI51072.1_1        GCAGCGTTCTCAGACACTGCTTCTAGGGAAGTAGTACACCCTTCAACACAGCCCTTGCTC 3531 
lcl|NM_013080.2_cds_NP_037212.2_1      CCTGCGCTCTCTGACACTGCTTCTAGTGAAGTATTACACCCTTCAACACAGCCCTTGCTC 3531 
                                        * **   *** *** ********** *** *  **   ******** **** ***  *  
 
lcl|M93426.1_cds_AAA60225.1_1          TATGAGACCTCAGCTTCTTTTAGTACTGAAGTATTGCTACAACCTTCCTTTCAGGCTTCT 3567 
lcl|BC151071.1_cds_AAI51072.1_1        TATGAGGCCGCAACTCCTTTTAATACTGAAGCGTTGCTGCAACCTTCCTTTCAGGCTTCT 3591 
lcl|NM_013080.2_cds_NP_037212.2_1      TATGAGGCCGCATCTCCTTTTAATACGGAAGCATTGCTGCAACCTTCCTTTCCGGCTTCT 3591 




lcl|M93426.1_cds_AAA60225.1_1          GATGTTGACACCTTGCTTAAAACTGTTCTTCCAGCTGTGCCCAGTGATCCAATATTGGTT 3627 
lcl|BC151071.1_cds_AAI51072.1_1        GATGTTGACACCTTGCTTAAAACTGCTCTCCCATCTGTGCCTAGTGATCCAATACTGGCT 3651 
lcl|NM_013080.2_cds_NP_037212.2_1      GATGTTGACACCTTGCTTAAAACTGCCCTTCCCTCTGGGCCTCGTGATCCAGTGCTGACT 3651 
                                       *************************  ** **  *** ***  ******** *  **  * 
 
lcl|M93426.1_cds_AAA60225.1_1          GAAACCCCCAAAGTTGATAAAATTAGTTCTACAATGTTGCATCTCATTGTATCAAATTCT 3687 
lcl|BC151071.1_cds_AAI51072.1_1        GGAACCCCCCAGGTTGAACAAAGTAGCTCTTCCGTGTCTCATCCCATGGCATCAGAGTCT 3711 
lcl|NM_013080.2_cds_NP_037212.2_1      GAAACCCCCATGGTTGAGCAAAGTAGCTCTTCCATGTCTCTTCCCCTGGCATCAGAGTCT 3711 
                                       * *******   *****  *** *** *** *  ***  * ** * * * **** * *** 
 
lcl|M93426.1_cds_AAA60225.1_1          GCTTCAAGTGAAAACATGCTGCACTCTACATCTGTACCAGTTTTTGATGTGTCGCCTACT 3747 
lcl|BC151071.1_cds_AAI51072.1_1        GGTTCAAGCGAAAGCATGCTGCACTTTACGTCTGTACCTATTCTCGATATATCACC---T 3768 
lcl|NM_013080.2_cds_NP_037212.2_1      GCTTCAAGCAAAAGCACGCTGCACTTTACATCTGTACCAGTTCTCAATATGTCACC---T 3768 
                                       * ******  *** ** ******** *** ********  ** *  ** * ** **   * 
 
lcl|M93426.1_cds_AAA60225.1_1          TCTCATATGCACTCTGCTTCACTTCAAGGTTTGACCATTTCCTATGCAAGTGAGAAATA- 3806 
lcl|BC151071.1_cds_AAI51072.1_1        TCTAAGGTGCACTCCACTCCACTTCAAGGCTTAACAGTTCCTCACTCGAGTAAGAAATTT 3828 
lcl|NM_013080.2_cds_NP_037212.2_1      TCTGATGTGCACCCCACTTCACTTCAACGCTTAACAGTTCCTCACTCGAGGGAGGAATAT 3828 
                                       *** *  ***** *  ** ******** * ** **  ** *  *  * **  ** ***   
 
lcl|M93426.1_cds_AAA60225.1_1          --TGAACCAGTTTTGTTAAAAAGTGAAAGTTCCCACCAAGTGGTACCTTCTTTGTACAGT 3864 
lcl|BC151071.1_cds_AAI51072.1_1        TCTGAACAAGGTTTGCTTAAGAGCAAAAGTCCCCAGCAAGTGCTGCCATCTTTGTTCAGC 3888 
162 
 
lcl|NM_013080.2_cds_NP_037212.2_1      TTTGAACAAGGTTTGCTTAAGAGCAAAAGTCCCCAGCAAGTCCTGCCGTCCTTGCACAGC 3888 
                                         ***** ** **** * ** **  ***** **** *****  * ** ** ***  ***  
 
lcl|M93426.1_cds_AAA60225.1_1          AATGATGAGTTGTTCCAAACGGCCAATTTGGAGATTAACCAGGCCCATCCCCCAAAAGGA 3924 
lcl|BC151071.1_cds_AAI51072.1_1        AATGACGAGTTTTTCCAAAGCGCACATCTGGACGTTAGCCAGGCCTATCCTCCAAAAGGG 3948 
lcl|NM_013080.2_cds_NP_037212.2_1      CATGACGAGTTTTTCCAAACTGCACATCTGGACATTAGCCAGGCCTACCCTCCAAAAGGA 3948 
                                        **** ***** *******  **  ** ****  *** ******* * ** ********  
 
lcl|M93426.1_cds_AAA60225.1_1          AGGCATGTATTTGCTACACCTGTTTTATCAATTGATGAACCATTAAATACACTAATAAAT 3984 
lcl|BC151071.1_cds_AAI51072.1_1        AGGCATGCATTTGTTACTCCTGTTTTATCAATTGATGAACCACAAAATACGCTTATAAAC 4008 
lcl|NM_013080.2_cds_NP_037212.2_1      AGGCATGCATTTGCTACTCCTATTTTATCAATCGATGAACCACAAAATACACTTATAAGC 4008 
                                       ******* ***** *** *** ********** *********  ****** ** ****   
 
lcl|M93426.1_cds_AAA60225.1_1          AAGCTTATACATTCCGATGAAATTTTAACCTCCACCAAAAGTTCTGTTACTGGTAAGGTA 4044 
lcl|BC151071.1_cds_AAI51072.1_1        AAGCTTGTGTATTCTGAGGACATTTTCTCGAGCACTGAGATTTCTATTACTGATAAGGTA 4068 
lcl|NM_013080.2_cds_NP_037212.2_1      AGGCTTGTGTATTCTGAGGACATTTTCATGCACCCTGAAATTTCTATTACTGATAAGGCA 4068 
                                       * **** *  **** ** ** *****      * *  * * **** ****** ***** * 
 
lcl|M93426.1_cds_AAA60225.1_1          TTTGCTGGTATTCCAACAGTTGCTTCTGATACATTTGTATCTACTGATCATTCTGTTCCT 4104 
lcl|BC151071.1_cds_AAI51072.1_1        CTTACTGGTCTCCCAACGCTTGCTTCTGATGTACTTTCATCTACTGACCATTCTGTTCCA 4128 
lcl|NM_013080.2_cds_NP_037212.2_1      CTTACTGGTCTACCAACGACCGTTTCTGATGTACTTATAGCTACTGACCATTCTGTTCCA 4128 




lcl|M93426.1_cds_AAA60225.1_1          ATAGGAAATGGGCATGTTGCCATTACAGCTGTTTCTCCCCACAGAGATGGTTCTGTAACC 4164 
lcl|BC151071.1_cds_AAI51072.1_1        TTAGGAAGTGGGCCCATTTCCTTGACAATGGTTTCTCCCAACAGAGATGATTCTGTGACC 4188 
lcl|NM_013080.2_cds_NP_037212.2_1      TTAGGAAGTGGGCCCATTTCCATGACAACTGTTTCTCCCAACAGAGATGATTCTGTGACC 4188 
                                        ****** *****   ** ** * ***   ********* ********* ****** *** 
 
lcl|M93426.1_cds_AAA60225.1_1          TCAACAAAGTTGCTGTTTCCTTCTAAGGCAACTTCTGAGCTGAGTCATAGTGCCAAATCT 4224 
lcl|BC151071.1_cds_AAI51072.1_1        ACAGCCAAGTTGCTTCTTCCTTCTACAGCTACTTCTAAGCTGACTCAGAGCGCCAGATCT 4248 
lcl|NM_013080.2_cds_NP_037212.2_1      ACAACCAAGTTGCTTCTTCCTTCTAAAGCTACTTCTAAGCCGACTCATAGTGCCAGATCT 4248 
                                        ** * ********  *********  ** ****** *** ** *** ** **** **** 
 
lcl|M93426.1_cds_AAA60225.1_1          GATGCCGGTTTAGTGGGTGGTGGTGAAGATGGTGACACTGATGATGATGGTGATGATGAT 4284 
lcl|BC151071.1_cds_AAI51072.1_1        GATGCCGATTTAGTGGGAGGTGGTGAAGATGGTGAT---GACTATGATGATGATGACTAT 4305 
lcl|NM_013080.2_cds_NP_037212.2_1      GATGCCGATTTAGTAGGAGGTGGTGAAGATGGTGAT---GACTATGATGATGATGATTAT 4305 
                                       ******* ****** ** *****************    **  ****** ******  ** 
 
lcl|M93426.1_cds_AAA60225.1_1          GATGACAGAGATAGTGATGGCTTATCCATTCATAAGTGTATGTCATGCTCATCCTATAGA 4344 
lcl|BC151071.1_cds_AAI51072.1_1        GATGACATAGATAGGGGTCGCTTTCCTGTGAATAAGTGTATGTCATGCTTGCCCTATAGA 4365 
lcl|NM_013080.2_cds_NP_037212.2_1      GATGACATAGATAGTGATCGCTTTCCCGTAAATAAGTGTATGTCATGTTCACCCTATAGA 4365 
                                       ******* ****** * * ****  *  *  **************** *   ******** 
 
lcl|M93426.1_cds_AAA60225.1_1          GAATCACAGGAAAAGGTAATGAATGATTCAGACACCCACGAAAACAGTCTTATGGATCAG 4404 
164 
 
lcl|BC151071.1_cds_AAI51072.1_1        GAATCCCGGGAAAAGGTAATGAATGACTCGGACACCCAGGAGAGCAGTCTTGTGGATCAG 4425 
lcl|NM_013080.2_cds_NP_037212.2_1      GAATCACAGGAAAAGGTAATGAATGACTCGGACACCCAAGAAAGCAGTCTTGTGGATCAG 4425 
                                       ***** * ****************** ** ******** ** * ******* ******** 
 
lcl|M93426.1_cds_AAA60225.1_1          AATAATCCAATCTCATACTCACTATCTGAGAATTCTGAAGAAGATAATAGAGTCACAAGT 4464 
lcl|BC151071.1_cds_AAI51072.1_1        AGTGACCCAATTTCACCTTTACTCTTTGAGAATACAGAAGAAGAAAATGGAGGCACAGGT 4485 
lcl|NM_013080.2_cds_NP_037212.2_1      AGTGACCCAATTTCACATTTGCTCTCTGAGAATACCGAAGAAGAAAATGGAGGCACGGGT 4485 
                                       * * * ***** ***   *  ** * ******* * ******** *** *** ***  ** 
 
lcl|M93426.1_cds_AAA60225.1_1          GTATCCTCAGACAGTCAAACTGGTATGGACAGAAGTCCTGGTAAATCACCATCAGCAAAT 4524 
lcl|BC151071.1_cds_AAI51072.1_1        GTA---------------ACTAGGGTGGAT------------AAGTCACCACCACCAAGT 4518 
lcl|NM_013080.2_cds_NP_037212.2_1      GTA---------------ACTAGGGTGGATAAAAGTCCTGATAAGTCACCACCACCAAGT 4530 
                                       ***               *** *  ****             ** ****** ** *** * 
 
lcl|M93426.1_cds_AAA60225.1_1          GGGCTATCCCAAAAGCACAATGATGGAAAAGAGGAAAATGACATTCAGACTGGTAGTGCT 4584 
lcl|BC151071.1_cds_AAI51072.1_1        ATGCTACCCCAGAATCACAATGATGGAAAAGAGGACAGTGACATCCAAATGGGTAGTGCT 4578 
lcl|NM_013080.2_cds_NP_037212.2_1      ATGCTACCCCAGAAGCACAATGATGGAAGAGAGGACCGTGACATTCAGATGGGTAGTGCT 4590 
                                         **** **** ** ************* ******   ****** ** *  ********* 
 
lcl|M93426.1_cds_AAA60225.1_1          CTGCTTCCTCTCAGCCCTGAATCTAAAGCATGGGCAGTTCTGACAAGTGATGAAGAAAGT 4644 
lcl|BC151071.1_cds_AAI51072.1_1        GTCCTTCCTCATACCCCAGGATCTAAAGCGTGGGCAGTTTTGACAAGTGATGAAGAGAGT 4638 
lcl|NM_013080.2_cds_NP_037212.2_1      GTCCTTCCTCACACCCCAGGATCTAAAGCATGGGCAGTTTTGACAAGTGATGAAGAGAGT 4650 
165 
 
                                        * *******  * *** * ********* ********* **************** *** 
 
lcl|M93426.1_cds_AAA60225.1_1          GGATCAGGGCAAGGTACCTCAGATAGCCTTAATGAGAATGAGACTTCCACAGATTTCAGT 4704 
lcl|BC151071.1_cds_AAI51072.1_1        GGGTCAGGGCAAGGCACCTCAGATAGCCTTAATGATAACGAGACGTCCACAGATTTCAGT 4698 
lcl|NM_013080.2_cds_NP_037212.2_1      GGGTCAGGGCAAGGCACCTCAGATAGCCTTAATGATAATGAGACTTCCACAGATTTCAGT 4710 
                                       ** *********** ******************** ** ***** *************** 
 
lcl|M93426.1_cds_AAA60225.1_1          TTTGCAGACACTAATGAAAAAGATGCTGATGGGATCCTGGCAGCAGGTGACTCAGAAATA 4764 
lcl|BC151071.1_cds_AAI51072.1_1        TTTCCAGATGTTAATGAAAAGGATACTGATGGTGTCCTGGAAACAGATGACACAGGCATA 4758 
lcl|NM_013080.2_cds_NP_037212.2_1      TTCCCAGATGTTAATGAAAAGGATGCTGATGGTGTCCTGGAAGCAGATGACACAGGCATA 4770 
                                       **  ****   ********* *** *******  ****** * *** **** ***  *** 
 
lcl|M93426.1_cds_AAA60225.1_1          ACTCCTGGATTCCCACAGTCCCCAACATCATCTGTTACTAGCGAGAACTCAGAAGTGTTC 4824 
lcl|BC151071.1_cds_AAI51072.1_1        GCTCCGGGATCTCCACGGTCCTCCACACCATCTGTTACTAGTGGGCACTCAGGAGTATCC 4818 
lcl|NM_013080.2_cds_NP_037212.2_1      GCTCCGGGATCTCCACGGTCCTCCACACCATCTGTTACTAGTGGGCATTCAGGAGTATCC 4830 
                                        **** ****  **** **** * *** ************* * * * **** *** * * 
 
lcl|M93426.1_cds_AAA60225.1_1          CACGTTTCAGAGGCAGAGGCCAGTAATAGTAGCCATGAGTCTCGTATTGGTCTAGCTGAG 4884 
lcl|BC151071.1_cds_AAI51072.1_1        AACAGTTCAGAGGCAGAGGCCAGTAATAGTAGCCATGAGTCTCGTATTGGTCTAGCTGAG 4878 
lcl|NM_013080.2_cds_NP_037212.2_1      AACAGTTCAGAGGCAGAGGCCAGTAATAGTAGCCATGAGTCTCGTATTGGTCTAGCTGAG 4890 




lcl|M93426.1_cds_AAA60225.1_1          GGGTTGGAATCCGAGAAGAAGGCAGTTATACCCCTTGTGATCGTGTCAGCCCTGACTTTT 4944 
lcl|BC151071.1_cds_AAI51072.1_1        GGGTTGGAGTCTGAGAAGAAAGCGGTTATACCCCTTGTGATCGTGTCTGCCCTGACTTTT 4938 
lcl|NM_013080.2_cds_NP_037212.2_1      GGGTTGGAGTCTGAGAAGAAGGCGGTTATACCCCTTGTGATCGTGTCTGCCCTGACTTTT 4950 
                                       ******** ** ******** ** *********************** ************ 
 
lcl|M93426.1_cds_AAA60225.1_1          ATCTGTCTAGTGGTTCTTGTGGGTATTCTCATCTACTGGAGGAAATGCTTCCAGACTGCA 5004 
lcl|BC151071.1_cds_AAI51072.1_1        ATCTGTCTAGTGGTTCTTGTTGGTATTCTCATCTATTGGAGAAAATGCTTCCAGACTGCT 4998 
lcl|NM_013080.2_cds_NP_037212.2_1      ATCTGTCTAGTGGTTCTTGTTGGTATTCTCATCTACTGGAGAAAATGCTTCCAGACGGCT 5010 
                                       ******************** ************** ***** ************** **  
 
lcl|M93426.1_cds_AAA60225.1_1          CACTTTTACTTAGAGGACAGTACATCCCCTAGAGTTATATCCACACCTCCAACACCTATC 5064 
lcl|BC151071.1_cds_AAI51072.1_1        CACTTTTATTTAGAAGACAATACATCCCCTCGAGTAATATCTACACCACCAACACCCATC 5058 
lcl|NM_013080.2_cds_NP_037212.2_1      CACTTTTATTTAGAAGACAATACATCCCCTCGAGTAATATCTACACCACCAACACCCATC 5070 
                                       ******** ***** **** ********** **** ***** ***** ******** *** 
 
lcl|M93426.1_cds_AAA60225.1_1          TTTCCAATTTCAGATGATGTCGGAGCAATTCCAATAAAGCACTTTCCAAAGCATGTTGCA 5124 
lcl|BC151071.1_cds_AAI51072.1_1        TTTCCAATTTCAGATGATATTGGAGCAATTCCAATAAAGCATTTTCCAAAGCACGTTGCA 5118 
lcl|NM_013080.2_cds_NP_037212.2_1      TTTCCAATTTCAGATGATATTGGAGCAATTCCAATAAAGCATTTTCCAAAGCACGTAGCA 5130 
                                       ****************** * ******************** *********** ** *** 
 
lcl|M93426.1_cds_AAA60225.1_1          GATTTACATGCAAGTAGTGGGTTTACTGAAGAATTTGAGACACTGAAAGAGTTTTACCAG 5184 
lcl|BC151071.1_cds_AAI51072.1_1        GATTTACATGCAAGTAATGGGTTCACTGAAGAATTTGAGACACTGAAAGAGTTTTACCAG 5178 
167 
 
lcl|NM_013080.2_cds_NP_037212.2_1      GACTTACATGCAAGTAATGGGTTCACTGAAGAATTTGAGACACTGAAAGAGTTTTACCAG 5190 
                                       ** ************* ****** ************************************ 
 
lcl|M93426.1_cds_AAA60225.1_1          GAAGTGCAGAGCTGTACTGTTGACTTAGGTATTACAGCAGACAGCTCCAACCACCCAGAC 5244 
lcl|BC151071.1_cds_AAI51072.1_1        GAAGTGCAGAGCTGTACTGCTGACTTAGGCATCACAGCAGACAGCTCCAATCACCCAGAC 5238 
lcl|NM_013080.2_cds_NP_037212.2_1      GAAGTGCAGAGCTGCACTGTTGACTTAGGTATTACAGCAGACAGCTCCAATCACCCAGAC 5250 
                                       ************** **** ********* ** ***************** ********* 
 
lcl|M93426.1_cds_AAA60225.1_1          AACAAGCACAAGAATCGATACATAAATATCGTTGCCTATGATCATAGCAGGGTTAAGCTA 5304 
lcl|BC151071.1_cds_AAI51072.1_1        AACAAGCACAAGAACAGATACGTCAATATCGTAGCCTATGATCATAGCAGGGTTAAGCTC 5298 
lcl|NM_013080.2_cds_NP_037212.2_1      AACAAGCACAAGAACAGATATGTCAACATCGTAGCCTATGATCATAGCAGGGTTAAGCTC 5310 
                                       **************  ****  * ** ***** **************************  
 
lcl|M93426.1_cds_AAA60225.1_1          GCACAGCTTGCTGAAAAGGATGGCAAACTGACTGATTATATCAATGCCAATTATGTTGAT 5364 
lcl|BC151071.1_cds_AAI51072.1_1        ACACAACTTGCTGAAAAAGATGGAAAACTGACTGATTACATCAATGCCAATTATGTTGAT 5358 
lcl|NM_013080.2_cds_NP_037212.2_1      ACACAACTTGCTGAAAAAGATGGAAAACTGACTGATTACATCAATGCCAATTATGTTGAT 5370 
                                        **** *********** ***** ************** ********************* 
 
lcl|M93426.1_cds_AAA60225.1_1          GGCTACAACAGACCAAAAGCTTATATTGCTGCCCAAGGCCCACTGAAATCCACAGCTGAA 5424 
lcl|BC151071.1_cds_AAI51072.1_1        GGTTACAACAGACCAAAGGCTTACATTGCTGCCCAGGGTCCACTGAAGTCCACAGCTGAA 5418 
lcl|NM_013080.2_cds_NP_037212.2_1      GGTTACAACAGGCCAAAGGCTTACATTGCTGCCCAGGGTCCACTGAAGTCCACAGCAGAA 5430 




lcl|M93426.1_cds_AAA60225.1_1          GATTTCTGGAGAATGATATGGGAACATAATGTGGAAGTTATTGTCATGATAACAAACCTC 5484 
lcl|BC151071.1_cds_AAI51072.1_1        GACTTCTGGAGAATGATCTGGGAGCATAATGTGGAAGTCATCGTCATGATCACAAACCTC 5478 
lcl|NM_013080.2_cds_NP_037212.2_1      GATTTCTGGAGAATGATATGGGAGCATAATGTGGAAGTCATCGTTATGATAACAAACCTC 5490 
                                       ** ************** ***** ************** ** ** ***** ********* 
 
lcl|M93426.1_cds_AAA60225.1_1          GTGGAGAAAGGAAGGAGAAAATGTGATCAGTACTGGCCTGCCGATGGGAGTGAGGAGTAC 5544 
lcl|BC151071.1_cds_AAI51072.1_1        GTGGAGAAAGGAAGAAGAAAATGTGACCAGTACTGGCCTACTGATGGTAGTGAAGAATAT 5538 
lcl|NM_013080.2_cds_NP_037212.2_1      GTGGAGAAAGGAAGAAGAAAATGTGACCAGTACTGGCCTACTGATGGCAGTGAAGAATAC 5550 
                                       ************** *********** ************ * ***** ***** ** **  
 
lcl|M93426.1_cds_AAA60225.1_1          GGGAACTTTCTGGTCACTCAGAAGAGTGTGCAAGTGCTTGCCTATTATACTGTGAGGAAT 5604 
lcl|BC151071.1_cds_AAI51072.1_1        GGGAGCTTCCTAGTCAACCAAAAGAGTGTTCAGGTGCTTGCTTATTATACTGTGAGGAAT 5598 
lcl|NM_013080.2_cds_NP_037212.2_1      GGGAGCTTCCTGGTCAACCAGAAGAATGTTCAGGTGCTTGCTTATTATACTGTGAGGAAT 5610 
                                       **** *** ** ****  ** **** *** ** ******** ****************** 
 
lcl|M93426.1_cds_AAA60225.1_1          TTTACTCTAAGAAACACAAAAATAAAAAAGGGCTCCCAGAAAGGAAGACCCAGTGGACGT 5664 
lcl|BC151071.1_cds_AAI51072.1_1        TTCACCCTAAGAAACACAAAGTTAAAGAAGGGCTCTCAGAAAGGAAGATCCAGTGGGCGC 5658 
lcl|NM_013080.2_cds_NP_037212.2_1      TTCACCCTAAGAAACACAAAGATAAAAAAGGGCTCTCAGAAAGGAAGATCCAGTGGACGC 5670 
                                       ** ** **************  **** ******** ************ ******* **  
 
lcl|M93426.1_cds_AAA60225.1_1          GTGGTCACACAGTATCACTACACGCAGTGGCCTGACATGGGAGTACCAGAGTACTCCCTG 5724 
169 
 
lcl|BC151071.1_cds_AAI51072.1_1        CTAGTCACACAGTATCATTACACCCAGTGGCCTGACATGGGTGTTCCCGAGTACTCCCTG 5718 
lcl|NM_013080.2_cds_NP_037212.2_1      CTAGTCACTCAGTATCATTACACCCAGTGGCCTGATATGGGTGTTCCCGAGTACTCCCTA 5730 
                                        * ***** ******** ***** *********** ***** ** ** ***********  
 
lcl|M93426.1_cds_AAA60225.1_1          CCAGTGCTGACCTTTGTGAGAAAGGCAGCCTATGCCAAGCGCCATGCAGTGGGGCCTGTT 5784 
lcl|BC151071.1_cds_AAI51072.1_1        CCCGTGCTGGCCTTTGTGAGAAAGGCTGCCCAGGCCAAGCGCCATGCAGTCGGGCCAGTT 5778 
lcl|NM_013080.2_cds_NP_037212.2_1      CCCGTGCTGGCCTTTGTGAGGAAGACTGCTCAGGCCAAGCGACATGCAGTCGGGCCAGTT 5790 
                                       ** ****** ********** *** * **  * ******** ******** ***** *** 
 
lcl|M93426.1_cds_AAA60225.1_1          GTCGTCCACTGCAGTGCTGGAGTTGGAAGAACAGGCACATATATTGTGCTAGACAGTATG 5844 
lcl|BC151071.1_cds_AAI51072.1_1        GTTGTCCACTGCAGTGCTGGCGTGGGGAGAACGGGGACATACATTGTGCTAGACAGTATG 5838 
lcl|NM_013080.2_cds_NP_037212.2_1      GTTGTCCACTGCAGCGCTGGCGTGGGGAGAACGGGCACATACATTGTACTAGACAGTATG 5850 
                                       ** *********** ***** ** ** ***** ** ***** ***** ************ 
 
lcl|M93426.1_cds_AAA60225.1_1          TTGCAGCAGATTCAACACGAAGGAACTGTCAACATATTTGGCTTCTTAAAACACATCCGT 5904 
lcl|BC151071.1_cds_AAI51072.1_1        CTGCAGCAGATTCAACATGAAGGAACCGTCAACATATTTGGCTTCTTAAAGCACATTCGT 5898 
lcl|NM_013080.2_cds_NP_037212.2_1      CTACAGCAGATTCAACACGAAGGAACCGTCAACATATTTGGTTTCTTAAAACACATTCGT 5910 
                                        * ************** ******** ************** ******** ***** *** 
 
lcl|M93426.1_cds_AAA60225.1_1          TCACAAAGAAATTATTTGGTACAAACTGAGGAGCAATATGTCTTCATTCATGATACACTG 5964 
lcl|BC151071.1_cds_AAI51072.1_1        TCTCAAAGGAATTATTTGGTGCAAACAGAGGAGCAGTATGTCTTCATTCACGATACACTG 5958 
lcl|NM_013080.2_cds_NP_037212.2_1      TCTCAAAGGAATTATTTGGTGCAAACAGAGGAGCAATACGTCTTCATTCACGACACACTG 5970 
170 
 
                                       ** ***** *********** ***** ******** ** *********** ** ****** 
 
lcl|M93426.1_cds_AAA60225.1_1          GTTGAGGCCATACTTAGTAAAGAAACTGAGGTGCTGGACAGTCATATTCATGCCTATGTT 6024 
lcl|BC151071.1_cds_AAI51072.1_1        GTCGAGGCCATACTCAGCAAGGAAACGGAGGTACCTGACAGCCACATTCACTCCTATGTT 6018 
lcl|NM_013080.2_cds_NP_037212.2_1      GTTGAGGCCATACTCAGCAAAGAGACAGAGGTGCCTGACAGCCACATCCATTCCTATGTT 6030 
                                       ** *********** ** ** ** ** ***** *  ***** ** ** **  ******** 
 
lcl|M93426.1_cds_AAA60225.1_1          AATGCACTCCTCATTCCTGGACCAGCAGGCAAAACAAAGCTAGAGAAACAATTCCAGCTC 6084 
lcl|BC151071.1_cds_AAI51072.1_1        AATACACTCCTCATACCCGGACCAACAGGCAAGACAAAACTAGAGAAACAATTCCAGCTT 6078 
lcl|NM_013080.2_cds_NP_037212.2_1      AATACACTCCTCATACCCGGACCATCAGGCAAGACAAAACTAGAGAAACAATTCCAGCTT 6090 
                                       *** ********** ** ****** ******* ***** ********************  
 
lcl|M93426.1_cds_AAA60225.1_1          CTGAGCCAGTCAAATATACAGCAGAGTGACTATTCTGCAGCCCTAAAGCAATGCAACAGG 6144 
lcl|BC151071.1_cds_AAI51072.1_1        CTGAGTCAGTCAAATATCCTCCAGAGTGACTACTCCACAGCCCTGAAGCAGTGTAACAGG 6138 
lcl|NM_013080.2_cds_NP_037212.2_1      CTGAGTCAGTCAAATATTCTTCAGAGTGACTACTCCACGGCCCTGAAGCAGTGTAACAGG 6150 
                                       ***** *********** *  *********** **  * ***** ***** ** ****** 
 
lcl|M93426.1_cds_AAA60225.1_1          GAAAAGAATCGAACTTCTTCTATCATCCCTGTGGAAAGATCAAGGGTTGGCATTTCATCC 6204 
lcl|BC151071.1_cds_AAI51072.1_1        GAGAAGAACAGAACATCGTCCATCATCCCTGTGGAAAGATCAAGGGTGGGCATTTCATCC 6198 
lcl|NM_013080.2_cds_NP_037212.2_1      GAGAAGAACAGAACATCCTCCATCATCCCCGTGGAAAGATCGAGGGTGGGCATTTCATCC 6210 




lcl|M93426.1_cds_AAA60225.1_1          CTGAGTGGAGAAGGCACAGACTACATCAATGCCTCCTATATCATGGGCTATTACCAGAGC 6264 
lcl|BC151071.1_cds_AAI51072.1_1        CTGAGTGGGGAAGGCACAGACTACATCAATGCATCCTATATTATGGGCTATTACCAGAGC 6258 
lcl|NM_013080.2_cds_NP_037212.2_1      CTGAGTGGGGAAGGCACAGACTACATCAATGCATCCTATATTATGGGTTATTACCAGAGC 6270 
                                       ******** *********************** ******** ***** ************ 
 
lcl|M93426.1_cds_AAA60225.1_1          AATGAATTCATCATTACCCAGCACCCTCTCCTTCATACCATCAAGGATTTCTGGAGGATG 6324 
lcl|BC151071.1_cds_AAI51072.1_1        AATGAATTCATCATCACCCAGCATCCCCTGCTGCACACCATCAAGGACTTCTGGAGAATG 6318 
lcl|NM_013080.2_cds_NP_037212.2_1      AATGAATTCATCATCACCCAGCACCCCCTTCTACACACCATCAAGGACTTCTGGAGAATG 6330 
                                       ************** ******** ** ** ** ** *********** ******** *** 
 
lcl|M93426.1_cds_AAA60225.1_1          ATATGGGACCATAATGCCCAACTGGTGGTTATGATTCCTGATGGCCAAAACATGGCAGAA 6384 
lcl|BC151071.1_cds_AAI51072.1_1        ATATGGGATCATAATGCCCAGCTGGTGGTTATGATTCCAGATGGTCAAAACATGGCAGAG 6378 
lcl|NM_013080.2_cds_NP_037212.2_1      ATATGGGATCATAATGCCCAGCTGGTGGTTATGATTCCAGATGGTCAAAACATGGCAGAG 6390 
                                       ******** *********** ***************** ***** **************  
 
lcl|M93426.1_cds_AAA60225.1_1          GATGAATTTGTTTACTGGCCAAATAAAGATGAGCCTATAAATTGTGAGAGCTTTAAGGTC 6444 
lcl|BC151071.1_cds_AAI51072.1_1        GATGAGTTTGTCTACTGGCCAAATAAAGATGAGCCCATAAATTGTGAAAGCTTCAAAGTC 6438 
lcl|NM_013080.2_cds_NP_037212.2_1      GATGAATTTGTTTACTGGCCAAATAAAGATGAGCCCATAAATTGCGAGAGCTTCAAAGTC 6450 
                                       ***** ***** *********************** ******** ** ***** ** *** 
 
lcl|M93426.1_cds_AAA60225.1_1          ACTCTTATGGCTGAAGAACACAAATGTCTATCTAATGAGGAAAAACTTATAATTCAGGAC 6504 
lcl|BC151071.1_cds_AAI51072.1_1        ACGCTTATGTCTGAAGAACACAAATGCCTTTCGAACGAGGAAAAACTGATCGTTCAAGAC 6498 
172 
 
lcl|NM_013080.2_cds_NP_037212.2_1      ACGCTTATGTCTGAAGAACACAAATGTCTTTCGAATGAGGAAAAACTGATAGTTCAAGAC 6510 
                                       ** ****** **************** ** ** ** *********** **  **** *** 
 
lcl|M93426.1_cds_AAA60225.1_1          TTTATCTTAGAAGCTACACAGGATGATTATGTACTTGAAGTGAGGCACTTTCAGTGTCCT 6564 
lcl|BC151071.1_cds_AAI51072.1_1        TTCATCTTGGAAGCAACACAGGATGACTATGTGCTGGAAGTAAGGCATTTCCAGTGCCCC 6558 
lcl|NM_013080.2_cds_NP_037212.2_1      TTCATCTTGGAAGCGACACAGGATGATTATGTGCTGGAAGTAAGGCATTTTCAGTGCCCG 6570 
                                       ** ***** ***** *********** ***** ** ***** ***** ** ***** **  
 
lcl|M93426.1_cds_AAA60225.1_1          AAATGGCCAAATCCAGATAGCCCCATTAGTAAAACTTTTGAACTTATAAGTGTTATAAAA 6624 
lcl|BC151071.1_cds_AAI51072.1_1        AAATGGCCAAATCCGGATAGTCCCATTAGTAAAACATTTGAACTTATAAGTATTATCAAA 6618 
lcl|NM_013080.2_cds_NP_037212.2_1      AAATGGCCAAATCCAGATAGTCCCATTAGTAAAACATTTGAACTTATAAGTATTATCAAA 6630 
                                       ************** ***** ************** *************** **** *** 
 
lcl|M93426.1_cds_AAA60225.1_1          GAAGAAGCTGCCAATAGGGATGGGCCTATGATTGTTCATGATGAGCATGGAGGAGTGACG 6684 
lcl|BC151071.1_cds_AAI51072.1_1        GAAGAAGCTGCTAACAGGGATGGGCCCATGATTGTTCACGATGAGCACGGGGGAGTAACA 6678 
lcl|NM_013080.2_cds_NP_037212.2_1      GAAGAAGCTGCTAACAGAGATGGGCCCATGATTGTTCACGATGAGCATGGAGGAGTAACA 6690 
                                       *********** ** ** ******** *********** ******** ** ***** **  
 
lcl|M93426.1_cds_AAA60225.1_1          GCAGGAACTTTCTGTGCTCTGACAACCCTTATGCACCAACTAGAAAAAGAAAATTCCGTG 6744 
lcl|BC151071.1_cds_AAI51072.1_1        GCAGGAACTTTTTGTGCTCTTACAACCCTTATGCACCAACTAGAAAAAGAAAACGCCATG 6738 
lcl|NM_013080.2_cds_NP_037212.2_1      GCAGGGACATTTTGTGCTCTCACAACCCTTATGCACCAACTAGAAAAAGAAAACTCCATG 6750 




lcl|M93426.1_cds_AAA60225.1_1          GATGTTTACCAGGTAGCCAAGATGATCAATCTGATGAGGCCAGGAGTCTTTGCTGACATT 6804 
lcl|BC151071.1_cds_AAI51072.1_1        GATGTTTACCAAGTAGCCAAGATGATCAATTTGATGAGGCCGGGAGTCTTCACTGACATT 6798 
lcl|NM_013080.2_cds_NP_037212.2_1      GATGTTTACCAAGTAGCCAAGATGATCAATTTGATGAGGCCGGGAGTCTTCACTGACATT 6810 
                                       *********** ****************** ********** ********  ******** 
 
lcl|M93426.1_cds_AAA60225.1_1          GAGCAGTATCAGTTTCTCTACAAAGTGATCCTCAGCCTTGTGAGCACAAGGCAGGAAGAG 6864 
lcl|BC151071.1_cds_AAI51072.1_1        GAGCAGTATCAGTTTCTGTACAAAGTAGTCCTCAGCCTCGTCAGCACAAGGCAGGAAGAG 6858 
lcl|NM_013080.2_cds_NP_037212.2_1      GAGCAGTACCAGTTTCTCTACAAAGTGGTCCTCAGCCTGGTCAGCACAAGGCAGGAAGAG 6870 
                                       ******** ******** ********  ********** ** ****************** 
 
lcl|M93426.1_cds_AAA60225.1_1          AATCCATCCACCTCTCTGGACAGTAATGGTGCAGCATTGCCTGATGGAAATATAGCTGAG 6924 
lcl|BC151071.1_cds_AAI51072.1_1        AACCCATCCACCTCTCTGGACAGTAATGGTGCAGCTTTGCCTGATGGAAATATAGCTGAA 6918 
lcl|NM_013080.2_cds_NP_037212.2_1      AATCCATCCACCTCCCTGGATAGTAATGGTGCAGCTTTGCCTGATGGAAATATAGCTGAA 6930 
                                       ** *********** ***** ************** ***********************  
 
lcl|M93426.1_cds_AAA60225.1_1          AGCTTAGAGTCTTTAGTTTAA 6945 
lcl|BC151071.1_cds_AAI51072.1_1        AGCCTGGAATCTTTAGTCTAA 6939 
lcl|NM_013080.2_cds_NP_037212.2_1      AGCCTGGAGTCTTTAGTCTGA 6951 
                                       *** * ** ******** * * 
Forward: 5’ GCCATGAGTCTCGTATTGGTCTA 3′ 
Reverse: 5’ GTAAAAGTGTGCAGTCTGGAAGC 3′ 
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Appendix 14. H & E staining of 4-week samples.  












Appendix 15. H & E staining of 8-week samples.  












Appendix 16. H & E staining of 16-week samples.  








    Appendix 17. B2M housekeeping gene PCR analysis. The samples layout in the 96-well plate and the qPCR analysis result. 
 
     
 
 Sample number              
   1 2 3 4 5 6 7 8 9 10 11 12  
 4 weeks A 432 432 441 441 428 428 597 597 583 583 595 595  
 8 weeks B 589 589 598 598 438 438 440 440 426 426 450 450  
 16 weeks C 599 599 585 585 427 427 430 430 584 584 425 425  
   D H2O H2O                      
               
 Cq value              
   1 2 3 4 5 6 7 8 9 10 11 12  
 4 weeks A 20.60 21.24 21.35 21.12 19.56 20.48 19.51 18.77 20.36 23.69 24.52 24.22  
 8 weeks B 21.82 21.34 19.36 18.95 23.22 22.94 18.77 19.73 22.08 23.64 20.84 22.77  
 16 weeks C 21.48 21.14 19.81 19.71 19.89 20.24 18.77 20.17 22.58 22.61 22.13 22.44  
   D 33.58 33.81                      
               
 Melting curve value             
   1 2 3 4 5 6 7 8 9 10 11 12  
 4 weeks A 79.95 80.92 80.92 79.66 80.24 80.05 80.14 79.76 80.34 80.05 79.56 80.73  
 8 weeks B 79.85 80.44 79.66 80.34 79.27 79.37 80.63 79.95 78.88 78.49 79.47 78.59  
 16 weeks C 79.56 80.44 79.85 80.14 80.73 80.05 80.92 80.14 81.02 80.63 79.76 79.47  
   D 74.13 75.10                      
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 Sample number              
   1 2 3 4 5 6 7 8 9 10 11 12  
 4 weeks A 432 432 441 441 428 428 597 597 583 583 595 595  
 8 weeks B 589 589 598 598 438 438 440 440 426 426 450 450  
 16 weeks C 599 599 585 585 427 427 430 430 584 584 425 425  
   D H2O H2O                      
               
 Cq value              
   1 2 3 4 5 6 7 8 9 10 11 12  
 4 weeks A 24.93 24.91 22.83 23.46 24.59 24.81 25.98 25.44 28.36 28.57 31.74 31.51  
 8 weeks B 27.85 27.93 25.94 25.11 30.61 27.09 24.04 24.05 26.04 25.99 23.73 23.86  
 16 weeks C 24.58 24.37 33.66 29.13 23.54 26.27 25.55 25.39 27.75 28.89 26.38 26.37  
   D 40.00 38.49                      
               
 Melting curve value             
   1 2 3 4 5 6 7 8 9 10 11 12  
 4 weeks A 81.15 81.25 80.65 80.27 80.95 80.17 79.97 81.53 81.05 81.05 80.86 81.05  
 8 weeks B 80.95 81.15 79.29 80.17 78.52 80.56 81.25 81.25 81.25 81.05 79.20 78.71  
 16 weeks C 80.17 80.75 77.93 78.32 79.88 78.03 81.34 81.15 79.97 78.71 81.24 81.72  
   D 72.50 72.69                      
               
179 
 
     Appendix 19. Midkine PCR gene analysis. The samples layout in the 96-well plate and the qPCR analysis result. 
  
 Sample number              
   1 2 3 4 5 6 7 8 9 10 11 12  
 4 weeks A 432 432 441 441 428 428 597 597 583 583 595 595  
 8 weeks B 589 589 598 598 438 438 440 440 426 426 450 450  
 16 weeks C 599 599 585 585 427 427 430 430 584 584 425 425  
   D H2O H2O                      
               
 Cq value              
   1 2 3 4 5 6 7 8 9 10 11 12  
 4 weeks A 25.69 26.46 25.28 26.20 27.58 28.14 30.33 30.42 29.54 30.03 35.31 33.60  
 8 weeks B 29.46 27.92 33.05 27.94 30.21 28.67 25.51 26.15 28.49 27.48 26.29 25.72  
 16 weeks C 28.63 27.24 29.54 38.28 33.48 26.28 24.02 24.86 29.55 28.57 29.01 29.04  
   D 34.19 33.71                      
               
 Melting curve value             
   1 2 3 4 5 6 7 8 9 10 11 12  
 4 weeks A 81.92 81.43 82.60 81.33 82.11 81.53 80.36 80.75 80.85 80.27 80.85 81.24  
 8 weeks B 81.04 82.21 80.65 82.69 81.04 83.47 83.18 82.69 81.92 82.89 81.33 81.53  
 16 weeks C 80.95 82.60 80.85 79.97 79.88 81.43 83.18 81.92 83.18 83.28 80.95 80.85  
   D 75.99 74.05                      
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          Appendix 20. Notch-2 PCR gene analysis. The samples layout in the 96-well plate and the qPCR analysis result. 
 
     
 
 Sample number              
   1 2 3 4 5 6 7 8 9 10 11 12  
 4 weeks A 432 432 441 441 428 428 597 597 583 583 595 595  
 8 weeks B 589 589 598 598 438 438 440 440 426 426 450 450  
 16 weeks C 599 599 585 585 427 427 430 430 584 584 425 425  
   D H2O H2O                      
               
 Cq value              
   1 2 3 4 5 6 7 8 9 10 11 12  
 4 weeks A 27.26 26.24 27.13 28.21 27.22 26.77 27.77 27.98 28.41 27.43 31.98 30.59  
 8 weeks B 29.15 28.51 25.25 25.15 28.70 27.79 23.19 23.63 25.52 32.58 23.90 24.62  
 16 weeks C 25.91 25.51 25.52 25.49 25.20 24.69 25.53 25.27 27.86 28.50 27.99 27.84  
   D 33.83 40.00                      
               
 Melting curve value             
   1 2 3 4 5 6 7 8 9 10 11 12  
 4 weeks A 81.98 82.85 82.37 82.27 81.79 82.56 81.98 82.08 82.66 82.08 82.85 82.66  
 8 weeks B 81.69 82.76 82.85 82.47 81.50 82.66 81.98 81.60 82.56 80.63 82.95 82.27  
 16 weeks C 81.69 82.47 81.89 81.69 81.79 83.14 82.27 82.56 83.24 82.37 82.18 82.95  
   D 74.16 62.75                      
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     Appendix 21. ALK PCR gene analysis. The samples layout in the 96-well plate and the qPCR analysis result. 
 Sample number              
   1 2 3 4 5 6 7 8 9 10 11 12  
 4 weeks A 432 432 441 441 428 428 597 597 583 583 595 595  
 8 weeks B 589 589 598 598 438 438 440 440 426 426 450 450  
 16 weeks C 599 599 585 585 427 427 430 430 584 584 425 425  
   D H2O H2O                      
               
 Cq value              
   1 2 3 4 5 6 7 8 9 10 11 12  
 4 weeks A 33.70 31.42 29.67 32.42 28.55 27.09 31.23 34.32 31.51 34.95 37.47 34.11  
 8 weeks B 29.89 37.00 32.55 28.94 31.67 36.64 26.22 29.59 31.43 31.05 26.86 25.65  
 16 weeks C 25.77 29.97 40.00 29.91 40.00 34.49 26.89 25.90 30.61 40.00 40.00 40.00  
   D 37.83 40.00                      
               
 Melting curve value             
   1 2 3 4 5 6 7 8 9 10 11 12  
 4 weeks A 75.58 76.07 75.97 75.87 75.87 76.55 76.26 76.46 76.26 75.68 71.12 76.94  
 8 weeks B 76.16 75.48 75.39 75.78 75.97 75.58 76.26 75.68 75.97 75.97 76.16 76.65  
 16 weeks C 76.36 75.58 75.10 75.87 79.85 75.39 76.07 76.65 76.46 75.68 75.39 61.02  
   D 71.31 70.82                      






      Appendix 22.  RPTPζ PCR gene analysis. The samples layout in the 96-well plate and the qPCR analysis result. 




Sample number             
  1 2 3 4 5 6 7 8 9 10 11 12 
4 weeks A 432 432 441 441 428 428 597 597 583 583 595 595 
8 weeks B 589 589 598 598 438 438 440 440 426 426 450 450 
16 weeks C 599 599 585 585 427 427 430 430 584 584 425 425 
  D H2O H2O                     
             
Cq value             
  1 2 3 4 5 6 7 8 9 10 11 12 
4 weeks A 35.54 38.06 35.09 40.00 35.88 40.00 40.00 40.00 40.00 38.59 40.00 40.00 
8 weeks B 40.00 40.00 34.49 31.80 37.75 36.60 30.65 32.59 40.00 32.54 38.27 32.09 
16 weeks C 30.48 40.00 40.00 30.45 40.00 37.12 33.94 35.76 35.53 40.00 33.77 34.43 
  D 40.00 40.00                     
             
Melting curve value            
  1 2 3 4 5 6 7 8 9 10 11 12 
4 weeks A 77.83 77.54 77.44 61.50 78.02 61.60 60.82 61.02 78.70 77.73 60.73 60.92 
8 weeks B 61.79 61.31 76.57 77.15 77.06 78.12 77.93 77.06 76.09 78.51 75.99 77.54 
16 weeks C 77.93 60.82 75.80 78.12 76.28 76.48 77.93 78.51 77.93 62.37 78.22 77.83 
  D 62.08 61.50                     
